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General introduction and outline
1Pulmonary embolism (PE) is defined as an obstruction of a pulmonary artery caused by a thrombotic embolus and was first described by Virchow in 1846 [1]. PE shares many 
characteristics of epidemiology and pathophysiology with deep vein thrombosis (DVT) 
and they are generally considered as two different presentations of the same disease 
called venous thromboembolism (VTE). With an annual rate of 1-2 per 1000 patients, 
PE is a relatively common disease [2-3]. A rapid diagnosis and accurate treatment is es-
sential, since PE can be a fatal disease.
The diagnostic management of suspected acute PE is challenging due to the non-
specific and highly variable signs and symptoms. As a consequence, the diagnosis has 
to be confirmed by a reliable objective test, which is nowadays computed tomography 
pulmonary angiography (CTPA) [4]. Many efforts have been made to exclude PE without 
the use of CTPA, since unrestricted use of CTPA is associated with several disadvantages, 
being radiation exposure, complications related to the administration of intravenous 
contrast and high health-care costs. An overview of the current diagnostic manage-
ment strategies, as well as current therapeutic management strategies, is presented in 
chapter 2.
The first part of this thesis focuses on the diagnostic management of suspected acute 
PE. First, we thoroughly investigated the performance of the currently most commonly 
applied diagnostic management strategy. In chapter 3, a systematic review and patient-
level meta-analysis is described that investigated the performance of the Wells clinical 
decision rule combined with a quantitative D-dimer test in order to exclude acute PE 
without CTPA, which is the most commonly used diagnostic strategy. The aim of chap-
ter 4 was to determine whether a normal CTPA alone is a safe criterion to rule out acute 
PE, particularly in patients with the highest clinical probability. Second, we evaluated 
two alternative diagnostic strategies in an attempt to further improve the efficiency, 
i.e. reducing the number of required CTPA, while maintaining the high safety of the 
diagnostic management. Chapter 5 discusses the potential of applying an increased 
D-dimer threshold in patients with the lowest clinical probability. The results from the 
YEARS study, a prospective multicentre cohort study investigating a simplified and more 
efficient diagnostic management strategy are provided in chapter 6.
The topic of the second part of this thesis is the therapeutic management of acute 
VTE. One of the key developments of recent years is the introduction of the direct oral 
anticoagulants for the treatment of acute VTE. In chapter 7, a meta-analysis is provided 
on the effectiveness and the safety of these drugs compared to vitamin K antagonists. 
The safety of considering a limited duration of anticoagulant treatment in patients 
with a second VTE that occurred after a relatively long interval, as recommended in the 
Dutch guideline and only based on indirect evidence, was evaluated in chapter 8. In 
the following chapters, some issues on the management of cancer-associated VTE are 
addressed. In chapter 9, the current recommendations regarding treatment duration 
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for cancer-associated VTE are evaluated, particularly whether it is safe to stop anticoagu-
lant treatment in patients cured from cancer. In chapter 10, the evidence from phase 
3 studies on the efficacy and safety of the direct oral anticoagulants in patients with a 
cancer-associated VTE is summarized in a meta-analysis. The final chapter focusses on 
PE diagnosed on computed tomography scanning not performed for suspected PE, the 
so called incidental PE. Incidental PE is a growing challenge for clinicians, particularly in 
cancer patients. Although it is a relatively common diagnosis the evidence regarding the 
optimal management is scarce. In chapter 11, we combined results from 11 individual 
cohort studies in order to provide the best available evidence on the management of 
incidental PE in cancer patients.
11
General introduction and outline
1
REFERENCES
 1. Dalen JE. Pulmonary embolism: what have we learned since Virchow? Natural history, patho-
physiology, and diagnosis. Chest. 2002; 122: 1440-56.
 2. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrom J. Inci-
dence and mortality ofvenous thrombosis: a population-based study. J Thromb Haemost 2007; 5: 
692–9.
 3. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ III. Trends in the incidence 
of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch 
Intern Med 1998; 158: 585–93.
 4. Konstantinides SV, Torbicki A, Agnelli G et al. 2014 ESC guidelines on the diagnosis and manage-
ment of acute pulmonary embolism. Eur Heart J 2014; 35: 3033–80.

 CHAPTER 2
Recent developments in the 
diagnosis and treatment of 
pulmonary embolism
T. van der Hulle, C.E.A. Dronkers, F.A. Klok, M.V. Huisman




Due to the nonspecific symptoms of the condition, a diagnosis of acute pulmonary 
embolism (PE) is frequently considered. However, PE will only be confirmed in 10–20% 
of patients. Because the imaging test of choice, computed tomography pulmonary 
angiography (CTPA), is costly and associated with radiation exposure and other com-
plications, a validated diagnostic algorithm consisting of a clinical decision rule and 
D-dimer test should be used to safely exclude PE in 20–30% of patients without the 
need for CTPA. Recently, the age-adjusted D-dimer threshold has been validated, and 
this has increased the proportion of patients at older age in which PE can be excluded 
without CTPA. Initial therapeutic management of PE depends on the risk of short-term 
PE-related mortality. Haemodynamically unstable patients should be closely monitored 
and receive thrombolytic therapy unless contraindicated because of an unacceptably 
high bleeding risk, whereas patients with low-risk PE may be safely discharged early from 
hospital or receive only outpatient treatment. The PESI score and Hestia decision rule are 
available to select patients in whom early discharge or outpatient treatment will be safe, 
although the safety of these strategies should be confirmed in additional studies. Stan-
dard PE therapy consists of low molecular weight heparin (LMWH) followed by vitamin 
K antagonists (VKAs). Recently, several nonvitamin K-dependent oral anticoagulants 
have been shown to be as effective as LMWH/VKAs, and maybe safer. Determining the 
optimal duration of treatment for a first unprovoked PE remains a challenge, although 
clinical prediction rules for estimating the risk of recurrence of venous thromboembo-
lism and anticoagulation-associated haemorrhage are under investigation. Using these 
prediction rules may lead to both more standardized and more individualized long-term 
treatment of PE.
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INTRODUCTION
Acute pulmonary embolism (PE) is a relatively common disease with an annual rate 
of 1–2 per 1000 patients [1, 2]. The clinical presentation of acute PE is nonspecific and 
highly variable, ranging from incidentally diagnosed asymptomatic thrombi to sudden 
death [3]. As a result, a clinical suspicion of PE is frequently raised, whilst the diagnosis is 
only confirmed in 10–20% of patients [4, 5]. Diagnostic algorithms have been developed 
to ensure reliable and efficient management of patients with clinically suspected PE.
Once acute PE is diagnosed, prompt initiation of anticoagulant therapy is indicated 
to prevent thrombus extension and recurrent (fatal) PE. However, the risk of such an ad-
verse outcome is highly variable, ranging from <1% to >15% [6]. Management decisions 
including early discharge or prescription of thrombolytic therapy should preferably be 
based on reproducible risk stratification of the individual patient [6, 7]. For the long-term 
treatment of acute PE, the decision to continue or stop anticoagulant therapy, after an 
initial period of 3 months, depends on the balance between the risk of recurrent venous 
thromboembolism (VTE) and of anticoagulant-associated haemorrhage.
Here, we will present an up-to-date overview of the therapeutic management of 
established PE, discussing conventional medical therapy, the recently introduced non-
vitamin K-dependent oral anticoagulants (NOACs), outpatient treatment, thrombolytic 
therapy and the duration of treatment. In particular, we will focus on recent advances as 
a follow-up to a review of a similar topic published in this journal in 2010 [8].
DIAGNOSTIC MANAGEMENT OF CLINICALLY SUSPECTED ACUTE PE
Symptoms that may suggest the presence of acute PE are the sudden onset of dyspnoea, 
pleuritic chest pain, haemoptysis, extremity swelling suggestive of deep vein thrombosis 
(DVT) and syncope [3]. Of note, these symptoms are nonspecific for PE and may also be 
present in many other acute cardiopulmonary conditions. In large diagnostic manage-
ment studies, the PE prevalence amongst patients with a clinical suspicion of PE ranged 
from 10% to 30% [4, 5, 9]. PE can only be diagnosed using an imaging test, at present 
usually computed tomography pulmonary angiography (CTPA), which is associated with 
high healthcare costs, radiation exposure and a risk of complications such as contrast-
induced nephropathy and allergic reactions [10-12]. Therefore, diagnostic management 
algorithms have been developed to exclude PE without the need for imaging tests in a 
proportion of patients. These algorithms start with a clinical decision rule (CDR), which 




CDRs and D-dimer testing
Various CDRs have been standardized and validated for use in clinical practice, of these, 
the Wells rule and revised Geneva score are the most widely validated for PE (Table 
1) [13, 14]. Originally, different items were awarded different scores, but for practical 
reasons, both rules have been simplified by assigning only one point to each item, 
without lowering their diagnostic accuracy [15, 16]. The CDRs are used to categorize 
patients into either ‘PE unlikely’ or ‘PE likely’ groups, with PE prevalences of 12–17% and 
37–43%, respectively, in European cohorts [4, 5]. The accuracy of the original and simpli-
fied versions of the Wells rule and revised Geneva score were shown to be similar, and 
the choice of a specific rule may therefore depend on local preference [4].
Table 1. Clinical decision rules.
Item Original version Simplified version
Wells rule
Previous PE or DVT 1.5 1
Heart rate >100 beats/min 1.5 1
Surgery or immobilization within 4 weeks 1.5 1
Haemoptysis 1 1
Active malignancy 1 1
Clinical signs of DVT 3 1
Alternative diagnosis less likely than PE 3 1
Clinical probability categories
PE unlikely ≤4 ≤1
PE likely >4 >1
Revised Geneva score
Previous DVT or PE 3 1
Heart rate 75–94 beats/min 3 1
Heart rate ≥95 beats/min 5 2
Surgery or fracture within 1 month 2 1
Haemoptysis 2 1
Active malignancy 2 1
Unilateral lower limb pain 3 1
Pain on lower limb deep vein palpation and unilateral oedema 4 1
Age >65 years 1 1
Clinical probability categories
PE unlikely ≤ 5 ≤2
PE likely > 5 >2
Note: DVT, deep vein thrombosis; PE, pulmonary embolism.
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The D-dimer level in plasma is a marker of fibrinolysis and is elevated in the presence 
of acute VTE as well as in many other clinical conditions. The sensitivity of D-dimer test-
ing for the latest generation of assays is very high (95–100%), whereas the specificity is 
moderate (43–93%) [17]. Accordingly, using the standard threshold of <500 μg/L, the 
negative predictive value of D-dimer testing allows for the exclusion of PE in patients 
with a PE unlikely clinical probability [4, 5, 9]. By applying this strategy, PE can be ruled 
out in 25–46% of patients without performing an imaging test, with a 3-month VTE 
incidence of 0.04–0.96% after anticoagulant therapy is withheld [18].
Recently, attempts have been made to increase the number of patients in whom PE 
can be ruled out without imaging tests. As D-dimer levels increase with age, an age-
dependent D-dimer cut-off level was proposed: age × 10 μg/L in patients over 50 years 
of age [19]. The safety of applying this age-dependent D-dimer cut-off was recently con-
firmed in a large prospective outcome trial [9]. The 3-month VTE incidence in patients in 
the PE unlikely category and with a D-dimer level >500 μg/L but below the age-adjusted 
threshold was only 0.3% (95% confidence interval (CI) 0.1–1.7). The absolute increase 
in the proportion of patients above 50 years old that could be managed without CTPA 
was 11.6%. In particular, patients aged 75 years and older could be more frequently 
managed safely without CTPA.
Imaging tests
The historical gold standard imaging test for diagnosing PE is pulmonary angiography, 
which is associated with a 3-month VTE incidence after a negative result of 1.7% (95% 
CI 1.0–2.7) [20]. Because pulmonary angiography is an invasive procedure, this test was 
first replaced by ventilation-perfusion lung scanning (V/Q scanning) and later by CTPA. 
Although it has been demonstrated that V/Q scanning is safe for excluding PE, with a 
3-month VTE incidence of only 0.9% (upper limit of 95% CI 2.3) after a normal result, 
its major disadvantage is an inconclusive result in 28–46% of patients, in whom the 
PE prevalence is still 10–30% and who thus require an additional imaging test [21, 22]. 
CTPA results in an inconclusive test result in only 0.9–4.6% of patients [23]. Furthermore, 
CTPA is more widely available with faster acquisition and the possibility of establishing 
an alternative diagnosis, although the value of the latter has recently been questioned 
[24]. A possible advantage of V/Q scanning is the lower radiation exposure compared to 
CTPA (1.1 vs. 2–6 mSv), which may be relevant for specific patient groups, particularly 
young (particularly female) patients and pregnant women. V/Q scanning may also be 
considered for patients with a known allergy to contrast medium [11, 12].
The sensitivity of multidetector row high-resolution CTPA is excellent and several 
outcome studies have consistently demonstrated the safety of withholding anticoagu-
lant therapy in patients with a negative CTPA alone [23]. In a meta-analysis, the pooled 
3-month VTE incidence after a negative CTPA alone in patients in whom CTPA was 
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indicated based on a validated CDR and/or D-dimer test was 1.2% (95% CI 0.8–1.8), 
compared to 1.1% (95% CI 0.6–2.0) after negative CTPA and subsequently negative 
lower limb compression ultrasonography, indicating that the safety could not be further 
improved by excluding asymptomatic DVT after a negative CTPA [23]. In addition to 
ionizing radiation, other potential concerns related to the easily available CTPA as the 
first-line imaging test are an increased incidence of contrast-induced nephropathy, a 
risk of unsuspected findings requiring additional medical attention and an increased 
incidence of isolated subsegmental PE, of which the clinical relevance has become 
increasingly under debate [10, 25-27].
Integrated approach
The first step in the diagnostic management of patients with clinically suspected acute PE 
is to determine whether the patient has signs and symptoms of haemodynamic shock. If 
so, patients should be immediately referred for additional imaging tests and thrombolytic 
therapy should be started without waiting for a CDR result or D-dimer level.
In patients who are haemodynamically stable, diagnostic management starts with 
the assessment of the clinical probability of PE using one of the validated CDRs (Table 
1). In patients with a PE unlikely clinical probability, a D-dimer test is indicated and PE 
can be ruled out without further imaging tests if the level is <500 μg/L or below the 
age-adjusted threshold for patients over the age of 50 years. In the remaining patients 
with either a PE unlikely CDR score in combination with an elevated D-dimer level or a 
PE likely CDR score, CTPA is indicated to determine the presence of PE (Figure 1).
Correct use of a validated diagnostic algorithm is required to ensure its safety; this 
is highlighted by several recent studies showing that a validated diagnostic algorithm 
is frequently not or incorrectly applied. This leads to the unnecessary use of CTPA and, 
even more relevant, to a higher 3-month VTE incidence in patients in whom anticoagu-
lant therapy is withheld [28]. A promising intervention to improve adherence may be 
the implementation of computerized clinical decision support for clinicians [29]. Future 
studies should focus on further simplification of the diagnostic algorithms to improve 
Figure 1.  Integrated approach for clinically suspected acute pulmonary embolism in haemodynamically 
stable patients.
Figure 1: Integrated approach for clinically suspected acute pulmonary embolism in 
haemodynamically stable patients. 
Note: CDR, clinical decision rule; CTPA, computed tomography pulmonary 
angiography; PE, pulmonary embolism.
Note: CDR, clinical decision rule; CTPA, computed tomography pulmonary angiography; PE, pulmonary 
embolism.
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the compliance and consequently the safety and efficiency of diagnostic management 
in daily clinical practice. Future studies should also investigate whether increasing the 
D-dimer threshold, for instance with variable D-dimer thresholds depending on the 
pretest probability, may further improve the efficiency without reducing the safety of 
the diagnostic algorithm [30].
TREATMENT OF ACUTE PE
Risk stratification of acute PE
Patients with acute PE should be stratified according to the short-term PE-related mor-
tality risk. Risk stratification starts with identifying patients in haemodynamic shock, 
who are classified as having high-risk or massive PE with an estimated 30-day PE-related 
mortality risk of >15% [7].
For the remaining haemodynamically stable patients, the ability of clinical prediction 
rules and several tests to distinguish patients with a low risk (<1%) from those with an 
intermediate risk (3–15%) of an adverse outcome has been investigated [7].
The Hestia decision rule consists of a set of criteria that can be used to select patients 
with low-risk PE who are candidates for early discharge or outpatient treatment (Table 2) 
[31]. The major strength of the Hestia decision rule is its clinician friendliness, as it consists 
of only 11 easy-to-use bedside criteria that should all be negative before early discharge 
or outpatient treatment can be considered. The Pulmonary Embolism Severity Index 
(PESI), which combines several clinical signs, symptoms and comorbidities (Table 3), is 
also available and is able to identify patients at low risk of short-term PE-related mortality 
[6]. To overcome its complexity, a simplified version (sPESI) has been proposed [32].
In addition to the Hestia decision rule and the PESI, several laboratory biomarkers 
have been shown to predict adverse outcome in haemodynamically stable patients. 
High concentrations of brain-type natriuretic peptides (BNPs) or the N-terminal of the 
prohormone of BNP (NT-proBNP) that are elevated during PE-associated right ventricular 
(RV) overload are strongly associated with mortality in acute PE with an OR of 7.6 (95% CI 
3.4–17), whereas normal levels identify patients with a low risk of short-term PE-related 
mortality (17% vs. 1.7%) [33]. In addition, elevated plasma troponin I or (high-sensitivity) 
troponin T levels are associated with a high risk of short-term mortality (18% vs. 2.3%) in 
haemodynamically stable patients with an OR of 5.90 (95% CI 2.7–13) [34].
Both echocardiography and CTPA images can be used to detect RV dysfunction, which 
is also associated with an elevated risk of short-term PE-related mortality in patients 
who are haemodynamically stable. At least 25% of patients with PE have signs of RV 
dysfunction on echocardiography, such as RV dilatation, an increased RV/left ventricular 
(LV) diameter ratio, hypokinesia of the free RV wall, increased tricuspid regurgitation 
Chapter 2
20
jet velocity or decreased tricuspid annulus plane systolic excursion. Echocardiographic 
signs of RV dysfunction in haemodynamically stable patients with PE are associated 
with an OR of 2.4 (95% CI 1.3–4.3) for short-term mortality [35]. The RV/LV dimensional 
ratio can also be assessed on axial or reconstructed four-chamber CTPA views, for which 
thresholds of ≥0.9 or ≥1.0 are generally used. CTPA-assessed RV dysfunction in haemo-
dynamically stable patients is associated with an increased risk of short-term mortality 
(7.8% vs. 5.1%) as well as with short-term PE-related mortality (2.2% vs. 0.2%) with ORs 
of 1.8 (95% CI 1.3–2.6) and 7.4 (95% CI 1.4–40), respectively [36]. Interestingly, several 
studies have shown that models combining prediction rules, biomarkers and imaging 
tests improve the predictive accuracy compared with the individual tests, although at 
present, none of these combinations can be recommended to guide management in 
daily clinical practice [37, 38].
Management of high-risk patients
Thrombolytic therapy is able to rapidly resolve thromboembolic obstruction enabling 
prompt reduction in pulmonary artery pressure and improvement in RV function. The 
results of one study suggested that a clinical and echocardiographic improvement can 
be observed in more than 90% of patients who receive thrombolysis [39]. Thrombolytic 
therapy is generally recommended for high-risk patients with PE with overt haemody-
namic instability without a high risk of bleeding complications, although there is a lack 
Table 2.  Hestia decision rule.
Haemodynamically unstable?a
Thrombolysis or embolectomy necessary?
High risk of bleeding?b
Oxygen supply to maintain oxygen saturation >90% for more than 24 h?
Pulmonary embolism diagnosed during anticoagulant treatment?
Intravenous pain medication for more 24 h?
Medical or social reason for treatment in hospital for more than 24 h?
Creatinine clearance <30 mL/min?c
Severe liver impairment?d
Pregnant?
Documented history of heparin-induced thrombocytopenia?
Interpretation
If the answer to at least one of the above questions is ‘YES’, the patient cannot be treated as an outpatient
Note: aIncludes, at the discretion of the physician, systolic blood pressure <100 mmHg with heart rate 
>100 beats/min; condition requiring admission to an intensive care unit; bgastrointestinal bleeding in the 
preceding 14 days, recent stroke (within 4 weeks), recent operation (within 2 weeks), bleeding disorder or 
thrombocytopenia (platelet count <75 x 109/L) and/or uncontrolled hypertension (systolic blood pressure 
>180 mmHg or diastolic blood pressure > 110 mmHg); ccreatinine clearance calculated according to the 
Cockroft–Gault formula; dat the discretion of the treating physician.
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of convincing supporting evidence from large randomized controlled trials. A meta-
analysis of randomized trials including haemodynamically unstable patients with PE 
demonstrated an OR of 0.53 (2.2% vs. 3.9%; 95% CI 0.32–0.88) for recurrent PE and death 
in patients who received thrombolytic therapy [40]. In addition, in an epidemiological 
study, haemodynamically unstable patients with PE who received thrombolytic therapy 
had a relative risk of 0.2 (95% CI 0.19–0.22) for PE-related in-hospital death compared to 
those who had not received thrombolytic therapy [41]. Of major concern, it was shown 
in a recent meta-analysis that thrombolytic therapy substantially increased the risk 
of major bleeding complications with an OR of 2.73 (9.2% vs. 3.4%; 95% CI 1.91–3.91) 
compared to standard anticoagulant treatment [40]. Percutaneous catheter-directed 
therapy and surgical embolectomy are alternatives to thrombolytic therapy, for example 
Table 3.  PESI score.
Parameter Original version Simplified version
Age Age in years 1 point (if age >80 years)
Male sex +10 points
Cancer +30 points 1 point
Chronic heart failure +10 points
1 point
Chronic pulmonary disease +10 points
Heart rate ≥110 beats/min +20 points 1 point
Systolic blood pressure <100 mmHg +30 points 1 point
Respiratory rate >30 breaths/min +20 points
Temperature <36 °C +20 points
Altered mental statusa +60 points
Arterial oxygen saturation <90%b +20 points 1 point
Risk strata
Class I: ≤65 points
very low 30-day mortality risk 
0–1.6%
0 points = 30-day mortality 
risk 1.0%
(95% CI 0–2.1)
Class II: 66–85 points
low mortality risk 
1.7–3.5%
≥1 point(s) = 30-day 
mortality risk 10.9%
(95% CI 8.5–13.2)
Class III: 86–105 points
moderate mortality risk 
3.2–7.1%
Class IV: 106–125 points
high mortality risk 
4.0–11.4%
Class V: >125 points
very high mortality risk
 10.0–24.5%
Note: PESI, Pulmonary Embolism Severity Index. aDefined as disorientation, lethargy, stupor or coma. bWith 
and without the administration of supplemental oxygen.
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in the case of a contraindication to thrombolysis or after thrombolytic therapy has failed 
or is deemed inadequate as first-line treatment, although these interventions have not 
been investigated in clinical outcome studies [42].
Management of nonhigh-risk patients
Amongst the nonhigh-risk haemodynamically stable patients, two key questions 
with regard to therapeutic management remain to be answered: (i) Do patients with 
intermediate-risk PE benefit from thrombolytic therapy? (ii) Which patients with low risk 
of adverse outcome are suitable candidates for outpatient treatment or early discharge?
The benefit of administering thrombolytic drugs to haemodynamically stable patients 
with intermediate-risk PE has been debated for many years. Individual small random-
ized trials have consistently demonstrated that thrombolytic therapy reduces the risk 
of haemodynamic deterioration and recurrent PE, at the cost of a higher risk of major 
haemorrhage without an effect on overall mortality [40, 43]. In 2014, the results of the 
randomized double-blind PEITHO trial were published. This study investigated the ef-
fects of a single dose of tenecteplase (varying from 30 to 50 mg depending on body 
weight) versus placebo in 1006 patients with an intermediate risk of PE [44]. Interme-
diate-risk PE was defined as a PESI score of III–V, elevated biomarkers of cardiac injury 
and signs of RV dysfunction on echocardiography or CTPA. The study demonstrated a 
significant reduction in the primary efficacy outcome (a composite of all-cause death or 
haemodynamic deterioration within 7 days of randomization), with an OR of 0.44 (2.6% 
vs. 5.6%; 95% CI 0.23–0.88). However, 7-day mortality was not different between the two 
groups: 1.2% of patients who received tenecteplase and 1.8% of patients who received 
placebo (OR 0.65; 95% CI 0.23–1.85). Of interest, patients who were randomly assigned 
to receive tenecteplase had a significantly higher risk of major extracranial bleeding and 
(predominantly haemorrhagic) stroke within 7 days with ORs of 5.6 (6.3% vs. 1.2%; 95% 
CI 2.3–13.4) and 12 (2.4% vs. 0.2%; 95% CI 1.6–93.4), respectively. It should be noted that 
only 23 patients (4.6%) from the placebo cohort eventually received rescue thrombolysis 
during follow-up because of in-hospital haemodynamic deterioration, and two of these 
patients died within 7 days.
In conclusion, thrombolytic therapy in haemodynamically stable intermediate-risk pa-
tients with PE reduces the risk of the composite endpoint consisting of haemodynamic 
deterioration and death at the cost of an increase in the incidence of major haemor-
rhage. Therefore, thrombolytic therapy cannot be recommended for haemodynamically 
stable intermediate-risk patients with PE. These patients should receive standard antico-
agulant therapy and close monitoring, whilst thrombolytic therapy should be reserved 
for patients with haemodynamic deterioration during the first days of treatment.
One randomized trial and two cohort studies evaluating outpatient treatment or early 
discharge for patients with PE have been completed and the results published. In the 
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largest study reported to date, there were initially 14 exclusion criteria (Table 4) and 
thereafter patients with a PESI class I or II were selected [45]. Patients were randomly as-
signed to either conventional in-hospital treatment or outpatient treatment (discharge 
after a mean of 0.5 days). Of the 1557 patients screened, 470 (30%) were potentially 
eligible for early discharge (<24 h) of whom 344 were eventually enrolled in the study. 
Only one of the 171 (0.6%) evaluable patients receiving outpatient treatment developed 
a nonfatal recurrent VTE during the 3-month follow-up, and two patients (1.2%) had 
a major haemorrhage within 14 days. Amongst the 168 evaluable patients treated in 
hospital, neither recurrent VTE nor major haemorrhage occurred within 14 days. Based 
on these results, the authors concluded that outpatient treatment was noninferior to 
in-hospital treatment [45]. A major limitation of this strategy is the complexity of scoring 
the 11 (items) of the PESI score combined with the many other exclusion criteria that 
were used in the study. Although this limitation may be partly overcome using the sPESI, 
it should be noted that the simplified score has not been validated in a prospective 
management study.
The Hestia decision rule has also been evaluated a. a selection tool for outpatient 
treatment (Table 2) [31]. In a prospective cohort study, 297 (51%) of the 581 consecu-
tive patients with acute PE were selected for outpatient treatment of whom six (2.0%) 
experienced a nonfatal recurrent VTE. Two patients (0.7%) experienced a major haemor-
Table 4.  Exclusion criteria in a randomized trial investigating outpatient treatment amongst PE patients 
with a PESI class I or II (from Aujesky et al. [45]).
Arterial hypoxaemia (oxygen saturation on room air <90% measured by pulse oximetry or a partial pressure of 
oxygen <60 mmHg on arterial blood gas analysis)
Systolic blood pressure <100 mmHg
Chest pain necessitating parenteral administration of opioids
Active bleeding or high risk of bleeding (defined as stroke during the preceding 10 days)
Gastrointestinal bleeding during the preceding 14 days or platelet count <75 x 109/L
Severe renal failure (creatinine clearance <30 mL/min based on the Cockcroft–Gault equation)
Extreme obesity (body mass >150 kg), history of heparin-induced thrombocytopenia or allergy
to heparins
Therapeutic oral anticoagulation at the time of diagnosis of PE (INR ≥2·0)




Diagnosis of pulmonary embolism >23 h before the time of screening (to avoid enrolling already stabilized 
patients)
Previous enrolment in the trial
Note: INR, international normalized ratio; PE, pulmonary embolism; PESI, Pulmonary Embolism Severity Index.
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rhage, one (0.3%) of whom suffered fatal intracranial bleeding. The major advantages of 
this strategy are the clinician friendliness and the high degree of simplicity.
NT-proBNP has also been evaluated in a cohort study as a tool for selecting patients 
for outpatient treatment [46]. Haemodynamically stable patients with a low NT-proBNP 
concentration (threshold <500 pg/mL) were discharged within 24 h of diagnosis. Of the 
351 patients in this cohort, 152 (43%) were treated as outpatients and none developed 
a recurrent VTE or major haemorrhage or died during 3 months of follow-up [46]. In the 
Vesta study, the results of which will be presented at the congress of the International 
Society of Thrombosis and Haemostasis in June 2015, a total of 550 patients were ran-
domly assigned to the Hestia decision rule combined with an NT-proBNP test or the Hes-
tia decision rule alone (NTR2603). Of the 275 patients managed according to the Hestia 
decision rule in combination with an NT-proBNP test, 34 (12%) had a concentration of 
NT-proBNP >500 ng/L and were managed as inpatients. None of these patients suffered 
from the primary outcome (30-day adverse outcome defined as PE or bleeding-related 
mortality, cardiopulmonary resuscitation or admission to the intensive care unit). Of the 
275 patients managed according to the Hestia decision rule alone, three (1.1%; 95% 
CI 0.2–3.2) experienced the primary outcome, all of whom had a normal NT-proBNP 
level, which were determined in a post hoc analysis. Therefore, the findings of this study 
confirm the safety of selecting patients who can be treated as outpatients and suggest 
that NT-proBNP measurements are of limited additional value.
In conclusion, it has been shown that outpatient treatment of patients with PE based 
on the Hestia decision rule or a combination of several exclusion criteria and the PESI 
score is safe. Of note, neither the PESI nor the sPESI rule has been evaluated as a sole 
test to select patients for outpatient treatment. The combination of a clinical prediction 
rule, laboratory biomarkers and/or findings on imaging tests to further optimize the 
identification of patients who can be safely managed in the outpatient setting remains 
to be evaluated.
Initial anticoagulant therapy (first 3 months)
Acute PE requires initial treatment with a direct-onset anticoagulant drug to prevent the 
extension of thrombosis or fatal recurrent VTE [7, 47]. Weight-adjusted subcutaneous 
low molecular weight heparin (LMWH) is the treatment of choice for the large majority 
of patients. Intravenous unfractionated heparin is reserved for patients with severe renal 
impairment (creatinine clearance <20–30 mL/min), patients with a high risk of haemor-
rhage including those receiving thrombolytic therapy, haemodynamically unstable 
patients and individuals who are extremely overweight or underweight. Fondaparinux 
is an alternative to LMWH and unfractionated heparin in patients with (a history of ) hep-
arin-induced thrombocytopenia [7, 48]. Monitoring of the anticoagulant effect of LMWH 
by determining the antifactor Xa activity is not generally recommended, although it can 
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be considered in specific circumstances (i.e. in patients with moderate renal impairment 
or during pregnancy). The target range measured 4 hours after administration is 1.0–2.0 
IU/mL for once-daily administration and 0.6–1.0 IU/mL for twice-daily administration of 
LMWH [7].
Patients with acute PE should be treated for at least 3 months. For decades, vitamin K 
antagonists (VKAs) have been the long-term treatment of choice and must be started in 
parallel with one of the parenterally administered direct-onset anticoagulant drugs for at 
least 5 days and until the international normalized ratio (INR) has reached a therapeutic 
range (between 2.0 and 3.0) on 2 consecutive days. VKA therapy is highly effective with 
a rate of recurrent VTE of 3–4% during the initial 3 months of therapy [49]. It has been 
estimated that the rate of major haemorrhage during the initial 3 months of VKA therapy 
is 1–2% [49]. A major disadvantage of VKA therapy is the need for frequent laboratory 
monitoring of the INR with tailored dosing, as a result of the variable pharmacokinetic 
and pharmacodynamic parameters, and interactions with food and drugs [50].
In recent years, several NOACs have become available for anticoagulant therapy (Table 
5). These drugs directly and specifically inhibit either thrombin (factor II) or factor Xa. The 
major advantage of this new drug class is the simplification of PE treatment, due to the 
rapid onset of action, the predictable anticoagulant effect and a low potential for drug 
and food interactions [50]. Rivaroxaban and apixaban were investigated with an initial 
higher dose for 3 weeks and 7 days, respectively, without the need for preceding LMWH 
therapy, whereas dabigatran and edoxaban were administered after a mean period of 
10 days of treatment with LMWH. These drugs can be prescribed in fixed doses and rou-
tine laboratory monitoring is not required. A noninferior efficacy compared to standard 
treatment with VKA has been demonstrated for all NOACs individually in phase III trials 
[51-55] and confirmed in a meta-analysis: the risk ratio for recurrent VTE was 0.9 (95% 
CI 0.7–1.1) [56]. Moreover, this meta-analysis demonstrated a beneficial safety profile of 
NOACs in terms of bleeding complications with a risk ratio for major haemorrhage of 0.6 
(95% CI 0.4–0.9); however, it should be noted that the absolute risk of major haemor-
rhage in real-world daily care may be higher than reported in the randomized controlled 
trials which applied strict patient selection criteria [57]. Based on these results and the 
practical advantages of NOACs, these drugs are likely to replace VKAs as the treatment 
of choice for the majority of patients with PE in the future.
A potential concern with regard to the NOACs is the current unavailability of specific 
antidotes, although the relevance of this in clinical practice may be limited due to the 
lower incidence of major haemorrhage as well as the shorter half-life of these drugs 
compared to VKAs [50]. Moreover, specific antidotes are currently under clinical investi-
gation and are likely to become available in the coming years. The humanized monoclo-
nal antibody idarucizumab, which is specifically designed as an antidote for dabigatran, 
directly binds to dabigatran with a higher affinity than thrombin and is currently being 
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tested in a phase III trial (NCT02104947). Andexanet alpha is a recombinant modified 
form of factor Xa that directly binds factor Xa inhibitors without procoagulant activity 
and is a potential universal antidote for the anti-Xa inhibitors as well as for LMWH. Two 
phase III trials have recently been initiated to evaluate the effects of andaxanet alpha in 
healthy volunteers (NCT02220725, NCT02207725) and a study in patients with a major 
haemorrhage whilst treated with a factor Xa inhibitor is planned (NCT02329327).
For the specific category of patients with cancer-associated PE, long-term LMWHs are 
the treatment of choice for at least the first 6 months of therapy, based on a higher 
efficacy [hazard ratio (HR) of recurrent VTE 0.48; 95% CI 0.30–0.77] in combination with a 
comparable risk of bleeding complications compared to VKA treatment [58]. Although a 
meta-analysis of patients with cancer included in the NOAC trials suggested a favourable 
efficacy and similar safety profile compared to VKAs, dedicated clinical trials comparing 
these drugs to LMWHs in patients with cancer are required [59]. Therefore, at present, 
NOACs cannot be recommended for the treatment of cancer-associated VTE. Finally, an 
inferior vena cava filter is a temporary alternative for patients with an absolute contrain-
dication to anticoagulant therapy [7].
Table 5.  Long-term anticoagulant therapy regimens.
Drug Standard dose Comments
VKA
Oral administration











-  Treatment of choice for cancer-associated PE for 
at least the first 6 months, evidence for the period 
beyond the first 6 months is lacking and a switch to 
a VKA may be considered
-  After the first month a dose reduction to 80% of the 
initial dose can be considered
-  Contraindicated if creatinine clearance <30 mL/min
Dabigatrana
Oral administration
150 mg b.i.d. -  A t least 5 days combined with a direct-action 
anticoagulant therapy (i.e. LMWH)
-  Almost completely renal clearance
-  Contraindicated if creatinine clearance <30 mL/min
Rivaroxabana
Oral administration
20 mg b.i.d. -  First 3 weeks, a higher dose of 15 mg b.i.d.
-  Contraindicated if creatinine clearance <30 mL/min
Apixabana
Oral administration
5 mg b.i.d. -  First 7 days, a higher dose of 10 mg b.i.d.
-  Contraindicated if creatinine clearance <25 mL/min
Edoxabana
Oral administration
60 mg o.d. -  At least 5 days combined with a direct-action 
anticoagulant therapy (i.e. LMWH)
-  Contraindicated if creatinine clearance <30 mL/min
Note: VKA, vitamin K antagonist; LMWH, low molecular weight heparin; b.i.d., twice daily; o.d., once daily; 
INR, international normalized ratio; PE, pulmonary embolism. aApproval may vary between countries.
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Long-term anticoagulant therapy (after the first 3 months)
To determine the optimal duration of treatment after the initial 3 months, the perceived 
risk of anticoagulant therapy-associated haemorrhage should be weighed against the 
risk of recurrent VTE in every patient individually.
It has been estimated that the risk of major haemorrhage after the initial 3 months of 
therapy is 2.74 per 100 patient-years, but the risk can vary widely depending on patient 
characteristics [60]. Known risk factors for bleeding complications are older age, previ-
ous gastrointestinal bleeding, previous stroke, chronic renal or liver disease, alcohol 
abuse, concomitant antiplatelet therapy, presence of serious comorbidities and poor 
control of anticoagulant therapy [7]. Several clinical prediction rules derived in patients 
with VTE as well as those derived and validated in patients with atrial fibrillation have 
been investigated. However, none of these prediction rules is currently validated to use 
in daily clinical practice as a result of low reproducibility, a low c-statistic indicating a 
limited predictive value and/or the lack of validation studies [61]. Moreover, it should 
be noted that the case-fatality rate of anticoagulant therapy-associated major haemor-
rhage (13.4%; 95% CI 9.4–17.4) has been reported to be higher than that of recurrent 
VTE (3.6%; 95% CI 1.9–5.7), and therefore, the clinical impact of major haemorrhage may 
be considered to be higher than that of recurrent VTE [49, 60].
Regarding the risk of recurrent VTE, it should be emphasized that extending the 
duration of anticoagulant therapy only postpones a potential recurrent VTE without di-
minishing the VTE recurrence risk after anticoagulant therapy is stopped [62]. In patients 
with PE related to a transient provoking factor (e.g. recent surgery, immobilization, 
pregnancy or oral contraceptive use), a recurrence risk of approximately 2.5% per year is 
usually considered low enough to discontinue anticoagulant therapy after 3 months [7, 
47]. On the other hand, the recurrence risk in patients with an active malignancy (20.7% 
during the first 12 months of therapy) [63], the antiphospholipid syndrome [64] or a pre-
vious episode of VTE (20.7% after 4 years of follow-up after initial 6 month therapy) [65] 
is considered to be high enough for guidelines to suggest that these patients should be 
treated for an extended or indefinite duration [7].
Because most recurrences occur shortly after cessation of anticoagulant therapy, it has 
been proposed that patients with a second VTE that occurred after a long interval fol-
lowing the first VTE may have a relatively low recurrence risk and therefore may benefit 
from a limited duration of treatment. However, in a recent cohort study, the incidence 
rate of a third VTE after an interval of >1 year following cessation of treatment for the first 
VTE was 12 per 100 patient-years (95% CI 7.4–19.0) and 5.6 per 100 patient-years (95% CI 
2.2–12.0) in patients with an unprovoked and a provoked second VTE, respectively [66]. 
Therefore, differentiation based on the interval between the first and second VTE cannot 
be recommended for patients with an unprovoked second VTE, whereas a limited dura-
tion of treatment can be considered in patients with a provoked second VTE.
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In patients with a first unprovoked PE not associated with cancer or the antiphos-
pholipid syndrome, which is associated with a recurrence risk of at least 4.5% per 
year, determining the optimal duration of treatment is usually more complicated. 
Standard screening for inherited and acquired thrombophilia is not recommended as 
studies have failed to demonstrate a benefit and the predictive value for a recurrent 
VTE of most thrombophilic factors is relatively low [67]. Measuring the D-dimer level 
as a general marker of coagulation activity may be valuable for predicting the recur-
rence risk, although results from prospective studies were inconsistent with incidence 
rates varying from 3.0% to 6.7% per year after anticoagulant therapy was stopped in 
patients with repeated negative D-dimer test results [68, 69]. The Vienna prediction 
model is a recently externally validated nomogram consisting of the variables sex, loca-
tion of the VTE and the D-dimer concentration and is currently being evaluated in a 
prospective management study [70, 71]. In this ongoing study, patients with a low-risk 
score (<180 points; expected 12-month recurrence risk 4.4%; 95% CI 2.7–6.2) receive 
anticoagulant therapy for 3–7 months, whilst therapy is continued in the remaining 
patients (NCT01972243). The “men continue and HER DOO2 prediction rule” consists of 
four variables: post-thrombotic signs, D-dimer concentration of ≥250 μg/L (whilst on 
anticoagulant therapy), body mass index ≥30 kg/m2 and age ≥60 years. In an observa-
tional study, this score differentiated between a low-risk category with an annual risk 
of 1.6% (≤1 point; 95% CI 0.3–4.6) and a higher-risk group with an annual risk of 14.1% 
(≥2 points; 95% CI 10.9–17.3) only in women and is currently being investigated in a 
prospective management study (NCT00967304) [72]. Finally, the DASH score has been 
derived from a patient-level meta-analysis and consists of four variables: an abnormal 
postcoagulation D-dimer concentration, age <50 years, male sex and hormonal therapy. 
This score was able to differentiate between groups with an annual VTE incidence of 
3.1% (95% CI 2.4–3.9) and 9.3% (95% CI 8.1–10.8) [73]. However, in the absence of results 
from prospective management studies, none of these scores can currently be recom-
mended for daily clinical practice.
The major concern with the use of anticoagulant therapy for an indefinite period is 
the persistent risk of major haemorrhage. Therefore, alternative strategies that may be 
associated with a lower risk of haemorrhage have been investigated, including low-
intensity VKA therapy with a target INR of 1.5–1.9 and aspirin. Low-intensity VKA therapy 
was less effective compared to conventional-intensity VKA therapy, with a similar risk of 
major haemorrhage [74]. Therefore, low-intensity VKA therapy cannot be recommended 
for the secondary prevention of VTE. More recently, two randomized trials have been 
conducted to investigate the effect of aspirin after standard anticoagulant therapy for 
long-term secondary VTE prevention. In the WARFASA trial, a significant reduction in 
VTE recurrence risk was observed from 11.2% per year for placebo to 6.6% for aspirin 
(OR 0.58; 95% CI 0.36–0.93), whilst the risk of major haemorrhage was similar (1/197 for 
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placebo vs. 1/205 for aspirin) [75]. The ASPIRE trial demonstrated only a nonsignificant 
decrease in the risk of VTE recurrence from 6.5% per year for placebo to 4.8% per year 
for aspirin (HR 0.74; 95% CI 0.52–1.05) together with a nonsignificant increase in the 
risk of major haemorrhage from 0.6% to 1.1% per year (HR 1.73; 95% CI 0.72–4.11) [76]. 
Although these results suggest that aspirin may reduce the VTE recurrence risk, it is clear 
that it does not provide reliable protection against recurrent VTE in comparison with 
long-term oral anticoagulation. Therefore, long-term secondary prevention with aspirin 
is not recommended by current treatment guidelines, although it may be considered as 
an alternative for extended treatment in patients who are unable to tolerate any type of 
oral anticoagulants [77].
The effects of dabigatran, apixaban and rivaroxaban on long-term secondary preven-
tion after initial management for VTE (either DVT or PE) have also been investigated. Only 
dabigatran has been compared to warfarin and was shown to be noninferior (HR 1.44; 
95% CI 0.78–2.64) for recurrent VTE with a nonsignificantly lower risk of major haem-
orrhage (HR 0.52; 95% CI 0.52–1.02) [78]. As expected, dabigatran was more effective 
than placebo (HR 0.08; 95% CI 0.02–0.25), whilst major haemorrhage occurred in only 
two of 684 patients (0.3%) versus none of 659 patients receiving placebo. Two doses of 
apixaban (2.5 and 5 mg twice daily) were compared to placebo for a period of 12 months 
after initial treatment [79]. These doses of apixaban were shown to be similarly effective 
with a recurrence risk of 1.7% in both groups compared to 8.8% in patients who re-
ceived placebo. Remarkably, both doses were not associated with a higher risk of major 
haemorrhage compared to placebo. Finally, rivaroxaban for an additional 6–12 months 
after initial treatment demonstrated superior efficacy compared to placebo (8/602 vs. 
42/594; HR 0.18; 95%CI 0.09-0.39) for recurrent VTE, whilst nonfatal major haemorrhage 
occurred in only four of 598 patients (0.7%) treated with rivaroxaban [80]. Although all 
studies were performed in highly selected groups of patients who completed initial 
therapy without complications and only dabigatran has been compared to VKA therapy, 
these findings together with the results from initial management studies suggest that 
NOACs are as effective as VKA therapy and have a lower risk of major haemorrhage than 
long-term VKA therapy. Therefore, the introduction of NOACs is likely to change the 
risk–benefit ratio of long-term anticoagulant therapy and may influence clinicians to 
extend the duration of treatment more often in selected patient groups.
CONCLUSIONS
The standardized diagnostic management of clinically suspected acute PE allows the 
exclusion of PE without imaging tests in approximately 30% of patients; this proportion 
can be further increased using the recently validated age-adjusted D-dimer threshold. 
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Future studies should focus on further limiting the number of required imaging tests 
as well as improving the implementation of standardized management in daily clinical 
practice, as nonadherence decreases safety and efficiency.
PE management is becoming increasingly more stratified by developing criteria to 
select patients who can be safely treated in the outpatient setting, and thrombolytic 
therapy should be reserved for patients with haemodynamic instability or those with 
haemodynamic deterioration during the first days after the diagnosis of PE. The intro-
duction of NOACs simplifies anticoagulant therapy and the associated risk of major 
haemorrhage seems to be lower than that of VKA therapy. Nevertheless, clinical predic-
tion rules to estimate the risk of anticoagulant therapy-associated major haemorrhage 
as well as clinical prediction rules to estimate the risk of recurrent VTE are required to 
come to a more tailored long-term management of PE.
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The performance of different diagnostic strategies for pulmonary embolism (PE) in 
patient subgroups is unclear.
Purpose
To evaluate and compare the efficiency and safety of the Wells rule with fixed or age-
adjusted D-dimer testing overall and in inpatients and persons with cancer, chronic 
obstructive pulmonary disease, previous venous thromboembolism, delayed presenta-
tion, and age 75 years or older.
Data Sources
MEDLINE and EMBASE from 1 January 1988 to 13 February 2016.
Study Selection
6 prospective studies in which the diagnostic management of PE was guided by the 
dichotomized Wells rule and quantitative D-dimer testing.
Data Extraction
Individual data of 7268 patients; risk of bias assessed by 2 investigators with the QUA-
DAS-2 (Quality Assessment of Diagnostic Accuracy Studies 2) tool.
Data Synthesis
The proportion of patients in whom imaging could be withheld based on a “PE-unlikely” 
Wells score and a negative D-dimer test result (efficiency) was estimated using fixed 
(≤500 μg/L) and age-adjusted (age × 10 μg/L in patients aged >50 years) D-dimer 
thresholds; their 3-month incidence of symptomatic venous thromboembolism (failure 
rate) was also estimated. Overall, efficiency increased from 28% to 33% when the age-
adjusted (instead of the fixed) D-dimer threshold was applied. This increase was more 
prominent in elderly patients (12%) but less so in inpatients (2.6%). The failure rate of 
age-adjusted D-dimer testing was less than 3% in all examined subgroups.
Limitation
Post hoc analysis, between-study differences in patient characteristics, use of various 
D-dimer assays, and limited statistical power to assess failure rate.
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Conclusion
Age-adjusted D-dimer testing is associated with a 5% absolute increase in the propor-
tion of patients with suspected PE in whom imaging can be safely withheld compared 
with fixed D-dimer testing. This strategy seems safe across different high-risk subgroups, 




The diagnosis of pulmonary embolism (PE) cannot be based on clinical features alone 
because the signs and symptoms of PE are not specific [1]. Objective imaging tests, in-
cluding computed tomography pulmonary angiography (CTPA), are therefore warranted 
to confirm or refute the presence of PE [2]. Only 15% to 25% of presenting patients have 
PE [3], so CTPA is not an appropriate first-line test because of radiation exposure, costs, 
and risk for contrast-induced nephropathy.
To guide decisions about who should be referred for imaging, various diagnostic 
algorithms have been developed over the past 2 decades. They aim to identify patients 
at low risk for PE in whom imaging and anticoagulant treatment can be safely withheld. 
One frequently used algorithm consists of the sequential application of the dichoto-
mized Wells rule [4], which estimates the clinical probability of PE, and D-dimer testing. 
Pulmonary embolism can be considered ruled out in patients with a Wells score of 4 or 
less and a negative D-dimer test result (conventionally ≤500 μg/L) [5]. This combina-
tion is present in approximately 30% to 40% of those with suspected PE [3]. The latter 
proportion is commonly called the “efficiency” of the algorithm. The proportion of these 
patients with symptomatic venous thromboembolism (VTE) during 3-month follow-up 
(the failure rate) is less than 1% [3]. It has recently been shown that the efficiency can 
be safely increased by applying an age-adjusted D-dimer positivity threshold, which is 
defined as the age of patients multiplied by 10 μg/L in those older than 50 years [6].
Although many studies have validated the clinical utility and safety of the dichoto-
mized Wells rule combined with D-dimer testing in excluding PE, an individual-patient 
data (IPD) meta-analysis can address important questions with greater precision and 
power. First, what is the overall efficiency and safety of the Wells rule and fixed D-dimer 
testing? Second, what is the performance of this strategy in clinically important sub-
groups? Third and most important, how do the efficiency and safety of age-adjusted 
D-dimer testing compare with fixed D-dimer testing? 
To answer these questions, we did a systematic review and IPD meta-analysis combin-
ing patient-level data from 6 large, prospective outcome studies in which diagnostic 
management of clinically suspected PE had been guided by the Wells rule and D-dimer 
testing. Using the fixed and age-adjusted D-dimer thresholds, we estimated the effi-
ciency and failure rate of this diagnostic algorithm overall; in inpatients; and in persons 
with cancer, chronic obstructive pulmonary disease (COPD), age 75 years or older, previ-
ous VTE, and delayed presentation.
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METHODS
We developed a protocol (Appendix, all appendixes are available at www.annals.org) 
and followed the guidance of the PRISMA-IPD (Preferred Reporting Items for Systematic 
reviews and Meta-Analyses of individual participant data) Statement [7].
Data Sources and Searches
We searched MEDLINE and EMBASE from 1 January 1998 (the year in which the Wells 
score was introduced) [8] to 13 February 2016. The search was based on a previously 
published search strategy [3], which included terms for “pulmonary embolism” and 
“D-dimer”, and an adapted search filter for diagnostic and prognostic studies [9]. We 
restricted the search to original studies in adults. No language restrictions were applied. 
The full search strategy is provided in Appendix Table 1. Two authors (N.E. and T.H.) inde-
pendently screened the titles and abstracts of the identified articles and independently 
assessed the full-text articles for eligibility. Conflicts were resolved by discussion.
Study Selection
Eligible studies included those that had prospectively enrolled, consecutive, hemody-
namically stable adults presenting in a secondary care setting (emergency department 
or inpatient ward) with signs and symptoms suggestive of acute PE. At the individual 
level, the clinical probability of PE had to be assessed by the Wells rule and followed by 
quantitative D-dimer testing in patients with a Wells score of 4 or less (indicating “PE 
unlikely”). According to the study protocol, patients with a PE-unlikely Wells score and 
a negative D-dimer test result were to be managed without imaging and anticoagulant 
therapy but prospectively followed for 3 months to document the occurrence of VTE 
(Appendix Figure). By applying these criteria, we aimed to identify all studies that pro-
spectively evaluated the current diagnostic management of patients with suspected PE 
in a secondary care setting.
Data Extraction and Quality Assessment
Authors of studies fulfilling the inclusion criteria were invited to provide IPD, and all agreed. 
We sought study-level information on D-dimer assays used; imaging tests done to confirm PE; 
and definitions of the outcomes, regardless of whether outcome measures were adjudicated 
by an independent committee. Patient-level data collected at baseline included information 
on demographics, risk factors for VTE, Wells score items, D-dimer levels (converted to μg/L), 
and results of imaging tests. We also collected follow-up data about anticoagulant treatment 
for reasons other than VTE, symptomatic VTE, mortality, or loss to follow-up. We followed the 
subgroup definitions used in each study without any adjustments and ascertained these 
definitions by the case report forms of the studies and variable labels in the study databases. 
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Two authors who were not involved in the original studies independently assessed each 
study for potential sources of bias and applicability concerns using the QUADAS-2 (Quality 
Assessment of Diagnostic Accuracy Studies 2) tool [10].
Data Synthesis and Analysis
Our analysis focused on the efficiency and failure rate of the diagnostic strategy. Ef-
ficiency was defined as the number of patients with a Wells score of 4 or less and a 
negative D-dimer test result relative to the total number of patients. We evaluated the 
efficiency of 2 D-dimer positivity thresholds: the conventional, fixed threshold of 500 
μg/L and an age-adjusted threshold, which was defined as the age of patients multiplied 
by 10 μg/L in patients older than 50 years. For example, the age-adjusted strategy in 
a patient aged 75 years would lead to a D-dimer positivity threshold of 750 μg/L. To 
evaluate age-adjusted D-dimer testing in our study, we reclassified patients enrolled 
in studies that evaluated fixed D-dimer testing according to the age-adjusted D-dimer 
threshold post hoc.
The failure rate was defined as the proportion of patients with symptomatic deep 
venous thrombosis, nonfatal PE, or fatal PE during 3-month follow-up or objectively 
confirmed PE at baseline that was previously ruled out on the basis of a Wells score of 4 
or less and a negative D-dimer test result. Death was considered to be caused by PE if it 
was confirmed by autopsy, if an imaging test for PE yielded positive results just before 
death, or in the case of sudden death due to unknown reasons.
The efficiency and failure rates were calculated overall and in clinically important 
high-risk subgroups, including inpatients and patients with cancer, COPD, age 51 to 74 
years, age 75 years or older, previous VTE, and symptoms lasting more than 7 days.
Statistical Analysis
To avoid bias associated with excluding missing data [11], we used multiple imputation 
separately within each study (10 times). The proportion of missing values is reported in 
Appendix Table 2. Results across the multiply imputed data sets were combined by using 
the Rubin rule [12] (Appendix).
A single-stage meta-analytic approach was used [13, 14] to analyze the efficiency and 
failure rates. The overall efficiency (the proportion of patients in whom imaging could 
be withheld) was estimated using a multilevel logistic regression model (also called a 
generalized linear mixed-effects model), with the combination of a Wells score of 4 or less 
and a negative D-dimer test result as the outcome variable. To account for the clustering 
of observations within studies, we specified a random effect for the intercept. For the 
analysis in subgroups, we used a full random-effects model [13] by adding the subgroup 
indicator as a covariate and allowing a study-specific random effect. From these models, 
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we calculated the marginal probabilities (with 95% CIs) of having a PE-unlikely Wells score 
and a negative D-dimer test result, both overall and in the different subgroups (Appendix).
Differences in efficiency between subgroups were tested by using the Wald test statistic 
with the significance level set at 0.05. The absolute difference in the efficiency of the fixed 
and age-adjusted D-dimer testing strategies was calculated by subtracting the point 
estimates of the marginal probabilities from the 2 models. The 95% CIs around these 
estimates were obtained by repeating the analyses in 500 bootstrap samples (Appendix).
Using similar methods, we estimated the failure rate: the proportion of patients with 
symptomatic VTE during 3-month follow-up in whom the Wells score and D-dimer 
test result had ruled out PE at baseline. The outcome variable in this multilevel logistic 
regression model was a final diagnosis of VTE. The analysis was restricted to patients 
with a Wells score of 4 or less and a negative D-dimer test result. Patients receiving 
anticoagulant treatment for reasons other than VTE and those lost to follow-up were 
excluded from this analysis. Failure rates in the subgroups were estimated using full 
random-effects models, with the subgroup indicator as the covariate. We calculated 
estimates of the marginal probabilities of the failure rates with 95% CIs.
Heterogeneity among the studies was assessed by calculating 90% prediction intervals 
around the estimates for the efficiency and failure rate based on the random intercept 
variance [13]. Because the proportion of missing baseline variables was higher in the RE-
PEAD study [15] than in the other studies (from 1% for duration of symptoms to 21% for 
cancer) (Appendix Table 2), we did a sensitivity analysis in which REPEAD was excluded.
To better understand and illustrate the association between age and the efficiency and 
associated failure rate for the fixed and age-adjusted D-dimer thresholds, we extended 
the base models by adding age as a continuous variable. Age was then plotted against 
the predicted proportions from these models. This analysis was restricted to patients 
older than 50 years because the age-adjusted D-dimer threshold, by definition, applies 
only to them.
Because patients with clinically suspected PE often have more than 1 risk factor for 
PE, the conditional effect of the potential predictors of a difference in efficiency was 
also evaluated with a multilevel, multivariable, logistic regression model in which all 
predefined subgroup indicators were included as covariates.
All statistical analyses were performed in R, version 3.2.2 (R Foundation for Statistical 
Computing; www.R-project.org), by using the mice package (version 2.22) for multiple 
imputation, the lme4 package (version 1.1-10) for multilevel logistic regression model-
ing, and the boot package (version 1.3-18) for bootstrapping. Specifications of all models 




Our search identifi ed 1099 articles, 59 of which were assessed for eligibility (Figure 1). Ex-
clusion criteria are provided in Appendix Table 4. Six studies fulfi lled the eligibility criteria 
[5, 6, 15–18], and IPD for all 7268 patients were obtained.
Basic characteristics and outcomes of the 6 included studies are summarized in Table 
1. These studies used a diagnostic strategy consisting of the Wells rule and subsequent 
D-dimer testing to guide the management of patients with suspected PE. Three studies 
enrolled both inpatients and outpatients [5, 15, 16].
Figure 1.  Systematic search and study selection.
Note: IPD: individual-patient data; PE: pulmonary embolism.
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Subgroup definitions were homogeneous across the studies. The definitions of cancer 
and previous VTE followed those as per the Wells score in all studies. Chronic obstruc-
tive pulmonary disease was defined as disease requiring treatment in 4 of 5 studies 
that captured this variable and as disease with or without treatment in one. The fixed 
D-dimer threshold of 500 μg/L was applied in 5 studies, whereas the age-adjusted D-
dimer threshold was used in one. D-Dimer testing was done using the locally available 
method: a quantitative latex-based assay or an enzyme-linked immunosorbent assay. In 
each study, imaging and anticoagulant therapy were withheld in patients with a Wells 
score of 4 or less and a negative D-dimer test result. They were followed prospectively 
for 3 months by telephone contact or a scheduled outpatient visit.
We identified potential sources of bias. Suspected venous thromboembolic events 
during 3-month follow-up were not centrally adjudicated in 2 studies [17, 18]. Quantita-
tive D-dimer testing was not done in 104 of 5202 patients (2.0%) with a Wells score of 4 
or less, and 11 patients (0.4%) in whom imaging was withheld at baseline were lost to 
follow-up. In all studies, the risk of bias with respect to patient selection, Wells scores, 
and D-dimer test results was judged to be low. Of note, concern for limited applicability 
in all domains was low (complete QUADAS-2 results are provided in the appendix).
Baseline patient characteristics are summarized in Appendix Table 5. The mean age 
was 56 years; 42% were men. The proportion of missing values for the baseline char-
acteristics and Wells score items ranged from 0% to 6%. Among patients across the 
studies with a PE-unlikely Wells score, 0% to 10% had missing quantitative D-dimer test 
results. When we checked the IPD, no other concerns were identified. At baseline, PE was 
diagnosed in 1527 patients (21%).
The overall efficiency of the diagnostic strategy when the fixed D-dimer threshold of 
500 μg/L was applied was 28% (95% CI, 21% to 37%) (Table 2). The summary estimate of 
the failure rate was 0.65% (CI, 0.38% to 1.11%) (Table 3), without any fatal events, among 
patients with a PE-unlikely Wells score and a negative D-dimer test result (without imag-
ing). Five percent of patients with a PE-unlikely Wells score had D-dimer levels between 
500 μg/L and the age-adjusted threshold. This resulted in an overall efficiency of 33% 
(CI, 25% to 42%) when the age-adjusted D-dimer threshold was applied. The failure rate 
among patients in whom imaging was withheld based on a Wells score of 4 or less and 
a D-dimer level below the age-adjusted threshold was 0.94% (CI, 0.58% to 1.5%), with 1 
fatal event.
The efficiency of the diagnostic algorithms in the prespecified subgroups of patients is 
presented in Table 2. When the fixed D-dimer threshold is applied, the efficiency varied 
from 7% in inpatients to 25% in persons having symptoms for more than 7 days. The effi-
ciency of age-adjusted D-dimer testing varied from 10% in inpatients to 32% in persons 
with COPD. Compared with fixed D-dimer testing, age-adjusted testing increased the 
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51-74 years (n=3,398)
≤ 50 years (n=2,661)
Yes (n=1,116)
No (n=6,143)
> 7 days (n=1,322)
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The failure rate of the diagnostic algorithms was greatest in patients with active cancer 
(2.6% [CI, 0.57% to 11.0%] when the fixed D-dimer threshold is applied) and those aged 
75 years or older (2.1% [CI, 0.71% to 5.9%] when the age-adjusted D-dimer threshold 
is applied) (Table 3). However, none of these subgroup differences reached statistical 
significance.
In the sensitivity analysis in which the REPEAD study was excluded because of a rela-
tively higher proportion of missing baseline variables, the point estimates for efficiency 
were slightly higher than in the main analysis owing to the high PE prevalence and low 
efficiency in REPEAD (Appendix Table 6). The sensitivity analysis yielded similar results to 
the main analysis with respect to the failure rates (Appendix Table 7). In the exploratory 
analysis, the absolute difference in efficiency between the age-adjusted and fixed D-
dimer thresholds increased with age from approximately 4% in patients aged 60 years to 
11% in patients aged 80 years, whereas the difference in failure rate increased from 0.4% 
in patients aged 60 years to 1.3% in patients aged 80 years (Figure 2).
In the multivariable analysis, all risk factors, except COPD status, were significantly as-
sociated with a lower chance of ruling out PE based on the Wells rule and fixed D-dimer 
Figure 2.  Association between age and the efficiency and failure rate of the Wells rule and D-dimer testing 
using the fixed or age-adjusted thresholds.
The failure rate is defined as the probability of VTE in patients with an Wells score <=4 
combined with a negative D-dimer test result. 
Patients who received anticoagulants for other reasons than VTE and those lost to follow-up 
were excluded from this analysis. The failure rate could not be estimated in the age 
subgroups and in inpatients when applying the fixed D-dimer threshold due to zero events.
Figure 2: Association between age and the efficiency and failure rate of the Wells 
rule and D-dimer testing using the fixed or age-adjusted thresholds. 
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testing (Appendix Table 8). Strong predictors of limited efficiency were age 75 years or 
older (adjusted odds ratio [OR], 0.12), inpatient status (adjusted OR, 0.21), and active 
cancer (adjusted OR, 0.30). In these 3 subgroups, the adjusted ORs for a Wells score of 4 
or less and a D-dimer level below the age-adjusted threshold were 0.33, 0.24, and 0.34, 
respectively.
DISCUSSION
This large IPD meta-analysis of 7268 patients with clinically suspected PE shows that the 
proportion of those managed without imaging and who have no need for anticoagula-
tion can be safely increased from 28% to 33% by applying the age-adjusted D-dimer 
threshold in those with a PE-unlikely Wells score. This absolute increase is more promi-
nent in patients with COPD and elderly patients presenting with suspected PE but is less 
prominent in inpatients or patients with cancer, previous VTE, or delayed presentation.
A strength of our study is that it includes IPD from many persons with clinically sus-
pected PE, which enabled robust subgroup analysis. In addition, our results pertain to 
the current evidence-based standards of the diagnostic management of PE [2, 19] be-
cause all patients were managed prospectively according to a widely used, uniform, and 
well-validated algorithm. This homogeneity in design of the included studies increased 
the precision of the efficiency and safety outcomes.
Our results are based in part on post-hoc analyses. The age-adjusted D-dimer thresh-
old had been prospectively evaluated in only one study [6], whereas the efficiency 
and failure rate associated with this threshold were recalculated for the other studies. 
Therefore, we have failure rates defined from both imaging and follow-up that are not 
fully interchangeable. As a consequence, we may have overestimated the failure rate 
because most patients with a Wells score of 4 or less and a D-dimer level between the 
fixed and age-adjusted thresholds had imaging, which may have led to the detection of 
clots with less clinical significance [20].
We observed considerable between-study heterogeneity as illustrated by the rela-
tively wide prediction intervals around the estimates. Because the included studies had 
a similar design, this heterogeneity was most likely due to differences in the patient 
population and, as a consequence, between-study differences in PE prevalence.
On average, 22% of the patients in our analysis had confirmed PE, which is substantially 
higher than proportions reported in most North American studies [21–23]. Therefore, 
the efficiency will likely be greater in settings with a lower PE prevalence. We restricted 
inclusion to studies conducted in secondary care; therefore, caution is warranted when 
extrapolating our results to, for example, primary care.
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Various D-dimer assays were used in the studies. Although these widely available 
quantitative latex-based and enzyme-linked immunosorbent assays have a high sen-
sitivity for diagnosing PE, their specificity may be somewhat different [24]. At present, 
evidence on the performance of the age-adjusted threshold with each assay is lacking 
[25]. Because patient-level information on the D-dimer testing method was not avail-
able for most studies, we could not compare the performance of the 2 assays. Yet we 
believe that this use of different D-dimer assays reflects clinical practice.
Overall, our findings are in line with previous studies that evaluated the performance 
of the age-adjusted D-dimer threshold. In a retrospective analysis by Douma and col-
leagues [26], the age-adjusted D-dimer threshold was associated with a 5% to 6% abso-
lute increase in efficiency in the 3 cohort studies not included with the present analysis. 
Similarly, in a post hoc analysis of 3 cohort studies, Penaloza and colleagues [27] found 
a 4.6% absolute increase in the proportion of patients with a low or moderate pretest 
probability and a negative D-dimer test result when the age-adjusted threshold was 
applied. The 5% overall increase in efficiency in our study was not offset by an increase in 
the failure rate. Hence, when the age-adjusted (instead of the fixed) D-dimer threshold 
is used in clinical practice, it is expected that PE can be safely ruled out in an additional 
1 of 20 patients.
This meta-analysis supports the findings of previous evaluations of the performance 
of clinical decision rules in combination with D-dimer testing in subgroups of patients 
with clinically suspected PE. We now know that such a diagnostic algorithm can safely 
rule out PE in patients with cancer [28, 29], COPD [30], age 76 years or older [30, 31], pre-
vious VTE [32, 33], and delayed presentation [34] as well as inpatients [31, 35]. However, 
the algorithm is less efficient in these subgroups than in the general population present-
ing with suspected PE. In most of these subgroups, the efficiency can be increased to 
more than 10% by applying the age-adjusted D-dimer threshold, which corresponds to 
a number needed to test of fewer than 10 patients to withhold 1 CTPA. For inpatients 
only, the efficiency of the diagnostic algorithm remains poor (10%). This is supported by 
the multivariate analysis, which indicated that inpatient status is the strongest predictor 
of a low efficiency when the age-adjusted D-dimer threshold is applied.
It is widely accepted that a diagnostic strategy for PE is considered safe if a failure rate 
of 3% can be excluded based on the upper limit of the 95% CI because even pulmonary 
angiography cannot detect all cases [36]. In our analysis, the point estimate of the failure 
rate was less than 3% across all subgroups and we found no evidence for a difference in 
failure rate between the subgroups. The statistical power was limited because of the low 
number of events, which was also reflected by the wide CIs.
On the basis of this analysis, we recommend using age-adjusted (rather than fixed) 
D-dimer testing with the Wells rule because it increases efficiency without jeopardizing 
safety in all studied subgroups. The improved efficiency is most pronounced in patients 
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with COPD and elderly patients and is considerable in those with cancer, previous VTE, 
or a delayed presentation. Although age-adjusted D-dimer testing increases the effi-
ciency among inpatients from 7% to 10%, its clinical utility in this subgroup remains 
limited given the corresponding number needed to test of 10 patients to withhold 1 
CTPA. Whether to rely on the Wells rule and D-dimer testing in these patients becomes 
a matter of judgment. It may still be valuable to avoid the risk for contrast-induced 
nephropathy in ill patients who often already have multiple comorbidities; however, 
based on the clinical presentation, physicians may decide to proceed to imaging directly 
without calculating a Wells score or ordering D-dimer testing.
Among patients with clinically suspected PE, the Wells rule combined with age-
adjusted D-dimer testing is associated with a 5% absolute increase in the proportion 
of those in whom imaging can be safely withheld compared with fixed D-dimer testing. 
This diagnostic approach seems to be safe across various subgroups, but its clinical util-
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A normal computed tomography pulmonary angiography (CTPA) remains a contro-
versial criterion for ruling out acute pulmonary embolism (PE) in patients with a likely 
clinical probability. We set out to determine the risk of VTE and fatal PE after a normal 
CTPA in this patient category and compare these risks to those after a normal pulmonary 
angiogram of 1.7% (95%CI 1.0-2.7%) and 0.3% (95%CI 0.02-0.7%).
Methods
A patient-level meta-analysis from 4 prospective diagnostic management studies that 
sequentially applied the Wells rule, D-dimer tests and CTPA to consecutive patients with 
clinically suspected acute PE. The primary outcome was the 3-month VTE incidence after 
a normal CTPA.
Results
A total of 6,148 patients were included with an overall PE prevalence of 24%. The 
3-month VTE incidence in all 4,421 patients in whom PE was excluded at baseline was 
1.2% (95%CI 0.48-2.6) and the risk of fatal PE was 0.11% (95%CI 0.02-0.70). In patients 
with a likely clinical probability the 3-month incidences of VTE and fatal PE were 2.0% 
(95%CI 1.0-4.1%) and 0.48% (95%CI 0.20-1.1%) after a normal CTPA. The 3-month inci-
dence of VTE was 6.3% (95%CI 3.0-12) in patients with a Wells rule >6 points.
Conclusion
This study suggests that a normal CTPA may be considered as a valid diagnostic criterion 
to rule out PE in the majority of patients with a likely clinical probability, although the 
risk of VTE is higher in subgroups such as patients with a Wells rule >6 points for which a 
closer follow-up should be considered.
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INTRODUCTION
Signs and symptoms of pulmonary embolism (PE) are highly variable and non-specific. 
As a result, PE is frequently considered, while in only approximately one fifth of patients 
the diagnosis is confirmed [1-3]. PE can only be demonstrated by an imaging test. This 
test, nowadays, is usually computed tomography pulmonary angiography (CTPA) due to 
several advantages over other imaging tests, i.e. widespread availability, small propor-
tion of inconclusive test results, fast acquisition time and the possibility of establishing 
an alternative diagnosis [4, 5]. Disadvantages of CTPA include radiation exposure, risk of 
contrast-induced nephropathy or allergic reactions, unsuspected findings and increased 
healthcare costs [6, 7].
In order to reduce the need for imaging tests for suspected PE, diagnostic algorithms 
have been developed for patients with suspected PE without shock or hypotension, 
starting with a validated clinical decision rule (CDR) to predict the clinical probability for 
PE, followed by a quantitative D-dimer test and/or a CTPA [8]. In patients with a low, mod-
erate or unlikely clinical probability according to a validated CDR (either the Wells score 
or the revised Geneva score) and a D-dimer concentration ≤500 µg/L or equal or below 
the age-adjusted D-dimer threshold in patients older than 50 years, PE can be safely 
excluded without further imaging tests in approximately one third of all patients [3, 9, 
10]. In the remaining patients with either an unlikely clinical probability in combination 
with an elevated D-dimer concentration or a high or likely clinical probability CTPA is 
indicated [8]. This diagnostic strategy has been demonstrated to be safe with a 3-month 
venous thromboembolism (VTE) incidence of 0.34% (95% confidence interval (95%CI) 
0.036-0.96%) in patients managed without CTPA and 1.2% (95%CI 0.8-1.8) in patients 
in whom PE was ruled out by CTPA [4, 11]. Importantly, it has been demonstrated that 
performing compression ultrasonography (CUS) of the lower extremities after a normal 
CTPA to rule out deep vein thrombosis (DVT) does not further diminish the risk of VTE 
during follow-up [4, 12-14]. Consequently, in daily clinical practice a normal CTPA alone 
is usually considered to be a valid diagnostic criterion to exclude PE [1-3, 15].
However, evidence on the safety of ruling out PE based on a normal CTPA in the subset 
of patients with a likely clinical probability of PE remains controversial. In the single 
post-hoc analysis of the Christopher study that investigated this issue, the 3-month VTE 
incidence after a negative CTPA was 1.7% (9 VTE events in 545 patients; 95%CI 0.9-3.1) in 
patients with a likely clinical probability compared to 0.7% (5 VTE events in 721 patients; 
95%CI 0.3-1.6) in patients with an unlikely clinical probability (p-value for difference = 
0.11) [1, 16]. Due to the limited evidence, in the recent guideline of the European Society 
of Cardiology (ESC) on the diagnosis and management of acute pulmonary embolism 
regarding ruling out PE in patients with a likely clinical probability are somewhat in-
consistent [8]. In this ESC guideline, a class IIa recommendation (level of evidence: B) is 
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included stating that a normal CTPA may safely exclude PE in patients with a likely clini-
cal probability, while in another paragraph a normal CTPA alone is recommended as a 
controversial criterion to rule out PE and further testing should be considered. Notably, 
the guideline does not provide any recommendation on which additional diagnostic 
strategy should be considered in case of a normal CTPA.
In order to address this issue, we evaluated the risk of VTE and fatal PE after a normal 
CTPA in patients with a likely clinical probability of PE by performing a patient-level 
meta-analysis of four large diagnostic management studies.
METHODS
Patients
Patient-level data were obtained from 4 previously published multicentre prospective 
diagnostic management studies of patients with clinically suspected acute PE, i.e. the 
Christopher study, the Prometheus study, the REPEAD study and the ADJUST-PE study 
[1-3, 15]. These studies were performed by our own collaboration network of several 
academic and non-academic hospitals in the Netherlands and had a highly comparable 
design as well as definition and assessment of outcomes. Also, the data of all studies are 
of high quality with nearly complete baseline and follow-up assessment. Study details 
are provided in Appendix A, available at https://th.schattauer.de. In all 4 studies, hemo-
dynamically stable, predominantly outpatients with suspected acute PE were included. 
Exclusion criteria were age <18 years, treatment with therapeutic doses of anticoagulant 
treatment for >24 hours, life expectancy <3 months, pregnancy, a contra-indication for 
CTPA (i.e. allergy to intravenous contrast agents, renal insufficiency) and logistic reasons 
such as unavailability of CTPA, patient too ill to undergo CTPA, geographic inaccessibility 
precluding follow-up. In the Prometheus study, a history of PE was an additional exclu-
sion criterion, and in the REPEAD study only patients with a history of PE were included. 
From the ADJUST-PE study, we only included patients from participating hospitals in the 
Netherlands who were all managed by the Wells score in the present analysis.
In all studies, an identical diagnostic management algorithm was used starting with 
the Wells CDR followed by quantitative D-dimer testing and/or CTPA, depending on the 
result of the Wells score. PE was excluded in case of an unlikely clinical probability (Wells 
score ≤4 points) in combination with a negative D-dimer test result. In the Christopher 
study, the Prometheus study and the REPEAD study a D-dimer threshold of 500 µg/L was 
used, whereas in the ADJUST-PE study the age-adjusted D-dimer threshold was applied, 
calculated by multiplying the patient’s age by 10 in patients 50 years or older. In patients 
with either a likely clinical probability (Wells score >4 points) or a positive D-dimer test 
result, CTPA was performed and they were managed according to the CTPA result. All 
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studies were approved by the institutional review boards of participating hospitals and 
patients provided written informed consent where relevant.
All patients were prospectively followed for 3 months for the occurrence of symp-
tomatic VTE (i.e. PE and/or DVT). Adjudication committees evaluated all episodes of 
suspected VTE and deaths. In case of clinically suspected PE or DVT, objective diagnos-
tic tests were required. In case of death, information was obtained from the hospital 
records. In case of clinically suspected VTE, an objective clinical test was performed 
including CTPA or ventilation-perfusion scintigraphy for suspected PE and compression 
ultrasonography for suspected DVT [9, 8, 17]. Deaths were classified as caused by PE if PE 
was confirmed by autopsy, if PE was demonstrated by objective testing prior to death or 
if PE could not be confidently excluded as a cause of death. Independent adjudication 
committees evaluated and adjudicated all suspected VTE and deaths during follow-up. 
Both objectively confirmed (non-fatal) VTE and deaths caused by PE were included as 
outcome events.
Objectives of present study and statistical analysis
The primary objective of the current analysis was to determine the 3-month incidence 
of objectively diagnosed symptomatic VTE and fatal PE after a normal CTPA in patients 
with a likely clinical probability of acute PE assessed by the Wells score, who were 
not treated with anticoagulant therapy. Secondary objectives were to determine the 
3-month incidence of VTE and fatal PE after exclusion of PE in the overall patient popula-
tion, in the subgroup of patients in whom PE was excluded based on an unlikely clinical 
probability in combination with a negative D-dimer test, and in those with an unlikely 
clinical probability but a positive D-dimer test. For all analyses, only patients in whom PE 
was excluded at baseline, who did not receive anticoagulant treatment, and who were 
not lost to follow-up were included.
In addition, the original 3-level diagnostic algorithm was investigated in a post-hoc 
analysis, in which 3 different clinical probability categories are identified: a low (Wells 
score <2 points), an intermediate (Wells score 2-6 points) and a high clinical probability 
(Wells score >6 points) category [18]. By using this original diagnostic algorithm, PE is 
excluded without imaging test in case of a D-dimer concentration ≤500 µg/L in combina-
tion with a low or moderate clinical probability, while CTPA is indicated in the remaining 
patients. This analysis was performed since the recent ESC guideline considers a normal 
CTPA alone as a controversial criterion also in patients with a high clinical probability 
according to the 3-level diagnostic algorithm. Finally, we explored which patient char-
acteristics at presentation were associated with the occurrence of VTE during 3 months 
of follow-up after PE was ruled out at baseline.
Patient characteristics and outcomes are reported for the total cohort and for the 
different clinical probability categories separately. For the purpose of this study and 
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to ensure comparability, we post-hoc applied the conventional D-dimer threshold of 
≤500 µg/L to the patients included in the ADJUST-PE study, instead of the age-adjusted 
D-dimer threshold.
To estimate the 3-month VTE incidence after a normal CTPA at baseline in patients 
with a likely clinical probability, we used multilevel logistic regression modelling with a 
VTE diagnosis during follow-up as the outcome and no covariates. We specified a ran-
dom effect for the intercept to account for the clustering of patients within studies. To 
express the 3-month VTE incidence, we estimated from this model the mean predicted 
3-month probability of VTE during follow-up for patient with a likely clinical probability 
and a normal CTPA at baseline. Using a similar approach, we estimated the mean pre-
dicted 3-month incidence of VTE and fatal PE for the different management categories 
(i.e. patients with an unlikely clinical probability and a negative D-dimer test result, 
those with an unlikely clinical probability and an increased D-dimer but a normal CTPA, 
and the different management categories of the original 3-level diagnostic algorithm). 
D-dimer testing was not performed in a substantial proportion of patients with a Wells 
score of 4.5-6 points, because this test was not required by the original study protocols. 
We used multiple imputation to replace missing values within each study, 10 times and 
estimates were pooled across the imputed datasets using Rubin’s rule [19]. Absolute 
numbers provided were derived from one of the imputed datasets.
The 3-month VTE incidence in the different management categories was compared to 
the 3-month VTE incidence of 1.7% (95%CI 1.0-2.7) and the incidence of fatal PE of 0.3% 
(95%CI 0.02-0.7) reported after a normal pulmonary angiography, traditionally the gold 
standard in PE diagnosis [20]. Consequently, we consider a strategy to be safe in case of 
a 3-month incidence of VTE and fatal PE that are equal or below these outcomes after a 
normal pulmonary angiography. In order to determine whether patient characteristics 
were associated with the occurrence of VTE during follow-up after a normal CTPA in 
patients with a likely clinical probability, odds ratios (OR) with 95%CI were calculated 
comparing patients without VTE during follow-up to those who developed VTE during 
follow-up using logistic regression analyses. An association was considered to be statis-
tically significant in case of a P-value below 0.05. All statistical analyses were performed 




The four studies available for the present analysis concerned a total of 7,975 patients. 
From the REPEAD study, 234 patients were overlapping with the Christopher or Pro-
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metheus study and therefore excluded from the present analysis. From the ADJUST-PE 
study, we included only the 1,753 patients from Dutch hospitals in whom the Wells PE 
CDR was used, leaving 6,148 patients with clinically suspected acute PE available for 
the present analysis (Table 1). Baseline characteristics for the individual studies are 
provided in Appendix B (available at https://th.schattauer.de). The PE prevalence at 
baseline varied from 19% to 39% between the four studies and the corresponding mean 
predicted PE prevalence at baseline was 24% (95%CI 18-32). In 267 patients (4.3%) CTPA 
was inconclusive or not performed although indicated; CTPA was not performed in 187 
patients in the ADJUST-PE study as the result of a D-dimer concentration between the 
conventional and the age-adjusted D-dimer threshold; 147 patients (2.4%) received 
anticoagulant treatment for reasons other than VTE and follow-up of 6 patients (0.1%) 
was incomplete, leaving 4,421 patients available for the analysis (Figure 1). The 3-month 
VTE incidence in all patients in whom PE was excluded at baseline was 1.2% (42 events 
in 4421 patients; 95%CI 0.48-2.6) and the 3-month incidence of fatal PE was 0.11% (8 
events in 4421 patients; 95%CI 0.02-0.70).










Mean age (SD) 57 (17) 56 (18) 58 (17)
Male sex 2581 (42) 1780 (42) 801 (42)
COPD 742 (12) 524 (12) 218 (12)
Heart failure 447 (7.3) 313 (7.4) 134 (7.1) 
Estrogen use 576 (9.4) 424 (10) 152 (8.0)
Inpatient 804 (13) 393 (9.2) 411 (22)
Duration of complaints ≥7 days 1523 (25) 1026 (25) 461 (24)
Wells items
Clinical signs of DVT 262 (4.3) 28 (0.7) 234 (12)
Alternative diagnosis less likely than PE 3342 (54) 1556 (37) 1786 (94)
Heart rate >100 bpm 1472 (24) 615 (14) 857 (45)
Surgery or immobilization <4 weeks 1158 (19) 381 (9.0) 777 (41)
History of VTE 993 (16) 387 (9.1) 606 (32)
Hemoptysis 301 (4.9) 187 (4.4) 114 (6.0)
Active cancer 885 (14) 462 (11) 423 (22)
PE at baseline 1307 (21) 551 (13) 756 (40)
Note: PE: pulmonary embolism; SD standard deviation; COPD: chronic obstructive pulmonary disease; DVT: 
deep vein thrombosis; bpm: beats per minute; n: number, VTE: venous thromboembolism.
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Incidence of VTE and fatal PE in the different management categories
A total of 4,254 patients (69%) had an unlikely clinical probability and 1,894 patients 
(31%) a likely clinical probability. The baseline PE prevalences in these groups were 
13% and 40% (Table 1), respectively. Of the 4,254 patients with an unlikely clinical 
probability, 1,586 patients (37%) had a D-dimer concentration ≤500 µg/L and could be 
managed without CTPA. In patients managed without CTPA, the 3-month VTE incidence 
was 0.71% (7 events in 1583 patients; 95%CI 0.40-1.3) and no fatal PE occurred in these 
patients (Table 2). In the remaining 2,668 patients with an unlikely clinical probability 
but an increased D-dimer and a normal CTPA, the 3-month incidence of VTE was 0.85% 
(14 events in 1792 patients; 95%CI 0.36-2.0) and of fatal PE 0.12% (3 events in 1792 
patients; 95%CI 0.01-1.4).
The 3-month VTE incidence after a normal CTPA in patients with a likely clinical prob-
ability varied from 0.5% to 5.8% across the individual studies, for an overall 3-month VTE 
incidence of 2.0% (21 events in 1046 patients; 95%CI 1.0-4.1; Figure 2A), and a 3-month 
incidence of fatal PE of 0.48% (5 events in 1046 patients; 95%CI 0.20-1.1; Figure 2B). Of 
the 21 patients with VTE during follow-up, 9 had active cancer (47%) while only 241 of 
the 1,024 (24%) without VTE during follow-up had active cancer (OR 2.6; 95%CI 1.1-6.3). 
Also, patients with VTE during follow-up more frequently had had signs and symptoms 
of DVT at initial presentation: 5 of the 21 patients with VTE during follow-up (24%) ver-
sus 81 of the 1,025 patients without VTE during follow-up (7.9%) (OR 4.1; 95%CI 1.4-12) 
(Table 3). Three of the 5 patients with clinical signs of DVT at baseline and VTE during 
follow-up underwent compression ultrasonography of the lower extremities at baseline, 
of which 2 were negative for DVT and 1 demonstrated DVT. The latter patient was adju-
Figure 1.  Flowchart patient selection.igure 1: Flowchar  pati nt selection
Note: PE: pulmonary embolism; CDR: clinical decision rule; CTPA: computed 
tomography pulmonary angiography. 
22
Note: PE: pulmonary embolism; CDR: clinical decision rule; CTPA: computed tomography pulmonary an-
giography.
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dicated as a failure of the algorithm. Of two other patients with clinical signs of DVT at 
baseline information on whether CUS had been performed could not be retrieved.
Of the 21 patients with VTE during follow-up, 13 patients were diagnosed with PE 
(±DVT) and 8 patients with DVT. Regarding the time between initial presentation and 
VTE during follow-up, 9 (4 with PE, 5 with DVT) were diagnosed within 1 month after 
presentation, 6 (4 with PE and 2 with DVT) were diagnosed between 1 and 2 months 
after presentation and 6 (5 with PE and 1 with DVT) were diagnosed more than 2 months 
after presentation. Of the 12 patients with VTE more than 1 month after initial presenta-
tion, 8 patients (67%) had active cancer and 9 were diagnosed with PE (±DVT).
The 3-level diagnostic algorithm
When the 3-level diagnostic algorithm would have been applied, 2,314 patients (38%) 
would have been categorized in the low clinical probability category, 3,538 patients 
(58%) in the moderate clinical probability and 296 patients (4.8%) in the high clinical 
probability category, with PE baseline prevalences of 7.9%, 27% and 56% respectively. 
Baseline characteristics for the different subgroups are available in Appendix C (https://
th.schattauer.de).
The 3-month VTE risk in patients managed without CTPA based on a low clinical prob-
ability and a D-dimer test ≤500 µg/L was 0.44% (3 events in 965 patients; 95%CI 0.17-1.2) 
and no fatal PE occurred among these patients. In patients with a low clinical probability 
and a D-dimer concentration >500 µg/L the 3-month VTE risk was 0.54% (5 events in 
920 patients; 95%CI 0.23-1.3) and the 3-month risk of fatal PE was 0.11% (1 events in 
920 patients; 95%CI 0.02-0.76) after a negative CTPA. In patients with an intermediate 
clinical probability, the 3-month VTE risk was 2.8% (18 events in 784 patients; 95%CI 
1.7-4.7) after a D-dimer concentration ≤500 µg/L and 1.2% (21 events in 1645 patients; 
95%CI 0.26-5.2) after a D-dimer concentration >500 µg/L and a negative CTPA. The 
corresponding 3-month risks of fatal PE were 0.29% (1 events in 784 patients; 95%CI 
Table 2.  The 3-month risk of VTE (A) and fatal PE (B) after PE was ruled out at baseline.
A: The 3-month risk of VTE B: The 3-month risk of fatal PE
Diagnostic criterion
3-month risk of VTE
%, (95%CI)
Diagnostic criterion
3-month risk of fatal PE
%, (95%CI)
Clinical probability Unlikely Likely Clinical probability Unlikely Likely
Wells score ≤4 >4 Wells score ≤4 >4
Normal D-dimer 
(Threshold ≤500 µg/L) 
0.71 
(0.40-1.3)

















0.07-1.1) and 0.29% (5 events in 1645 patients; 95%CI 0.09-0.92) respectively. In patients 
with a high clinical probability, the 3-month VTE risk after negative CTPA was 6.3% (7 
events in 111 patients; 95%CI 3.0-12.6) and a 3-month risk of fatal PE was 0.90% (1 event 
in 111 patients; 95%CI 0.13-6.1).
DISCUSSION
The key findings of our study are the 3-month incidence of VTE of 2.0% and the risk 
of fatal PE of 0.48% after a normal CTPA as single imaging test in patients with a likely 
clinical probability of PE according to the Wells rule. In order to determine whether these 
Figure 2.  The 3-month risk of (A) VTE and fatal PE (B) after a normal CTPA in patients with a likely clinical 
probability.
A: The 3-month risk of VTE
B: The 3-month risk of fatal PE
Note: VTE: venous thromboembolism; PE: pulmonary embolism; CTPA: computed tomography pulmonary 
angiography.
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results support ruling out PE by a normal CTPA alone, several considerations should be 
taken into account.
First and most importantly, the incidence of VTE of 2.0% as well as the incidence of fatal 
PE of 0.48% after a normal CTPA in patients with a likely clinical probability identified in 
our study compare well to the same incidences after a normal pulmonary angiography 
- 1.7% (95%CI 1.0-2.7) for VTE and 0.3% (95%CI 0.02-0.7) for fatal PE - which is the gold 
standard in PE diagnosis [20].
Second, although our results demonstrate that the VTE incidence after a negative 
CTPA is higher in patients with a likely clinical probability compared to the incidences 
observed in patients with an unlikely clinical probability, this has to be interpreted as 
an inevitable consequence of Bayes’ theorem. Since the sensitivity of CTPA - as for all 
other relevant available diagnostic tests for PE - is known to be slightly less than 100%, 
a higher clinical probability results in a slight decrease of the negative predictive value. 
Therefore and in general, the overall PE prevalence in study population should always 
be taken into account when interpreting the VTE incidence after PE had been ruled out. 




Patients in whom 
PE was excluded 











Mean age (SD) 58 (17) 57 (17) N.A.
Male sex 397 (39) 5 (24) 0.49 (0.18-1.4)
COPD 147 (14) 2 (9.5) 0.64 (0.15-2.8)
Heart failure 81 (7.9) 2 (9.5) 1.3 (0.3-5.9)
Estrogen use 67 (6.5) 3 (14) 2.7 (0.77-9.7)
Inpatient 229 (22) 5 (24) 1.1 (0.39-3.0)
Duration of complaints ≥7 days 237 (23) 4 (19) 0.80 (0.26-2.4)
Wells items
Clinical signs of DVT 81 (7.9) 5 (24) 4.1 (1.4-12)
Alternative diagnosis less likely than PE 968 (94) 19 (90) 0.43 (0.10-1.9)
Heart rate >100 bpm 474 (46) 9 (43) 0.92 (0.38-2.2)
Surgery or immobilization <4 weeks 419 (41) 11 (52) 1.9 (0.76-4.8)
History of VTE 297 (29) 8 (38) 1.5 (0.62-3.7)
Hemoptysis 55 (5.4) 1 (4.8) 0.95 (0.13-7.3)
Active cancer 241 (24) 9 (43) 2.6 (1.1-6.3)
Note: PE: pulmonary embolism; VTE: venous thromboembolism; CI: confidence interval; n: number of 
patients; CTPA: computed tomography pulmonary angiography; SD: standard deviation; COPD: chronic 
obstructive pulmonary disease; DVT: deep vein thrombosis; bpm: beats per minute; N.A: not applicable.
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In our study, the PE prevalence in patients with a likely clinical probability was 40%. In 
the studies included in the meta-analysis of van Beek and colleagues in which the safety 
of a normal pulmonary angiography was investigated, the PE prevalence varied from 
20% to 33% [20]. Consequently, it can be reasonably expected that the VTE incidence 
after a normal pulmonary angiogram in our patients with a likely clinical probability, in 
whom the PE prevalence of 40% was notably higher, would have exceeded the 1.7% re-
ported in this meta-analysis. Moreover, a recent SSC recommendation suggested using a 
diagnostic safety threshold in PE studies that is dependent on the disease prevalence at 
baseline [21]. According to the suggested formula, the safety threshold for studies with 
a baseline PE prevalence of 40% is 2.0%, which is in line with our findings.
We acknowledge that when focussing on the small subgroup of patients with a high 
clinical probability according to the Wells rule (less than 5% of total study population), 
the 3-month VTE incidence is non negligible. Importantly, there is no diagnostic test 
after CTPA available that has been shown to improve the patient’s prognosis, except for 
CUS in patients who also have symptoms of DVT [4]. Our results thus demonstrate that 
clinicians should be alert on the occurrence of VTE at follow-up after a normal CTPA in 
these latter patients.
In our view, an individualized patient management is much preferred over performing 
additional diagnostic tests in all patients, since it is highly unlikely that such a strategy 
will lead to an acceptable yield, when performed in all patients.
Active cancer and signs of DVT were shown to be predictive of developing VTE during 
follow-up. The first patient category has an intrinsic very high risk of VTE, with an overall 
OR varying from 4.1 to 6.7 compared to patients without cancer resulting in an annual risk 
varying from 0.5 to 20% [22-24]. Consequently, the question arises whether VTE in can-
cer patients after a normal CTPA could be newly formed VTE rather than initially missed 
VTE. With regard to the latter category, at least 3 of the 5 patients with a negative CTPA 
but clinical signs of DVT and a VTE during follow-up were subjected to CUS at baseline. 
A negative CUS did not prevent the occurrence of VTE, which supports previous studies, 
indicating that baseline CUS after negative CTPA in patients without signs of DVT does 
not further diminish the VTE incidence during follow-up [4, 12-14]. Of note, a positive 
baseline CUS may be regarded as a somewhat doubtful criterion for failure of the PE 
algorithm since the algorithm aims to rule out PE and not symptomatic DVT. Moreover, 
CT venography might be considered as an additional test after a normal CTPA, since the 
PIOPED 2 study demonstrated an improvement of the sensitivity by adding this test to a 
4 to 16-row CTPA [25]. However, it should be emphasized that the PIOPED 2 study was a 
diagnostic accuracy study. In a clinical outcome study the key question is the incidence 
of recurrent VTE during follow-up in those patients with initially normal diagnostic tests. 
By design, this question could not be answered by the PIOPED-2 study and as a result 
the true value of adding CT venography with respect to clinical outcome at 3 months 
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is still uncertain. Moreover, the CTPA technology used in the PIOPED-2 study, i.e. 4 to 
16-row CTPA, has become outdated since in current clinical practice 254-row CTPA is 
used with resulting higher sensitivity. Therefore, future studies are required in order to 
determine whether our findings still reflect current daily clinical practice.
Recently, another study investigated the safety of excluding PE based on a normal 
CTPA alone [26]. In this observational study, 134 patients with a high clinical probability 
(Wells rule score >6 points) but a normal CTPA were described. Of these patients, 48 
patients (36%) underwent additional testing, either CUS or ventilation/perfusion-
scanning, after which 4 patients were diagnosed with DVT and 2 with PE. It should be 
noted that it is unclear how these patients were selected and whether these 4 patients 
with DVT had symptoms suggesting of DVT. Likely, this was based on their symptoms 
and other clinical characteristics. These patients represented a highly selected subgroup 
from a total cohort of 3237 patients (1.5%). Together with 2 symptomatic PE diagnoses 
during follow-up, the hypothetical 3-month VTE incidence after a normal CTPA would 
have been 5.2% (7/134; 95%CI 1.5-9.0). These results are quite in line with our findings 
and underline our suggested strategy of a stricter follow-up of patients with a high clini-
cal probability but a normal CTPA and considering additional testing only in selected 
patients.
Strengths of our study are the large number of included patients, the availability of 
patient-level data from 4 large prospective studies and the highly comparable study de-
signs of all included studies. Additionally, it should be noted that in three of the included 
studies single row and 4-row CTPA were used, of which the sensitivity is known to be 
relatively low compared to nowadays multi-row CTPA [1, 2, 15]. Therefore, the safety of 
a normal CTPA reported in this study may even be an underestimation of the safety of 
the multi-row CTPA machines currently used in clinical practice, further supporting our 
conclusion. The major limitation of our study is the fact that we only evaluated 4 studies 
and did not perform a full systematic review and meta-analysis of all available literature, 
but rather used data from 4 homogeneous studies. Also, differences in the CT imaging 
quality between the individual studies were present among the individual studies and 
we could not retrieve information on CUS examinations of 2 of the 5 patients with a 
likely probability of PE and symptoms suggestive of DVT at baseline, who were diag-
nosed with VTE during follow-up after a normal CTPA. Nonetheless, we do not dispute 
the clear indication for CUS in those particular patients. Last, the post-hoc analysis of 
the group of patients with an intermediate clinical probability (Wells score 2-6 points) 
may have introduced differential verification bias since patients with a Wells score of 
4.5-6 points underwent CTPA regardless of their D-dimer result. Consequently, we may 
have overestimated the failure rate in patients with an intermediate probability and a 
negative D-dimer due to false-positive CTPA results and PE that would have resolved 
without anticoagulant treatment otherwise.
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In conclusion, our study suggests that the risk of VTE and fatal PE after a normal CTPA 
in patients with a likely clinical probability is comparable to these risks after a normal 
pulmonary angiogram. Therefore, a normal CTPA alone may be considered as a valid 
diagnostic criterion to rule out PE in the majority of patients with a likely clinical prob-
ability of PE assessed by the Wells rule. Nevertheless, the risk of fatal PE after a normal 
CTPA alone is relatively high, particularly in patients with concomitant signs of DVT, 
active cancer and those with a Wells rule >6 points. Consequently, clinicians should 
consider a closer follow-up in selected patients preferably with a personalised approach. 
Further studies are required to determine whether the modern multi-row CTPA result in 
a higher accuracy than the 4 to 64-row CTPA used in the included studies.
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Computed tomography pulmonary angiography (CTPA) is frequently requested using 
diagnostic algorithms for suspected pulmonary embolism (PE). For suspected deep vein 
thrombosis, it was recently shown that doubling the D-dimer threshold in patients with 
low pretest probability safely decreased the number of ultrasonograms. We evaluated 
the safety and efficiency of a similar strategy in patients with suspected PE.
Methods
We performed a post-hoc analysis of 2213 consecutive patients of two cohort studies 
with suspected PE who were managed according to current standards: PE ruled out in 
case of unlikely probability (Wells rule ≤ 4 points) and a D-dimer level < 0.5 μg/mL. CTPA 
was performed in all other cases. All patients were followed for 3 months. We calculated 
3-month venous thromboembolism (VTE) incidence and the number of required CTPAs 
for selective D-dimer thresholds in patients with low clinical probability (< 2 points, 
D-dimer threshold < 1.0 μg/mL) and intermediate probability (2–6 points, D-dimer 
threshold < 0.5 μg/mL).
Results
Using standard management, PE could be excluded without CTPA in 26% of patients, 
with a 3-month VTE incidence of 0.88% (95% confidence interval [CI] 0.29–2.1%). Using 
selective D-dimer thresholds, PE could be excluded without CTPA in 36% of patients, 
with a 3-month VTE incidence of 2.1% (95% CI 1.2–3.4%) in patients managed without 
CTPA, an increase of 1.2 percentage points (95% CI −0.3 to 2.2).
Conclusions
Applying selective D-dimer thresholds reduces the need for CTPA by 11 percentage 
points but is associated with an increased failure rate. Prospective studies should evalu-
ate the safety and net clinical benefit of this approach.
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INTRODUCTION
The preferred diagnostic algorithm for patients with suspected acute pulmonary em-
bolism (PE) combines sequential testing with a clinical decision rule (CDR), categorizing 
patients into either unlikely or likely pretest clinical probability, followed by D-dimer 
testing and computed tomography pulmonary angiography (CTPA). This algorithm has 
been demonstrated to be safe and efficient with a 3-month venous thromboembolism 
(VTE) incidence < 2% [1]. Importantly, this diagnostic strategy obviates the need for 
CTPA in 20–30% of all referred patients and allows a fast and effective management 
decision in 98% of cases [1, 2]. Nonetheless, the low specificity of both D-dimer tests 
and CDR leads to a high frequency of false-positive results, in turn leading to a high 
number of 70–80% negative CTPAs [2, 3]. Since CTPA is associated with long-term radia-
tion complications, allergic reactions to iodinated contrast material, contrast-induced 
nephropathy, and higher health care costs, one of the major challenges in the diagnostic 
workup of patients with suspected PE is to safely diminish the number of CT scans [4-6].
Several attempts have been made to accomplish a higher specificity of the D-dimer 
test for the diagnosis of acute PE. Previous studies that attempted to improve D-dimer 
specificity by increment of the D-dimer or CDR score cutoff levels led to increases in 
3-month VTE incidence [7, 8]. For example, increasing the threshold of the CDR from 4 
to 5 points resulted in a 3-month VTE incidence of 1.5% (95% confidence interval [CI] 
0.6–3.0%) instead of 0.9% (95% CI 0.3–2.4%) and only increasing the D-dimer threshold 
from ≤ 0.5 μg/mL to ≤ 0.6 μg/mL resulted in a 3-month VTE incidence of 2.2% (95 CI 
1.1–4.0%) [8]. The introduction of an age-dependent D-dimer threshold from < 0.5 μg/
mL to patient’s age × 10 ng/mL (for patients aged > 50) led to a decrease in the number 
of performed CT scans of 6 percentage points in a post-hoc analysis with 3-month VTE 
incidence of 0.2% (95% CI 0–1.0%) [9]. The safety of this strategy is currently being 
evaluated prospectively. However, no previous study investigated variable D-dimer 
thresholds dependent on pretest probability in PE-suspected patients.
A recent study reintroduced the three pretest probability categories, instead of two 
categories, of the Wells decision rule in patients with suspected deep venous thrombo-
sis (DVT) to evaluate whether a higher D-dimer cutoff level (< 1.0 μg/mL instead of < 0.5 
μg/mL) is safe in the lowest pretest probability category [10]. This strategy reduced the 
proportion of required ultrasonography by 7.6 percentage points without a decrease 
in the negative predictive value (NPV). This would be of particular interest for patients 
with suspected PE, since it has been estimated that nearly one-third of all CTPAs are 
performed in patients with a D-dimer level < 1.0 μg/mL [11].
Therefore, we evaluated the safety and efficiency of a comparable strategy, an al-
gorithm with three different pretest probability categories and an increased D-dimer 
threshold of 1.0 μg/mL in patients with a low pretest probability. We will compare the 
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3-month VTE incidence rate and the required number of CTPAs of this strategy to the 
current standard algorithm with a two-level Wells rule outcome and a fixed 0.5 μg/mL 
D-dimer threshold for patients with a ‘PE unlikely’ risk score.
METHODS
Patients
Data were obtained from two previously published multicenter prospective manage-
ment studies performed in the Netherlands in patients with suspected PE [2, 3]. Both 
inpatients and outpatients with suspected PE were included. Exclusion criteria were 
treatment with therapeutic doses of unfractionated or low-molecular-weight heparin 
for > 24 hours, treatment with vitamin K antagonists, life expectancy < 3 months, 
pregnancy, geographic inaccessibility precluding follow-up, age < 18 years, allergy to 
intravenous contrast agents, renal insufficiency (creatinine clearance < 30 mL/min), 
logistic reasons (e.g. unavailability of CT, patient too ill to undergo CT scanning), and 
hemodynamic instability. In the Prometheus study, previous PE also was an exclusion 
criterion. In all patients, the Wells rule was calculated [12]. The Christopher Study was a 
prospective cohort study conducted from November 2002 through December 2004 to 
evaluate a diagnostic algorithm consisting of sequential application of a clinical deci-
sion rule, D-dimer testing, and a CT scan within 24 hours of presentation [2]. According 
to the study protocol, D-dimer tests were performed only in case of an unlikely clinical 
probability assessed with use of the Wells rule. Even so, in 5 of 12 participating hospitals, 
D-dimer levels were also measured post-hoc in patients with a likely clinical probability 
for scientific purposes. Only patients from these hospitals (1614 of a total of 3306 pa-
tients) were included in the present analysis. The Prometheus study, conducted from 
July 2008 through November 2009, aimed to compare four clinical decision rules for 
suspected acute PE, including the Wells rule, using a computerized scoring system [3]. By 
protocol, D-dimer levels were assessed in all patients. In both studies, PE was ruled out 
in patients with an unlikely clinical probability in combination with a normal D-dimer 
test. In case of either a likely clinical probability or an elevated D-dimer level, patients 
were referred for CTPA and managed according to the CTPA result. All patients provided 
informed consent, and both studies were approved by the institutional review boards of 
all participating hospitals. Among the study centers, different high-sensitivity D-dimer 
assays were used: VIDAS D-Dimer Assay (bioMérieux, Marcy-l’Étoile, France), Tina-Quant 
Assay (Roche Diagnostica, Mannheim, Germany), STA Liatest D-Di (Diagnostica Stago, 
Asnières-sur-Seine, France), or Innovance D-Dimer (Siemens, Marburg, Germany).
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Outcome and follow-up
All patients were followed for 3 months to evaluate the occurrence of symptomatic VTE 
(i.e. PE and/or DVT). An independent adjudication committee evaluated all episodes of 
suspected VTE and deaths. Deaths were classified as caused by PE in case of confirma-
tion by autopsy, in case of an objective test positive for PE before death, or if PE could 
not be confidentially excluded as the cause of death. In case of clinically suspected VTE, 
an objective clinical test was performed (i.e. compression ultrasound for suspected DVT 
and a ventilation-perfusion scintigraphy or CTPA for suspected PE). Primary outcomes 
of the current analysis were the objective diagnosis of symptomatic DVT or PE in the 
3-month period following study inclusion.
Standard diagnostic algorithm
Patients with a Wells score ≤ 4 points were categorized as ‘PE unlikely’, and patients with 
a Wells score > 4 points as ‘PE likely’. In patients with a ‘PE unlikely’ score, a D-dimer test 
was indicated. In patients with a D-dimer level < 0.5 μg/mL, a PE was excluded without 
further testing. In patients with a D-dimer level ≥ 0.5 μg/mL or a ‘PE likely’ risk score, 
CTPA was indicated [1, 2].
Study algorithm
Patients with a Wells score < 2 points were categorized as low risk, patients with a Wells 
score of 2–6 points as moderate risk, and patients with a Wells score > 6 points as high 
risk. In patients with a lowrisk score, we evaluated an increased D-dimer threshold of < 
1.0 μg/mL, while the D-dimer threshold in patients with a moderaterisk score remained 
at < 0.5 μg/mL. In patients with a D-dimer level equal to or above the specific threshold 
and in patients with a highrisk score, CTPA was indicated. In addition, we evaluated 
D-dimer thresholds between 0.5 μg/mL and 1.0 μg/mL with increments of 0.1 μg/mL 
in patients with a lowrisk category, while the threshold in patients with a moderaterisk 
score remained at < 0.5 μg/mL. Finally, we performed the analysis for hospitalized pa-
tients and outpatients separately.
Statistics
For each predefined pretest probability/D-dimer threshold scenario, the diagnostic 
failure rates, defined as the 3-month VTE incidence, were calculated in patients man-
aged without CTPA and in all patients in whom a PE was excluded at baseline (including 
occurrences after a negative CTPA), with exact binomial 95% CIs. The difference of the 
3-month VTE incidence between the standard algorithm and the study algorithm were 
assessed with use of 95% CIs. The number of CTPAs performed was calculated. The 
sensitivity, specificity, NPV, and positive predictive value (PPV) for both algorithms were 
calculated. For this calculation, we defined a positive test result as either a ‘PE likely’ or 
Chapter 5
84
high-risk Wells score or a D-dimer level equal to or above the specific D-dimer threshold. 
A diagnosis of PE was defined as either PE at baseline or DVT or PE during 3-month 
follow-up.
RESULTS
Of 2421 eligible patients, 159 were excluded because of missing D-dimer results, 3 
because individual items of the Wells score were missing, and 46 because of treatment 
with anticoagulants for reasons other than VTE during follow-up, leaving a total of 2213 
patients available for the current analysis (Table 1). Mean age was 53 years, and 57% 
of patients were female. The overall prevalence of PE was 23% (488 patients diagnosed 
with PE at baseline and 13 in the 3-month follow-up period). The mortality attributable 
to PE was 1.0% (5 of 488, 95% CI 0.3–2.4%) in patients diagnosed with PE at baseline 
and 15.4% (2 of 13, 95% CI 1.9–45.5%) in those who were diagnosed with PE during the 
follow-up period after a PE was excluded at baseline. Of these two patients, one had a 
CDR risk score of 4.5 points and a D-dimer level of 2400 μg/mL and the other patient 
had a CDR risk score of 5.5 points and a D-dimer level of 449 μg/mL. Based on these 
results, both patients were subjected to CTPA using the standard algorithm, with a false-



















Age in years 53 (SD 18) 52 (SD 18) 56 (SD 18) 51 (SD 18) 54 (SD 18) 58 (SD 16)
Female sex (n, %) 1259 (57%) 868 (57%) 391 (56%) 444 (59%) 750 (56%) 65 (59%)
Estrogen use (n, % of females) 260 (21%) 194 (22%) 66 (17%) 94 (21%) 155 (21%) 11 (17%)
Immobilization > 3 days or surgery 
(n, %)
480 (22%) 140 (9.2%) 340 (49%) 72 (9.5%) 331 (25%) 77 (69%)
History of VTE (n, %) 232 (10%) 90 (5.9%) 142 (20%) 62 (8.2%) 139 (10%) 31 (28%)
COPD (n, %) 220 (9.9%) 152 (10%) 68 (10%) 78 (10%) 133 (9.9%) 9 (8.1%)
Heart failure (n, %) 167 (7.5%) 115 (7.6%) 52 (7.5%) 61 (8.1%) 98 (7.3%) 8 (7.2%)
Malignancy (n, %) 375 (17%) 212 (14%) 163 (23%) 76 (10%) 247 (18%) 52 (47%)
Outpatients (n, %) 1729 (78%) 1267 (84%) 462 (66%) 646 (86%) 1013 (75%) 70 (63%)
PE at baseline (n, %) 488 (22%) 216 (14%) 272 (39%) 53 (7.0%) 371 (28%) 64 (58%)














Note: CDR: clinical decision rule; SD: standard deviation; VTE: venous thromboembolism; COPD: chronic 
obstructive pulmonary disease; PE: pulmonary embolism; IQR: interquartile range.
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negative result. However, when the study algorithm would have been applied, this CTPA 
would have been withheld in the latter patient. Table 1 additionally depicts the baseline 
characteristics for all different risk categories by the Wells rule. VTE risk factors, including 
previous VTE, recent immobilization or surgery, and malignancy, were more prevalent 
in categories with a higher pretest probability. The median D-dimer levels were higher 
in patients with a higher pretest probability. Table S1 (available at http://onlinelibrary.
wiley.com/journal/10.1111/(ISSN)1538-7836/) provides baseline characteristics of the 
patients included in the original studies.
With use of the dichotomized algorithm, 69% (1517 of 2213) of patients had a ‘PE 
unlikely’ pretest probability and 31% (696 of 2213) had a ‘PE likely’ pretest probability, 
with a PE incidence at baseline of 14% and 39%, respectively. When applying the original 
three-level CDR risk score, 34% (755 of 2213) were categorized as low, 61% (1347 of 
2213) as moderate, and 5% (111 of 2213) as high clinical probability. The PE incidences 
at baseline in these categories were 7.0%, 28%, and 58%, respectively.
In the standard algorithm, using the dichotomized Wells rule combined with a 
D-dimer threshold of < 0.5 μg/mL, additional testing with CTPA was needed in 74.4% 
(1646 of 2213) of the patients, of whom 30% showed PE. The 3-month VTE incidence in 
patients in whom PE was excluded with CDR and D-dimer was 0.88% (5 of 567, 95% CI 
0.29–2.1%), and it was 0.93% (16 of 1717, 95% CI 0.53–1.5%) in all patients in whom a 
PE was excluded at baseline (Table 2). The sensitivity of the algorithm was 99.0% (95% 
CI 97.7–99.7%), with a specificity of 32.8% (95% CI 30.6–35.1%), NPV of 99.1% (95% CI 
98.0–99.7%), and PPV of 30.1% (95% CI 27.9–32.4%), and the area under the receiver 
operating characteristic (ROC) curve was 0.66 (95% CI 0.64–0.68). Of the five patients 
with a false-negative algorithm result, four patients had a PE (three had peripherally 









































n % (95% CI) % (95% CI)



















located PE, in one patient the exact location was not specified) and one patient had a 
DVT. None of these patients died during follow-up.
Using the three Wells categories in combination with a D-dimer threshold in the low-
risk and the moderate-risk category of < 0.5 μg/mL, CTPA was needed in 70.8% (1566 
of 2213) of the patients, of whom 31% were positive for PE. The 3-month VTE incidence 
in patients in whom PE was excluded based on a low CDR risk score or a moderate-risk 
score and D-dimer < 0.5 μg/mL was 1 of 346 and 9 of 301, respectively, resulting in a 
3-month VTE recurrence rate in patients managed without CTPA of 1.5% (10 of 647, 95% 
CI 0.74–2.8%). The 3-month VTE recurrence rate in all patients in whom PE was excluded 
at baseline was 1.2% (20 of 1722, 95% CI 0.71–1.8%). The sensitivity of the algorithm was 
98.0% (95% CI 96.4–99.0%), the specificity was 37.2% (95% CI 34.9–39.6%), the NPV was 
98.5% (95% CI 97.2–99.3%), the PPV was 31.4% (95% CI 29.1–33.7%), and the area under 
the ROC curve was 0.68 (95% CI 0.65–0.70).
When raising the D-dimer cutoff level to 1.0 μg/mL, the number of needed CT scans 
in the total cohort decreased from 74.4% (1646 of 2213) to 63.7% (1409 of 2213) (differ-
ence with the current standard algorithm of 10.7 percentage points [95% CI 8.0–13.4]). 
The 3-month VTE incidence was 8 of 503 in patients with a low-risk CDR score and a 
negative D-dimer threshold and 9 of 301 in patients with a moderate-risk CDR score and 
a negative D-dimer threshold, resulting in a 3-month VTE incidence of 2.1% (17 of 804, 
95% CI 1.2–3.4%). The diagnostic failure rate in all patients in whom PE was excluded 
at baseline was 1.5% (27 of 1729, 95% CI 1.0–2.3%). The differences with the standard 
algorithm were 1.2 percentage points (95% CI −0.3 to 2.2) in patients managed without 
CTPA and 0.57 percentage point (95% CI −0.2 to 1.3) in all patients in whom a PE was 
excluded at baseline (thus including patients with a CTPA negative for PE at baseline). 
Also, this scenario resulted in an increase of the specificity to 46.0% (95% CI 43.6–48.4%) 
and a decrease of the NPV to 97.9% (95% CI 96.6–98.8%). The sensitivity was 96.6% (95% 
CI 94.9–98.0%), the PPV was 34.4% (95% CI 31.9–36.9%), and the area under the ROC 
curve was 0.71 (95% CI 0.69–0.74). Of the additional 11 patients in whom PE was falsely 
excluded by applying the study algorithm, 6 patients had a subsegmental PE, 2 had a 
segmental PE, 2 patients had a central PE, and in 1 patient the exact localization was not 
specified.
Applying fixed D-dimer thresholds levels between 0.5 and 1.0 μg/mL (with increments 
of 0.1 μg/mL) in the low-risk category while the D-dimer threshold remained at < 0.5 
μg/mL in the moderate-risk group did not result in more favorable diagnostic failure 
rates (data not shown). When analyzing outpatients only with the study algorithm, the 
3-month VTE incidence rate was 1.9% (95% CI 1.0–3.1%) in patients managed without 
CTPA and 1.3% (95% CI 0.8–2.0%) in all patients in whom PE was excluded at baseline. 
The number of patients who were managed without CTPA increased from 31.4% to 
43.2%, an increase of 11.8 percentage points (95% CI 8.5–15.0). When we performed the 
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same analysis in hospitalized patients only, the 3-month VTE incidence rates were 5.3% 
(95% CI 1.1–14.6%) and 2.6% (95% CI 1.2–4.8%), respectively. The number of patients 
managed without CTPA increased from 5.0% to 11.8%, an increase of 6.8 percentage 
points (95% CI 3.2–9.9).
DISCUSSION
We investigated the safety of applying variable D-dimer thresholds in patients with a 
low clinical probability, using the three-level original pretest probability Wells score in 
a large cohort of patients with a clinically suspected PE, in an attempt to reduce the 
number of CTPA. Our study has the following interesting findings.
In patients with suspected PE, the combination of a low-risk CDR score and a D-dimer 
threshold of 1.0 μg/mL or an intermediate-risk CDR score with a D-dimer threshold of 
0.5 μg/mL decreases the necessity of CTPA by 11 percentage points. This comes at the 
cost of an increase in the 3-month VTE failure rate in patients managed without CTPA of 
1.2 percentage points (95% CI −0.3 to 2.2) and 0.57 percentage point (95% CI −0.2 to 1.3) 
in all patients in whom a PE was excluded at baseline. Also, all other D-dimer threshold 
modifications between 0.5 μg/mL and 1.0 μg/mL that we studied resulted in a higher 
3-month VTE incidence. We were unable to define a modification of the algorithm that 
did not result in this increase of the 3-month VTE incidence. This contrasts with the 
results of the recently published study in DVT-suspected patients by applying a compa-
rable algorithm [10]. One explanation for this difference may be the three times higher 
disease prevalence (23%) in our study cohort compared with the DVT cohort (7.1%); this 
overall DVT prevalence was lower than the PE prevalence of 7.4% in our low-risk category 
alone. Based on the high 3-month incidence rates of the study algorithm in hospitalized 
patients, we concluded that this strategy is not safe for hospitalized patients. Therefore, 
it seems reasonable to include outpatients only in a prospective validation study.
Traditionally, a 3-month VTE incidence of 1.7% with an upper limit of the 95% CI of 
2.7% serves as the gold standard for safety in prospective diagnostic PE studies, which 
is the 3-month VTE incidence after a negative pulmonary angiography [13]. Although 
the 3-month VTE incidence in this post-hoc analysis exceeds this safety margin in pa-
tients managed without CTPA, the safety margin was not exceeded in the total cohort 
(all patients without PE at baseline). However, due to the design of the study, we were 
unable to determine the clinical outcome of the additional missed diagnoses of PE by 
the selective D-dimer algorithm. Therefore, these 3-month VTE incidence rates have to 
be interpreted cautiously. Furthermore, some observations in previous studies might 
suggest that subsegmental PEs may be clinically less relevant and may not require treat-
ment [14]. First, in a diagnostic study that compared a strategy involving ventilation-
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perfusion lung scanning to a CTPA-based algorithm, an additional 5.0% of patients 
were diagnosed with PE at baseline after CTPA compared with ventilation-perfusion 
lung scanning. However, the 3-month VTE incidence in patients with normal tests was 
not different between the strategies [15]. Second, it is known that the introduction of 
CTPA is associated with a rising PE incidence with only a minimal decrease in PE-related 
mortality, suggesting overdiagnosis [16]. The fact that the majority of the PEs that would 
have been missed were subsegmentally located might support this hypothesis. There-
fore, only a prospective study will be able to determine the true clinical implications of 
the selective D-dimer strategy.
When considering the potential of applying the selective D-dimer threshold strategy 
in clinical practice, both its safety and feasibility should be taken into account. For that 
matter, the somewhat higher complexity of patients management in busy emergency 
departments using altered D-dimer thresholds in three probability categories compared 
with one general D-dimer threshold in two probability categories should be balanced 
against its benefit (i.e. a large saving of CTPAs, which may increase its clinical accep-
tation). The advantages of a diagnostic algorithm with an 11-percentage-point lower 
number of necessary CTPAs would be a reduction in valuable time, costs, and complica-
tions associated with performing CTPA. These complications include radiation exposure, 
allergic reactions to iodinated contrast material, and contrast-induced nephropathy [4-
6]. The radiation dose of a single CTPA ranges from 3 to 5 mSv, with an estimated risk of 
150 excess cancer deaths per 1 million exposures to a single CTPA [17]. The incidence of 
contrast-induced nephropathy ranges between 6.5% and 19% depending on the stud-
ied population and the definition of contrast-induced nephropathy that is used [4, 18].
Strengths of this analysis are the inclusion of two large and accurately documented 
cohorts from previous prospective management studies and the assessment of the pri-
mary outcome by an independent adjudication committee. The fact that our study was 
a post-hoc analysis is the most important study limitation. By design, we were therefore 
unable to establish the clinical course of the patients with a false-negative outcome of 
the algorithm since they received anticoagulant treatment. Another limitation is a result 
of the design of the original management studies, in which not all patients underwent 
the reference standard at baseline, CTPA. The fact that not all patients in whom PE was 
excluded in the study algorithm based on a low or intermediate probability combined 
with a negative D-dimer test result underwent the same verification test (i.e. clinical 
follow-up or CTPA) may have introduced verification bias. Furthermore, the exclusion of 
patients in whom no D-dimer test was performed is a limitation.
In conclusion, raising D-dimer thresholds in different pretest probability categories 
results in a decrease in the number of required CTPAs and an increase in the failure 
rate of the chosen algorithm. Applying the original three-level Wells rule for PE with 
a D-dimer cutoff level of < 1.0 μg/mL for patients with a low pretest probability for PE 
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and a cutoff level of < 0.5 μg/mL for patients with an intermediate pretest probability 
for PE resulted in a 3-month VTE incidence of 2.1% in patients managed without CTPA 
and 1.5% in whom a PE was excluded at baseline. However, since the outcome of the 
undiagnosed PE patients is unknown in this post-hoc analysis, a prospective study is 
needed to evaluate the safety and net clinical benefit of this approach. Also, a formal 
cost-effectiveness analysis will aid in conclusively establishing whether changing the 
current standard diagnostic strategy will result in a more optimal diagnostic manage-
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Validated diagnostic algorithms in patients with suspected pulmonary embolism are 
often not used correctly or only benefit subgroups of patients, leading to overuse of 
computed tomography pulmonary angiography (CTPA). The YEARS clinical decision rule 
that incorporates differential D-dimer cutoff values at presentation, has been developed 
to be fast, to be compatible with clinical practice, and to reduce the number of CTPA 
investigations in all age groups. We aimed to prospectively evaluate this novel and 
simplified diagnostic algorithm for suspected acute pulmonary embolism.
Methods
We did a prospective, multicentre, cohort study in 12 hospitals in the Netherlands, 
including consecutive patients with suspected pulmonary embolism between Oct 
5, 2013, and July 9, 2015. Patients were managed by simultaneous assessment of the 
YEARS clinical decision rule, consisting of three items (clinical signs of deep vein throm-
bosis, haemoptysis, and whether pulmonary embolism is the most likely diagnosis), and 
D-dimer concentrations. In patients without YEARS items and D-dimer less than 1000 
ng/mL, or in patients with one or more YEARS items and D-dimer less than 500 ng/mL, 
pulmonary embolism was considered excluded. All other patients had CTPA. The pri-
mary outcome was the number of independently adjudicated events of venous throm-
boembolism during 3 months of follow-up after pulmonary embolism was excluded, 
and the secondary outcome was the number of required CTPA compared with the Wells’ 
diagnostic algorithm. For the primary outcome regarding the safety of the diagnostic 
strategy, we used a per-protocol approach. For the secondary outcome regarding the 
efficiency of the diagnostic strategy, we used an intention-to-diagnose approach. This 
trial is registered with the Netherlands Trial Registry, number NTR4193.
Findings
3616 consecutive patients with clinically suspected pulmonary embolism were screened, 
of whom 151 (4%) were excluded. The remaining 3465 patients were assessed of whom 
456 (13%) were diagnosed with pulmonary embolism at baseline. Of the 2946 patients 
(85%) in whom pulmonary embolism was ruled out at baseline and remained untreated, 
18 patients were diagnosed with symptomatic venous thromboembolism during 3-month 
follow-up (0.61%, 95% CI 0.36–0.96) of whom six had fatal pulmonary embolism (0.20%, 
0.07–0.44). CTPA was not indicated in 1651 (48%) patients with the YEARS algorithm com-
pared with 1174 (34%) patients, if Wells’ rule and fixed D-dimer threshold of less than 500 





In our study pulmonary embolism was safely excluded by the YEARS diagnostic algo-
rithm in patients with suspected pulmonary embolism. The main advantage of the 
YEARS algorithm in our patients is the absolute 14% decrease of CTPA examinations in 




The clinical diagnosis of pulmonary embolism is non-specific and should therefore be 
followed by objective testing. Because of its diagnostic accuracy and wide availability, 
multidetector row computed tomography pulmonary angiography (CTPA) is the imag-
ing test of choice to confirm acute pulmonary embolism in most patients. Increasing use 
of CTPA with diminishing prevalence of pulmonary embolism —to even less than 10% 
[1]— has led to overdiagnosis of mostly subsegmental pulmonary embolism and unnec-
essary risks of radiation exposure and contrast medium induced nephropathy [2–6]. To 
avoid these problems, validated diagnostic algorithms for suspected acute pulmonary 
embolism, using sequential testing, have been introduced [7]. In these algorithms, a 
normal D-dimer test result in patients with low probability safely excludes pulmonary 
embolism [8]. Correct application of these algorithms obviates the need for CTPA in 
20–30% of patients, with an overall 3-month diagnostic failure rate of less than 1.5% 
after initial negative ruling of the algorithm [7–9]. An age-adjusted D-dimer threshold 
(age × 10 ng/mL for patients aged >50 years) has been validated prospectively, reporting 
an absolute reduction of 11.6% (95%CI 10.5–12.9) in the need for CTPA [10]. Importantly, 
only patients aged 50 years or older, and foremost those older than 75 years benefit 
from this strategy whereas when considering the life-time attributable cancer risk, the 
exposure to unnecessary radiation is considered more relevant to younger individuals, 
particularly women [3]. 
Despite firm evidence of its safety and efficiency, adherence to recommended di-
agnostic strategies in clinical practice is variable. This variation might be partly due to 
complexity of these strategies, and insufficient time at busy emergency departments, 
which hampers the use of sequential tests [11–14]. In daily practice, D-dimer testing is 
frequently ordered and known at low clinical threshold or even before the clinical as-
sessment [15,16]. Improved adherence to the algorithm, for instance by implementation 
of a clinical decision support system, has been shown to significantly decrease the mean 
number of diagnostic tests used along with —and more importantly— the number of 
diagnostic failures [17,18].
On the basis of a post-hoc derivation and validation study [19], three items of the 
original Wells’ clinical decision rule —ie, clinical signs of deep vein thrombosis, hae-
moptysis, and whether pulmonary embolism is the most likely diagnosis— were the 
most predictive for pulmonary embolism. They allowed the use of a differential D-dimer 
threshold based on the presence of one of these items, without losing sensitivity. Hence, 
this algorithm —which we call YEARS— involves the simultaneous assessment of only 
the three abovementioned items and a D-dimer test threshold of 500 ng/mL in pres-
ence, and 1000 ng/mL in absence of one of the YEARS items. The YEARS algorithm was 




nostic strategies, and to further decrease the number of necessary CTPA examinations 
in patients of all ages. In this study, we aimed to prospectively evaluate this novel and 
simplified diagnostic algorithm for suspected acute pulmonary embolism.
METHODS 
Study design and patients 
We did a prospective, multicentre, cohort outcome study evaluating the safety and ef-
ficiency of the YEARS algorithm in patients with suspected acute pulmonary embolism 
between Oct 5, 2013, and July 9, 2015 (Figure 1) [19]. The algorithm was implemented 
as standard diagnostic strategy in 12 participating hospitals in the Netherlands. The full 
study protocol is available at www.thelancet.com.
Consecutive outpatients and inpatients with clinically suspected acute (first or recur-
rent) pulmonary embolism were eligible for inclusion if they were aged 18 years or older. 
Exclusion criteria were treatment with therapeutic doses of anticoagulants initiated 
24 hours or more before eligibility assessment, life expectancy less than 3 months or 
geographic inaccessibility precluding follow-up, pregnancy, or allergy to intravenous 
contrast agent. The protocol was centrally approved by the institutional review board of 
the Leiden University Medical Center, Leiden, Netherlands, which waived the need for 
informed consent; this decision was endorsed by the local institutional review board of 
each participating centre. 
Procedures 
An attending physician who suspected acute pulmonary embolism assessed the pa-
tients, and then evaluated the YEARS score by assessing the presence or absence of each 
of the YEARS items —ie, symptomatic deep vein thrombosis, haemoptysis, and whether 
pulmonary embolism is the most likely diagnosis— (scored as yes or no) with the pretest 
probability dependent threshold of the D-dimer test (Figure 1). D-dimer concentra-
tions were measured upon presentation of the patient, according to local practice, with 
automated well validated high-sensitive quantitative D-dimer assays (Vidas D-dimer 
Exclusion, Biomerieux, Marcy-L’Étoile, France; Tinaquant, Roche Diagnostica, Mannheim, 
Germany; STA-LIA, DiagnosticaStago, Asnieres, France; and Innovance, Siemens, Mar-
burg, Germany). Our study reflected daily clinical practice in which D-dimer concentra-
tions are often determined at presentation to the emergency ward. Physicians were not 
blinded for the D-dimer test result when they assigned the YEARS items.
In patients with no YEARS items and a D-dimer concentration less than 1000 ng/mL, 
pulmonary embolism was considered excluded and further testing was withheld. In pa-
tients with one or more YEARS items and a D-dimer concentration less than 500 ng/mL, 
Chapter 6
98
pulmonary embolism was also considered excluded and further testing was withheld. All 
other patients —ie, either with no YEARS item and a D-dimer concentration of 1000 ng/
mL or more, or with one or more items and a concentration of 500 ng/mL or more— were 
referred for CTPA to show or exclude the diagnosis of pulmonary embolism. The appendix 
available at www.thelancet.com shows the full CTPA scan protocol. Patients in whom pul-
monary embolism was ruled out were left untreated and followed up for 3 months. They 
were instructed to return to the hospital in the event of symptoms of venous thromboem-
bolism, after which objective diagnostic tests were done to confirm or refute the disease. 
Follow-up consisted of a scheduled outpatient visit or telephone interview after 3 months. 
At this visit, information about complaints suggestive of venous thromboembolism was 
obtained. Patients in whom acute pulmonary embolism was confirmed at baseline were 
treated with anticoagulants according to international guidelines.
Outcomes 
The primary outcome was the 3-month incidence of symptomatic venous thrombo-
embolism in the overall population and in patients managed with and without CTPA 
separately. The diagnosis of pulmonary embolism or deep vein thrombosis was based 
on predefined criteria (appendix, available at www.thelancet.com). In case of clinically 
suspected pulmonary embolism or deep vein thrombosis, objective diagnostic tests 
were required, including CTPA for suspected pulmonary embolism and compression ul-
trasonography for suspected deep vein thromboembolism. In case of death, information 
was obtained from the hospital records. Deaths were classified as caused by pulmonary 
Figure 1.  The YEARS algorithm.





embolism if it was confirmed by autopsy, was shown by objective testing before death, 
or could not be confidently excluded as a cause of death. An independent adjudica-
tion committee assessed and adjudicated all suspected venous thromboembolism and 
deaths during follow-up.
The secondary outcome was the proportion of required CTPA examinations to 
complete the YEARS algorithm at baseline, as compared post-hoc with the theoretical 
proportion of CTPA examinations that would have been required if the algorithm, using 
the two-level Wells’ rule outcome and fixed D-dimer threshold of less than 500 ng/mL, 
would have been applied in the study population and to historical data [20]. Finally, we 
compared the efficiency to the scenario in which the age-adjusted D-dimer concentra-
tion would have been applied (calculated by age ×10 μg/L in patients >50 years). This 
comparison was done post hoc because the final evidence supporting this approach 
was not available at the moment of drafting of the protocol [10]. The Wells’ rule was 
calculated by an independent researcher (TvdH) based on the YEARS criteria entered in 
the case record form and information from the medical charts.
Statistical analysis 
On the basis of derivation cohort of the YEARS algorithm, we expected a failure rate of 
1.2% in patients managed without CTPA [19]. The sample size was based on this assump-
tion, with the aim to keep the upper limit of the 95% CI of this point estimate below 2.7% 
[21]. This number reflects the 3-month incidence of venous thromboembolism after 
normal conventional pulmonary angiography. Any venous thromboembolism incidence 
with a complete confidence interval below this safety threshold was considered to be 
safe. We calculated that we needed to include 1333 patients managed without CTPA, 
with a two-sided α of 5% and a β of 80%. Because 44% of patients in the combined 
YEARS derivation and validation cohort could have been managed without CTPA and 
accounting for up to 7.5% loss to follow-up, a total of 3260 patients with suspected pul-
monary embolism would be required [19]. For the primary outcome regarding the safety 
of the diagnostic strategy, we used a per-protocol approach. For the secondary outcome 
regarding the efficiency of the diagnostic strategy, we used an intention-to-diagnose 
approach. The difference between approaches was how to report the number of CTPA 
that were done but not indicated by the strategy. By using this approach, pulmonary 
embolism diagnosed at presentation on a CTPA that was not indicated was considered 
as failures of the diagnostic strategy.
For the secondary outcome analysis, we determined the absolute difference in the 
number of required CTPA examinations between the different clinical scenarios. Finally, 
we reported outcomes of not predefined post-hoc analyses for relevant subgroups: 
patients with malignancy, patients 50 years or older, patients with a history of venous 
thromboembolism, and inpatients and patients with complaints for more than 7 days. 
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All descriptive parameters and exact 95% CIs around the observed incidences were 
calculated. All analyses were done with SPSS (version 23). This study is registered with 
the Netherlands Trial Register, number NTR4193.
Role of the funding source 
This study was an academically sponsored trial. The steering committee, consisting of 
the authors, had final responsibility for the study design, oversight, and data verification 
and analyses. The sponsor was not involved in the study. All members of the steering 
committee contributed to the interpretation of the results, approved the final version 
of the manuscript, and vouch for the accuracy and completeness of the data reported. 
The final decision to submit the manuscript was made by the corresponding author on 
behalf of all coauthors.
RESULTS 
From Oct 5, 2013, to July 9, 2015, 3616 consecutive patients with clinically suspected 
pulmonary embolism were screened in the 12 participating hospitals, of whom 151 
(4.2%) were excluded (Figure 2). Table 1 summarises the baseline characteristics. Over-
all, pulmonary embolism was detected in 456 (13%) of 3465 patients: in 55 (3.2%) of 
1743 patients with none of the YEARS items and 401 (23%) of 1722 patients with one or 
more YEARS items.
Table 1.  Baseline characteristics of patients with suspected pulmonary embolism. 
Mean age, years (SD) 53 (18)
Female, n (%) 2154 (62)
Duration of complaints, days (median and IQR) 3 (1-8)
COPD with treatment, n (%) 423 (12)
Heart failure with treatment, n (%) 137 (4.0)
Estrogen use, n (% of women)  337 (16)
Immobilization or surgery in the previous 4 weeks 407 (12)
Outpatient, n (%) 2996 (86)
Heart rate greater than 100/min, n (%) 683 (20)
Previous history of PE or DVT, n (%) 359 (10)
Malignancy, n (%) 336 (9.7)




According to the intention-to-diagnose approach, of the 2946 (85%) patients in 
whom pulmonary embolism was ruled out at baseline, who remained untreated, and 
completed the follow-up period, 18 patients were diagnosed with symptomatic venous 
thromboembolism during 3-month follow-up, with an incidence of 0.61% (95% CI 
0.36–0.96). The incidence of fatal pulmonary embolism was 0.20% (six patients, 95% 
CI 0.07–0.44; Table 2). In a worst case scenario, accounting the five patients who were 
lost to follow-up (four patients had pulmonary embolism excluded without CTPA and 
one patient had a negative CTPA) as recurrent venous thromboembolism, the 3-month 
incidence would have been 0.78% (23 of 2951 patients, 95% CI 0.49–1.2). For the per-
protocol approach, the failure rate of the diagnostic algorithm was 0.51% (15 of 2943 
patients, 95% CI 0.31–0.84) with a 0.20% 3-month risk of fatal pulmonary embolism (six 
of 2943 patients, 0.08–0.46).
In the intention-to-diagnose approach, CTPA was not done in 1611 (46%) patients 
and it was not indicated in 1651 (48%) patients following the per-protocol approach. If 
the standard diagnostic algorithm using Wells’ rule and D-dimer with fixed threshold of 
<500 ng/mL would have been applied, 1174 (34%) patients could have been managed 
without CTPA at baseline, for an absolute difference of 13% (difference in intention-to-
diagnose approach 437 CTPA examinations, 95% CI 10–15%) and 14% (difference in per-
protocol approach 477 CTPA examinations, 12–16%) in favour of the YEARS algorithm.
If Wells’ rule and the age-adjusted D-dimer threshold would have been applied, 1348 
(39%) patients could have been managed without CTPA at baseline, an absolute dif-
ference of 8.7% (difference in per-protocol approach CTPA examinations 303, 95% CI 
6.4–11%) and of 7.6% (difference in intention-to-diagnose approach CTPA examinations 
263, 95% CI 5.3–9.9%).
Table 2.  Primary outcomes of venous thromboembolism events during 3-month follow-up.


















Note: Patients in whom pulmonary embolism was excluded by either a low YEARS score or CT scanning 
were left untreated. Outcomes calculated for patients who remained untreated and were not lost to follow-




























































































































































































































































































































In the subgroups of patients younger than 50 years and 50 years and older, a 14% 
absolute reduction in the number of required CTPA examinations was observed when 
the YEARS algorithm was applied compared with the standard diagnostic algorithm, 
with failure rates of 0.11% (one of 894 patients, 95% CI 0.02–0.63) and 0.81% (six of 
740 patients, 0.37–1.8), respectively. Table 3 summarises the results for the other 
subgroups.
Figure 2 shows the management of all 3465 included patients. Of the 1651 patients 
who should have been managed without CTPA, the protocol was violated in 40 patients. 
CTPA showed pulmonary embolism in three patients who were treated with anticoagu-
lants. These observations were considered diagnostic failures and are included in the 
primary outcome. Furthermore, 18 (1.1%) of 1651 patients were treated with oral antico-
agulants for other reasons (ie, eight atrial fibrillation, one superficial thrombophlebitis, 
and nine other reasons including idiopathic pulmonary hypertension and peripheral 
arterial disease) and four (0.24%) of 1651 patients were lost to follow-up. Four of the re-
maining 1589 patients returned with symptomatic events of venous thromboembolism 
(Table 4). The 3-month incidence of venous thromboembolism in patients who did not 
have CTPA according to the YEARS algorithm was 0.43% (seven of 1629 patients, 95% CI 
0.17–0.88) and of fatal pulmonary embolism was 0.12% (two of 1629 patients, 0.01–0·44; 
Table 2). Seven other patients (0.43%) died of non-venous-thromboembolism-related 
causes.
Of the 1358 patients in whom CTPA ruled out pulmonary embolism, 40 patients 
(2.95%) were treated with anticoagulants for other reasons (ie, 20 atrial fibrillation, three 
superficial thrombophlebitis, one splanchnic vein thrombosis, one thrombus in the left 
ventricle, one high-dose thrombosis prophylaxis, one suspected but later ruled out 
pulmonary vein thrombosis, one vena cava superior syndrome due to mediastinal mass, 
and 12 other reasons including idiopathic pulmonary hypertension and peripheral 
arterial disease) and one patient (0.07%) was lost to follow-up. Of the 1317 remaining 
patients, 11 patients returned with symptomatic events of venous thromboembolism 
(Table 5). The 3-month incidence of venous thromboembolism was 0.84% (11 of 1317 
patients, 95% CI 0.47–1.5) and incidence of fatal pulmonary embolism was 0.30% (four 
of 1317 patients, 0.12–0.78; Table 2). 85 other patients (6.5%) died of non-venous-
thromboembolism-related causes.
DISCUSSION 
Our study showed that the YEARS algorithm safely excluded acute pulmonary embolism. 
An absolute 14% decrease in the need for CTPA was achieved, compared with the stan-

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































did not undergo CTPA was in line with that observed in studies using algorithms with 
sequential diagnostic testing and traditional two-level Wells’ score, and a fixed cutoff 
concentration of D-dimer of 500 ng/mL: 0.43% (95% CI 0.17–0.88) in our study versus 
0.34% (0.036–0.96) reported by a meta-analysis [20]. Moreover, the risk of recurrent 
venous thromboembolism in patients with a normal CTPA was comparable to the risk 
observed in previous studies using standard algorithms: 0.84% (95% CI 0.47–1.5) versus 
1.2% (0.8–1.8) [22]. Additionally, fatal pulmonary embolism occurred in 0.30% (95% CI 
0.12–0.78) of patients in our study compared with 0.6% (0.4–1.1) in another study using 
standard algorithms [22]. 
The advantage of the YEARS algorithm over existing algorithms is the large reduction 
in the need for CTPA, which reduces radiation exposure and overdiagnosis,[1-4,23] and 
is achieved by using variable D-dimer thresholds depending on the clinical probability. 
This study is the first prospective outcome study that validated a D-dimer threshold of 
1000 ng/mL in patients with a low clinical probability.
While our study was ongoing, another strategy to reduce the number of CTPA has 
been validated in a prospective outcome study: the age-adjusted D-dimer threshold 
[10]. If this strategy would have been applied to our study population, the YEARS algo-
rithm would have led to an absolute reduction of 8.7% (95% CI 6.4–11) of CTPA. The main 
reason for this difference is the applicability of the YEARS algorithm to patients with 
suspected acute pulmonary embolism in all ages, and not only in patients older than 50 
years. In patients younger than 50 years, the YEARS algorithm leads to a 14% absolute 
reduction of CTPA. Of note, reducing the number of CTPA is very relevant for young 
patients, particularly women, in whom concerns have been raised about long-term ef-
fects of radiation on the risk of breast cancer.
Methodological strengths of the study include the large number of consecutive pa-
tients, the near complete follow-up, and the independent adjudication of endpoints. 
Furthermore, by studying a real-world cohort of patients in daily practice, we expect that 
the YEARS algorithm can be easily implemented outside the participating study sites, 
and that our data for safety and efficiency are representative for non-trial conditions. Ad-
ditionally, our results are in line with the numbers reported in the initial derivation and 
retrospective validation study of our algorithm [19]. Of note, although haemodynamic 
instability was not a formal exclusion criterion of this study, we have described a cohort 
of only haemodynamically stable patients.
Limitations of our the study are the absence of a control group because we did not 
do a randomised study and could therefore not directly compare the risk of venous 
thromboembolism with a control group that would have been managed with traditional 
algorithms. However, the low observed 3-month risk of venous thromboembolism and 
near complete follow-up strongly support the chosen study design. Moreover, although 




hardly scarcely done. As a consequence, it was difficult to exclude pulmonary embolism 
as a possible cause of death in six patients during follow-up. These patients already had 
or developed extensive comorbidity, or went into the final stage of a terminal illness 
during the follow-up period, with most of them dying in an outpatient setting. Even so, 
although pulmonary embolism was conservatively adjudicated as the cause of death 
in these patients, the recurrence rate observed in our study remained well below the 
safety threshold, reinforcing the validity of our findings. Furthermore, the prevalence of 
pulmonary embolism was higher than observed in large cohorts in North America, but 
lower than observed in previous studies in Europe. The study patients were relatively 
young, but identical to those in an earlier large diagnostic management study by our 
group [7]. The results of the subgroup analyses, however, confirm the validity of applying 
the YEARS algorithm in a patient cohort with higher pulmonary embolism prevalence 
of up to 30% and provide evidence of the generalisability of our findings. Lastly, there 
were 43 violations of the study protocol, with a D-dimer test not done in three patients 
and a non-indicated CTPA done in 40 patients, of which three confirmed the presence of 
acute pulmonary embolism. This number is comparable to that in the Christopher study, 
in which two of 25 unjustified CTPA examinations revealed pulmonary embolism [7]. 
Finally, because of the small number of patients with cancer included in our study, the 
safety of this algorithm for patients with suspected pulmonary embolism in the pres-
ence of cancer remains to be determined.
In conclusion, the YEARS diagnostic algorithm safely ruled out acute pulmonary em-
bolism in patients presenting with clinically suspected pulmonary embolism, with a low 
risk for venous thromboembolism during a 3-month follow-up. The main advantage of 
the YEARS algorithm is the absolute 14% decrease in the number of CTPA examinations 
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New direct oral anticoagulants (NOAC) constitute a novel treatment option for acute 
venous thromboembolism (VTE), with practical advantages. Individual studies have 
demonstrated comparable efficacy to that of vitamin K antagonists (VKA) and have sug-
gested a more favorable safety profile. We performed a meta-analysis to determine the 
efficacy and safety of NOAC as compared with those of VKA in patients with acute VTE.
Methods
We searched MEDLINE, EMBASE, the Cochrane Database of Systematic Reviews and 
the Clinical Trials Registry up to October 2013. Eligible studies included phase 3 trials 
comparing NOAC with VKA in patients with acute VTE. Relative risks (RR), absolute risk 
differences and numbers needed to treat (NNT) to prevent one event were calculated 
for recurrent VTE, fatal pulmonary embolism (PE), overall mortality, major bleeding, and 
other bleeding complications, with random-effects models.
Results
Five studies were included, investigating four NOAC (rivaroxaban, dabigatran, apixaban, 
and edoxaban) in 24 455 patients with acute VTE. RR for recurrent VTE, fatal PE and over-
all mortality for NOAC vs. VKA were 0.88 (95% confidence interval [CI] 0.74–1.05), 1.02 
(95% CI 0.39– 5.96), and 0.97 (95% CI 0.83–1.14), respectively. The RR for major bleeding 
was 0.60 (95% CI 0.41–0.88). The NNT with NOAC instead of VKA to prevent one major 
bleed was 149. The RR and NNT for fatal bleeding were 0.36 (95% CI 0.15–0.87) and 1111. 
A fixed-effect network analysis did not demonstrate significant differences between 
individual NOAC and rivaroxaban.
Conclusions
NOAC have comparable efficacy to that of VKA, and are associated with a significantly 
lower risk of bleeding complications, although the NNT to prevent one major bleed was 
relatively high.
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INTRODUCTION 
Vitamin K antagonists (VKA) constitute the standard treatment for venous thromboem-
bolism (VTE), which includes acute pulmonary embolism (PE) and deep vein thrombosis 
(DVT). VKAs are highly effective for the prevention of recurrent VTE, with a relative risk (RR) 
reduction of ~ 85% as compared with placebo, resulting in a recurrence risk of ~ 3% while 
patients are on treatment [1]. Two important limitations of VKA treatment are the need for 
tailored dosing based on frequent International Normalized Ratio monitoring, and the rate 
of major bleeding complications of ~ 2.1% during the first 6 months of treatment, with a 
case-fatality rate of 11% [2]. Intracranial bleeding account for 8.7% of major bleeds, and is 
associated with a mortality risk of ~  46% [3]. Most major bleeds occur during the first weeks 
of VKA treatment, presumably because of an underlying bleeding predisposition [3,4].
In recent years, new direct oral anticoagulants (NOAC) have been developed, includ-
ing factor IIa (thrombin) and FXa inhibitors, which lack some of the limitations of VKA 
treatment. The relatively stable pharmacokinetics and pharmacodynamics of these 
agents obviate the need for routine laboratory monitoring [5]. Several trials in patients 
with acute VTE have demonstrated comparable efficacy to that of VKA in terms of VTE 
recurrence rates, with lower risks of bleeding complications [6–10]. Nonetheless, the ab-
solute risk of bleeding was low, ranging from 0.6% for fatal bleeding to 10.6% for a first 
major or clinically relevant non-major bleeding, most differences being non-significant. 
However, detailed knowledge about bleeding complications is imperative for the use 
of NOAC in patients with acute VTE. We therefore performed a systematic review and 
meta-analysis to assess the risks of recurrent VTE and bleeding complications in patients 
with acute VTE during treatment with NOAC as compared with VKA.
METHODS 
Data sources and searches 
We searched MEDLINE (via PubMed), EMBASE, the Cochrane Database of Systematic 
Reviews and the Clinical Trials Registry for peer-reviewed publications comparing NOAC 
with standard VKA treatment from inception to 25 October 2013. Our strategy included 
the National Library of Medicine’s Medical Subject Headings keyword nomenclature and 
text words for VTE and NOAC, and validated search terms for randomized controlled 
trials. The complete search string is detailed in Data S1 (all supplementary files are avail-
able at http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1538-7836/). The electronic 
search was complemented with a manual review of reference lists of included articles 
and review articles. For unreported data, we additionally searched the authorization 
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documents available through the European Medicines Agency (www.ema.europa.eu/
ema), and requested the manufacturer to provide unreported data.
Study selection and quality assessment 
Search results were combined and duplicates were removed. Studies were screened 
for relevance by two independent reviewers, on the basis of title and abstract (T.vdH. 
and P.L.dE.). Discrepancies were resolved by consensus or by contacting a third reviewer 
(F.A.K.). Fulltext articles identified by either reviewer as potentially relevant were retrieved 
for further evaluation by the two reviewers. Inclusion criteria for eligible studies were as 
follows: (i) a phase 3 randomized controlled trial in patients with acute VTE comparing 
an orally administered direct FIIa inhibitor (including but not limited to dabigatran) or a 
direct FXa inhibitor (including but not limited to edoxaban, rivaroxaban, and apixaban) 
with VKA treatment; (ii) concerning a population with objectively diagnosed acute DVT, 
PE, or both; (iii) randomly allocating patients to the intervention groups; (iv) reporting 
outcomes after at least 3 months of follow-up, including the diagnosis of acute recur-
rent VTE based on predefined objective criteria in accordance with current international 
standards [11] and the rate of both major and clinically relevant non-major bleeding 
events, and adjudication of outcomes by an independent adjudication committee; and 
(v) publication in a peer-reviewed journal. Exclusion criteria were as follows: (i) studies 
concerning ximelagatran, as its use was rejected by the Food and Drug Administration, 
owing to concerns about potential liver toxicity; and (ii) studies evaluating extended 
anticoagulant treatment, as a proportion of patients in these studies were also included 
in the acute-phase studies, and we were only interested in patients with acute VTE, as 
most bleeding complications occur shortly after the initiation of anticoagulant treat-
ment [3,4].
Risk of bias was evaluated in accordance with the Cochrane Collaboration’s tool for as-
sessing risk of bias in randomized trials [12]. This tool evaluates the presence of random 
sequence generation, allocation concealment, blinding of participants and personnel, 
blinding of outcome assessment, incomplete outcome data, selective reporting, and 
other risks of confounding.
Study outcomes and definitions 
Efficacy outcomes were recurrent VTE, fatal PE, and overall mortality. Safety outcomes 
were major bleeding, non-fatal major bleeding at a critical site, clinically relevant non-
major bleeding, non-fatal intracranial bleeding, major gastrointestinal bleeding, and 
fatal bleeding during anticoagulant treatment.
Recurrent symptomatic VTE included fatal and non-fatal PE and DVT. Recurrent VTE 
was considered as a cause of death if there was objective documentation in terms of 
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autopsy, or if death could not be attributed to another documented cause of death and 
PE could not be ruled out.
The definition of major bleeding was similar for all included studies: overt and associ-
ated with a decrease in the hemoglobin level of ≥ 2 g/dL, requiring transfusion of at 
least two units of blood, occurring in a critical site (intracranial, intraspinal, intraocular, 
pericardial, intra-articular intramuscular with compartment syndrome, retroperitoneal), 
or contributing to death [13]. In all included studies, except for the Re-Cover study, 
clinically relevant non-major bleeding was defined as overt bleeding not meeting the 
criteria for major bleeding complications, but associated with medical intervention, con-
tact with a physician, interruption of study drug, or discomfort or impairment in carrying 
out activities in daily life [14]. In the Re-Cover study, several criteria were established for 
clinically relevant non-major bleeding that are comparable with the definition used in 
the other trials.
Data extraction 
Data extraction was independently performed by two reviewers. For each included 
study, we extracted the number of participants, follow-up period, number of patients 
with DVT, PE, or both, unprovoked VTE, active malignancy, previous VTE, and the mean 
time spent in therapeutic range (TTR) during VKA therapy.
Data synthesis and analysis 
Data were analyzed with the Mantel–Haenszel random-effects model, by the use of 
Review Manager (V. 5.1; The Nordic Cochrane Centre, The Cochrane Collaboration, 
Copenhagen). RRs with corresponding 95% confidence intervals (CI) were reported. 
Comparisons were performed for all endpoints. Statistical heterogeneity was assessed 
and quantified with the Cochrane Q-test and the I2-statistic, respectively. Absolute risk 
differences with CI and the number needed to treat (NNT) with NOAC in order to prevent 
one outcome event were calculated. The NNT calculation was based on the point esti-
mate of the absolute risk difference. The presence of publication bias was evaluated with 
funnel plots, with formal tests for funnel plot asymmetry being used only in the case of 
inclusion of at least 10 studies.
In the absence of trials making direct comparisons between NOAC, we performed 
a fixed-effect network analysis based on inverse variance weighting. In this analysis, 
dabigatran, apixaban and edoxaban were compared with rivaroxaban. Rivaroxaban was 






The initial search identified 889 records in PubMed, 453 unique records in EMBASE, 67 
unique records in the Cochrane Database of Systematic Reviews, and 74 records from the 
Clinical Trials Registry, resulting in a total of 1483 references. On the basis of screening 
of titles and abstracts, 14 studies were selected for full text review. Of these 14 studies, 
four were excluded because they were not phase 3 trials [12,15–17], the Re-Cover II study 
was excluded because this study had not yet been published in a peer-reviewed journal 
[18], the THRIVE II/V study was excluded because of the use of ximelagatran (application 
rejected by the Food and Drug Administration because of concerns about potential liver 
toxicity) [19], and three references were excluded because extended treatment of VTE was 
investigated [20–22]. Therefore, five studies were eligible for inclusion (Figure 1) [6–10].
Characteristics of included randomized controlled trials 
One study evaluated dabigatran in patients with PE and/ or DVT (Re-Cover I study) [6], 
one investigated rivaroxaban in patients with DVT (Einstein-DVT study) [7], one investi-
gated rivaroxaban in patients with PE (Einstein-PE study) [8], one investigated apixaban 
in patients with DVT and/or PE (Amplify study) [9], and one investigated edoxaban in 
patients DVT and/or PE (Hokusai study) [10]. In total, 24 455 patients were included, of 
whom 57% were male. The mean age ranged between 55 and 58 years. The percentage 
of patients with unprovoked VTE varied from 62% to 90%. Overall, PE was present in 
10 796 patients (44%), and 13 607 (56%) had isolated proximal DVT. Active malignancy 
was present in 1465 patients (6%), 4651 patients (19%) had experienced a previous VTE, 
and the TTR ranged from 58% to 64% (Table 1). Dabigatran (150 mg twice daily) and 
edoxaban (60 mg once daily, or 30 mg once daily in the case of a creatinine clearance 
of 30–50 mL/min or a body weight of < 60 kg) were combined with weight-adjusted 
therapeutic-dose low molecular weight heparin or unfractionated heparin as initial 
Figure 1.  Flow diagram of study selection.
Note: VTE, venous thromboembolism.
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treatment for at least 5 days, whereas rivaroxaban (15 mg twice daily for 3 weeks, fol-
lowed by 20 mg once daily) and apixaban (10 mg twice daily for 7 days, followed by 
5 mg twice daily) were used as single-drug regimens. In the Re-Cover study and the 
Amplify study, patients were treated for 6 months; in the Einstein studies and the Hoku-
sai study, the treating physician determined the treatment duration. In the Einstein-DVT 
study, 63% of the patients were treated for 6 months, 25% for 12 months, and 12% for 3 
months. In the Einstein-PE study, 57% of the patients were treated for 6 months, 37% for 
12 months, and 5% for 3 months. In the Hokusai study, 12% of the patients were treated 
for 3 months, 26% for 3–6 months, and 61% for > 6 months.
All included studies were of good quality as determined by the Cochrane Collabo-
ration’s tool for assessing risk of bias in randomized trials (Figure 2). Most important 
potential risks of bias were associated with the open label design of the two Einstein 
studies [7,8], and all five studies were sponsored and managed by the pharmaceutical 
industry. As our meta-analysis included only five studies, we did not perform formal 
tests for funnel plot asymmetry (Data S2).
Meta-analysis: efficacy outcomes 
During anticoagulant treatment, recurrent VTE occurred in 241 of the 12 151 patients 
(2.0%) treated with NOAC and in 273 of the 12 153 patients (2.2%) treated with VKA. In 
accordance with the results of the individual studies, the combined RR for recurrent VTE 
did not demonstrate a significant difference between these drug classes: 0.88 (95% CI 
0.74–1.05) (Table 2; Figure 3). Fatal PE occurred in nine of the 12 151 patients (0.07%) 
treated with NOAC and in nine of the 12 153 patients (0.07%) treated with VKA. In total, 
290 of the 12 197 patients (2.4%) treated with NOAC and 298 of the 12 193 patients (2.4%) 
treated with VKA died during follow-up. The RR for all-cause mortality was 0.97 (95% CI 
0.83–1.14). The I2 of all evaluated efficacy outcomes was 0%, indicating low heterogeneity.
Figure 2.  Results of Cochrane Collaboration’s tool for assessing risk of bias. 
Re-Cover 2009 + + + + + + -
Einstein-DVT 2010 + + - + + + -
Einstein-PE 2012 + + - + + + -
Amplify 2013 + + + + + + -


























































































Note: key: +: Low risk of bias; -: High risk of bias.
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Meta-analysis: safety outcomes 
All combined RR were significantly lower for the patients treated with NOAC, except that 
for major gastrointestinal bleeding (Table 2; Figure 4). Major bleeding occurred in 1.1% 
of the patients treated with NOAC and in 1.7% of the patients treated with VKA, with an 
accompanying combined RR of 0.60 (95% CI 0.41–0.88) and an I2 of 62%. The combined 
absolute risk difference for major bleeding was -0.67% (95% CI -1.13 to -0.21), resulting 
in an NNT with NOAC instead of VKA of 149 (95% CI 88–476).
Non-fatal bleeding at a critical site occurred in 0.23% of the patients treated with 
NOAC and in 0.63% of the patients treated with VKA. The combined RR was 0.38 (I2 = 
13%; 95% CI 0.23–0.62) and the absolute risk difference was -0.38% (95% CI -0.65 to 
-0.10), resulting in an NNT of 263 (95% CI 153–1000).



































































































Note: NOAC: new direct oral anticoagulants; VKA: vitamin K-antagonists; NNT: number needed to treat; CI: 
confidence interval; VTE: venous thromboembolism; PE: pulmonary embolism.
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The combined RR for clinically relevant non-major bleeding was 0.76 (95% CI 
0.58–0.99). This risk varied considerably between the individual studies (I2 of 88%). In 
the studies investigating rivaroxaban (Einstein-DVT and Einstein-PE), the RR were very 
similar, whereas in the studies investigating dabigatran, apixaban, and edoxaban, the RR 
were in favor of NOAC.
Non-fatal intracranial bleeding occurred in 0.09% of the patients treated with NOAC-
and in 0.25% of the patients treated with VKA, resulting in a combined RR of 0.39 (95% CI 
0.16–0.94). Only in the Einstein-DVT study was the incidence higher in patients treated 
with rivaroxaban than in those treated with VKA: two events in 1718 patients vs. 0 in 
1711 patients. In the EINSTEIN-PE study, which also evaluated rivaroxaban, the opposite 
Figure 3.  Effi  cacy outcomes.
Note: NOAC: New Direct Oral anticoagulants; VKA: vitamin-K antagonists.
Figure 4.  Safety outcomes.
Note: NOAC: New Direct Oral anticoagulants; VKA: vitamin-K antagonists.
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association was observed. Owing to the low incidence rates of intracranial bleeding and 
the wide CI, the I2 was only 20%.
The incidence of major gastrointestinal bleeding was not reported in the Hokusai 
study, and the combined RR of the other four studies for NOAC was 0.68 (I2 = 37%; 
95% CI 0.36–1.30); only the Re-Cover study, the only study that investigated a direct 
thrombin inhibitor (dabigatran), reported a higher risk. In this study, the incidence rates 
were 0.71% (9/1273) in patients treated with dabigatran and 0.39% (5/1266) in patients 
treated with VKA, a difference of 0.31% (95% CI -0.26 to 0.89).
Fatal bleeding occurred in seven of the 12 179 patients (0.06%) treated with NOACand 
in 21 of the 12 193 patients (0.17%) treated with VKA, with a combined RR of 0.36 (95% 
CI 0.15–0.87) and an NNT of 1111 (95% CI 588–0). All studies demonstrated RR in favor of 
NOAC, with wide CI because of the low incidence rates, resulting in an I2 of 0%.
Fixed-effect network analysis 
In a fixed-network analysis, dabigatran, apixaban and edoxaban were compared with 
rivaroxaban for the predefined efficacy and safety endpoints. No statistically significant 
differences were observed for all outcomes. For recurrent VTE, P-values ranged from 0.74 
to 0.85, and for major bleeding they ranged from 0.48 to 0.60. The results of the other 
evaluated outcomes are provided in Data S3.
DISCUSSION 
For all of the evaluated efficacy outcomes, the pooled RR were comparable between 
patients treated with NOAC and patients treated with VKA. In contrast, statistically 
significantly lower risks were observed for all evaluated bleeding complications dur-
ing treatment with NOAC than during treatment with VKA, except for the risk of major 
gastrointestinal bleeding. This is probably attributable to a lack of power, as the Hokusai 
study did not report major gastrointestinal bleeding separately, and therefore could not 
be included in this specific analysis. We asked for this information from the manufacturer 
in vain.
Despite the lower bleeding risk with the new agents, our analyses indicate that the 
advantage of NOAC in absolute terms is somewhat limited for patients with acute VTE 
who need anticoagulant treatment for a relatively short duration. This is reflected by the 
high NNT for treatment with NOAC instead of VKA, ranging from 56 to prevent a clini-
cally relevant non-major bleeding to even 1111 to prevent one fatal bleeding. Although 
the inclusion criteria of the trials ruled out patients with any bleeding risks, the relatively 
high NNT cannot be explained by an overall low incidence of bleeding, as the bleeding 
incidences from the pooled studies are very similar to those of other large VTE treat-
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ment studies [3]. Therefore, when NOAC are introduced as a generally accepted therapy 
for acute VTE, the relatively small net benefit should be weighed against the financial 
consequences of using this costly drug class.
Last year, the first meta-analysis of the efficacy and safety of NOAC for the treatment of 
acute VTE was published, with partly overlapping patient cohorts [23]. The major differ-
ence between that meta-analysis and our study is the inclusion of relatively small phase 
2 trials with shorter durations of follow-up and different NOAC dosages, and studies on 
ximelagatran by Fox et al [12,19]. By including the recently published trials on apixaban 
and edoxaban, we exceed their sample size while restricting our analysis to robust data 
of high quality.
Regarding the extended treatment of VTE, i.e. beyond the treatment during the first 3–6 
months, the efficacy and safety of NOAC as compared with VKA are still unclear. In only 
one study was dabigatran randomly compared with VKA during extended treatment; 
hazard ratios for recurrent VTE of 1.44 (95% CI 0.78–2.64) and 0.54 (95% CI 0.41–0.71) for 
major or clinically relevant non-major bleeding were reported [21]. In two other studies, 
apixaban and rivaroxaban were randomly compared with placebo and were included in 
a recently published meta-analysis [24]. As expected, these drugs showed high efficacy 
as compared with placebo, but their efficacy and safety as compared with VKA remain 
to be demonstrated.
Given the absence of the possibility of direct comparisons between the individual 
NOAC, we performed an indirect comparison of dabigatran, apixaban and edoxaban 
with rivaroxaban. Although differences in efficacy and safety outcomes between indi-
vidual drugs can be reasonably expected, no significant differences in efficacy and safety 
outcomes were observed. Owing to the relatively low incidence rates of all outcomes, 
large randomized controlled trials in > 20 000 patients would be required to identify 
potentially relevant differences between the NOAC. For practical reasons, it seems very 
unlikely that such studies will be initiated in the (near) future. Therefore, pooling the re-
sults of all separate studies evaluating different NOAC in comparison with VKA provides 
the best available evidence for deciding whether NOAC constitute a suitable alternative, 
or are even preferable, to VKA for the treatment of acute VTE.
Although not identified by the fixed-effect network analysis, reasonably expected 
differences between the individual drugs may be the reason for the high heterogeneity 
observed for major bleeding (I2 = 62%) and clinically relevant non-major bleeding (I2 = 
88%).
Considering major bleeding, all studies demonstrated RR in favor of NOAC, but the ef-
fect size differed. For clinically relevant non-major bleeding, in particular, the RRreported 
in the Einstein studies differed from the other RR. This might be explained by a specific 
effect of rivaroxaban, or it could be a result of the PROBE design of the Einstein studies, 
as the other studies were double-blind studies. For major gastrointestinal bleeding, the 
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relatively high heterogeneity (I2 = 37%) seems to be explained by the higher RR reported 
in the Re-Cover study. This might be explained by an individual drug effect or a differ-
ence between drug classes (FIIa inhibitors and FXa inhibitors).
The more favorable safety profile of NOAC may be ascribed to their more stable 
anticoagulant effect than that of VKA [5]. The lower risk of intracranial bleeding may 
be a consequence of maintaining normal concentrations of FVII and the formation of 
FVIIa–tissue factor complexes, which play an important role in cerebral vascular damage 
[25]. Other supposed mechanisms are the reduced suppression of thrombin at the site 
of cerebral injury, and the inability of rivaroxaban to substantially penetrate the blood–
brain barrier [26].
A concern regarding NOAC is the absence of specific antidotes. On the basis of 
experimental studies, non-specific prohemostatic agents are recommended for direct 
reversal of the anticoagulant effect [27,28]. It is of note that patients with a major bleed 
while on dabigatran had a better prognosis than patients with a major bleed while on 
VKA[29]. Furthermore, the lower bleeding risk and the presumed introduction of specific 
antidotes in the coming years put this concern in perspective.
Our study has limitations. First, because of the absence of studies comparing the same 
drugs, we were unable to perform a random-effects Bayesian network meta-analysis. 
Even so, the alternatively performed fixed-effect network analysis did not demonstrate 
significant differences between the individual drugs. Second, we were unable to per-
form subgroup analyses for patients with PE and DVT. Third, we could not differentiate 
between early and late bleeding occurrences, as detailed data were lacking. Fourth, 
treatment durations were not identical throughout the studies, although most pa-
tients were subjected to a 6-month anticoagulant course. Fifth, in the Hokusai study, 
the safety outcomes of fatal PE and overall mortality were only reported for the total 
follow-up duration. Sixth, the results of this meta-analysis should not be generalized to 
all patients with acute VTE, as specific populations, including the elderly, patients with 
cancer, patients with renal insufficiency, patients with rare localizations of VTE (e.g. distal 
DVT, splanchnic thrombosis, and cerebral vein thrombosis), and patients with morbid 
obesity, were underrepresented or excluded. Finally, two studies had a PROBE design, 
in which participants and researchers were aware of the treatment allocation, and only 
the adjudication committee was blinded. It has been suggested that the open design of 
PROBE studies leads to a more real-world study population, owing to the easier recruit-
ment of patients, although the risk of reporting bias might be increased. Furthermore, 
this design may influence decisions regarding other medical treatments. Hence, it has 
been suggested that the PROBE design could result in overoptimistic results in favor of 
NOAC. Even so, recent studies evaluating NOAC in patients with atrial fibrillation or VTE 
have not demonstrated such an effect [30,31].
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In conclusion, NOAC show comparable efficacy to VKA in patients with acute VTE, as 
well as greater practical simplicity and a more favorable bleeding profile, although the 
absolute benefit was somewhat limited, owing to the high NNT.
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 CHAPTER 8
Recurrence risk after anticoagulant 
treatment of limited duration for late, 
second venous thromboembolism
T. van der Hulle, M. Tan, P.L. den Exter, M.J.G. van Roosmalen,





Patients with a second venous thromboembolism generally receive anticoagulant treat-
ment indefinitely, although it is known that the recurrence risk diminishes over time 
while the risk of hemorrhage persists with continued anticoagulation and increases with 
age. Based on these arguments and limited evidence for indefinitely prolonged treat-
ment, the Dutch guidelines recommend considering treatment of a limited duration (i.e. 
12 months) for a ‘late’ second venous thromboembolism, defined by a second venous 
thromboembolism diagnosed more than 1 year after discontinuing treatment for a first 
event. It is hypothesized that the risk of continued anticoagulation might outweigh the 
benefits in such circumstances. We evaluated this management in daily practice.
Since 2003, limited duration of treatment was systematically considered at our hospi-
tal in consecutive patients, in whom we determined the recurrence risk. Of 131 patients 
with late second venous thromboembolism, 77 were treated for a limited duration, of 
whom 26 developed a symptomatic third venous thromboembolism thereafter during a 
cumulative follow-up of 277 years, resulting in an incidence rate of 9.4/100 patient-years 
(95% confidence interval: 6.1–14). The incidence rates in patients with unprovoked and 
provoked venous thromboembolism were 12/100 patient-years (95% confidence inter-
val: 7.4–19) and 5.6/100 patient-years (95% confidence interval: 2.2–12), respectively 
[adjusted hazard ratio 2.8 (95% confidence interval: 1.1–7.2)].
The recurrence risk after treatment of limited duration for ‘late’ second venous throm-
boembolism exceeded the risk of hemorrhage associated with extended anticoagula-
tion. Most patients may, therefore, be better served by treatment of indefinite duration, 
although the risk-benefit ratio of extended anticoagulation should be weighed for every 
patient.
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INTRODUCTION
The optimal duration of treatment for a first episode of venous thromboembolism (VTE), 
whether deep vein thrombosis (DVT) or pulmonary embolism (PE), has been studied and 
debated extensively. In general, 3 months of anticoagulant treatment is recommended 
for patients with a provoked VTE. For those with an unprovoked VTE, it is recommended 
that treatment lasts at least 3 months, after which the patient should be evaluated 
for the risk-benefit ratio of extended therapy [1].  In contrast to the numerous studies 
evaluating the optimal duration of treatment for a first VTE, only one study has evalu-
ated the optimal duration of treatment for a second VTE [2]. In that study, a cumulative 
VTE recurrence rate of 21% was reported during 4 years of follow-up in patients treated 
for 6 months, in contrast to a rate of 2.6% in patients in whom treatment was continued 
[relative risk 8.0; 95% confidence interval (CI): 2.5–26]. As expected, a limited duration of 
treatment resulted in a lower cumulative incidence of major hemorrhage (2.7% versus 
8.6%; relative risk 0.3; 95% CI: 0.1–1.1).
Mainly based on this study, the Dutch multidisciplinary guidelines on the diagnosis 
and treatment of VTE suggests an indefinite duration of treatment for a second VTE, 
without making a distinction between provoked and unprovoked VTE [American Col-
lege of Chest Physician (ACCP) level of evidence 2B] [3].
The guidelines also suggest considering a limited duration of treatment of 12 months 
for a ‘late’ second VTE in patients with a long interval between cessation of anticoagu-
lant treatment for the first VTE and the second VTE (ACCP level of evidence 2C). A long 
interval was arbitrarily defined as a period of more than 12 months. The rationale for the 
latter recommendation is that patients with a late second VTE have a relatively limited 
risk of recurrent VTE, which is supported by indirect evidence that the risk of VTE recur-
rence is highest shortly after cessation of anticoagulant treatment for a first VTE and 
then rapidly decreases [4,5]. Taking into account that the anticoagulant-associated risk 
of hemorrhage persists while anticoagulant treatment is continued and considerably 
increases with age, it is argued that the risk of hemorrhage associated with long-term 
anticoagulant treatment may outweigh the reduction of risk of recurrent VTE associated 
with continued anticoagulant treatment in such circumstances [6].
In accordance with the Dutch multidisciplinary guidelines, a limited duration of treat-
ment of 12 months has been systematically considered in all patients diagnosed with 
a late second VTE since 2003 in the Department of Thrombosis and Hemostasis of our 
hospital. As this recommendation is supported by only limited evidence, its evaluation 





We included all consecutive patients who were diagnosed with a late second VTE in the 
period 2003–2012 in the Department of Thrombosis and Hemostasis of the Leiden Uni-
versity Medical Center (LUMC), Leiden, the Netherlands in a prospective registry. Specific 
inclusion criteria for the current analysis were: (i) a previously documented symptomatic 
first provoked or unprovoked VTE; (ii) a documented symptomatic second provoked or 
unprovoked VTE, and (iii) more than 1 year between cessation of anticoagulant treat-
ment for the first VTE and the diagnosis of the second VTE.
In our hospital, suspected recurrent VTE is managed by using an algorithm starting 
with determination of pretest probability, followed by either D-dimer and or radiologi-
cal imaging tests if indicated. The radiological criteria for diagnosing ipsilateral recurrent 
DVT are a compression ultrasonography that shows incompressibility of a different ve-
nous segment than at a reference examination or, in the case of a pronounced increase 
in vein diameter (≥4 mm), of a previous non-compressible venous segment [7].
The treatment protocol recommended a limited duration of treatment for a late sec-
ond VTE in the absence of another indication for anticoagulant treatment, but the final 
decision was made by the treating physician during the first visit of the included patients 
at our outpatient clinic, approximately 6 weeks after the diagnosis of the second VTE. 
Patients were rarely tested for hereditary thrombophilic factors, and no standardized 
model for predicting recurrence risk was used. Diagnostic procedures in the case of sus-
pected recurrence were applied in a standard manner, in accordance with the national 
and international guidelines [1,3]. For all patients, follow-up was completed for at least 
2 years or until March 2014, the patient’s death or the primary endpoint was reached. 
The ethics committee of the LUMC approved this study and waived the requirement for 
informed consent since the study evaluated standard clinical practice.
The primary endpoint of the analysis was a symptomatic third DVT and/or PE dur-
ing follow-up, demonstrated by objective diagnostic tests according to the guidelines 
[1,3,7]. The secondary outcome was the risk of major hemorrhage, defined according to 
the International Society of Thrombosis and Haemostasis criteria [8].
Provoked VTE was defined as VTE occurring after major surgery or immobilization 
for at least 3 days within 4 weeks preceding the diagnosis, in a patient with active ma-
lignancy (a diagnosis of cancer within 6 months prior to enrolment, any treatment for 
cancer within the previous 6 months, or recurrent or metastatic cancer), after a recent 
long flight (>4 hours), during pregnancy or the peripartum period and in patients taking 
oral contraceptives or hormone replacement therapy. Unprovoked VTE was defined as 
VTE occurring without any of these provoking factors. Patients were classified according 
to whether they received treatment of a limited duration, defined as treatment for 12 
months or less, or treatment of indefinite duration. Incidence rates of the primary and 
137
Safety of a treatment of limited duration for a second venous thromboembolism
8
secondary endpoints were calculated and the Kaplan-Meier life table method was used 
to estimate the cumulative event rate.
A Cox proportional hazard model was used to calculate hazard ratios (HR) for clinical 
characteristics. We performed subpopulation analyses for: (i) patients with unprovoked 
and provoked second VTE; (ii) patients with unprovoked first and second VTE and those 
with provoked first and second VTE; (iii) DVT or PE as the second VTE; (iv) patients <65 
years old and those ≥65 years old; (v) patients with an anticoagulant effect within the 
therapeutic range for <60% and ≥60% of the time, calculated by the Rosendaal method 
[9,10]; and (vi) a limited duration of treatment for the second VTE of 12 months and less 
than 12 months. Hazard ratios were adjusted for age, sex, type of the second VTE (DVT 
or PE±DVT) and whether the second VTE was provoked or unprovoked. Analyses were 
performed using SPSS version 20 (SPSS inc., Chicago, IL, USA).
RESULTS
Between 2003 and 2012, 131 patients were diagnosed with a late second VTE. One 
patient was excluded from the analysis, because she died before the planned cessation 
of anticoagulant treatment after 12 months. The baseline characteristics of the whole 
cohort are shown in Table 1.
Limited duration of treatment
Overall, 77 patients were treated for a limited duration: five patients for a total of 3 
months, 26 patients for 6 months and 46 patients for 12 months. All these patients were 
followed up for at least 2 years with a median duration of follow-up of 34 months after 
treatment cessation. The mean age at the time of diagnosis of the second VTE was 52 
years, and 35 patients were male (46%).
In 50 patients (65%) the second VTE was a DVT, leaving 27 patients (35%) diagnosed 
with PE as the second VTE, with or without symptomatic DVT. The type of the first VTE 
and second VTE was different in only 15 patients, while in the other 62 patients both 
events were of the same type. In 46 patients both the first and second VTE were DVT, in 
29 (63%) cases the recurrent DVT was ipsilateral to the first, whereas in 17 (37%) cases 
the second DVT was contralateral to the first. The median time between the first and 
second VTE was 7.2 years (interquartile range, 3.6 – 13 years). A provoking risk factor 
for the second VTE was reported for 30 of 77 patients (39%): recent surgery and/or 
immobilization in 14 patients, oral contraceptive use in eight patients (one of whom 
also had a history of recent surgery and/or immobilization), a long flight in five patients 
(one of whom was also taking an oral contraceptive), pregnancy in four patients and 
malignancy in one patient, leaving 47 patients (61%) with unprovoked, late second VTE. 
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Mean age (SD) 53 (16) 52 (15) 54 (16)
Male sex 62 (47) 35 (46) 27 (50)
Known heart failure 3 (2.3) 2 (2.6) 1 (1.9)
Known COPD 4 (3.1) 2 (2.6) 2 (3.7)
Type of first VTE
DVT 86 (66) 57 (74) 29 (54)
PE ± DVT 45 (34) 20 (26) 25 (46)
Unprovoked first VTE 58 (44) 33 (43) 25 (46)
Type of second VTE
DVT 87 (66) 50 (65) 37 (69)
PE ± DVT 44 (34) 27 (35) 17 (31)
Unprovoked second VTE 80 (61) 47 (61) 33 (61)
Concordant versus discordant type (regarding the first and second VTE)
2 times DVT, ipsilateral 45 (34) 29 (38) 16 (30)
2 times DVT, contralateral 27 (21) 17 (22) 10 (19)
2 times PE 30 (23) 16 (21) 14 (26)
1 DVT and 1 PE 29 (22) 15 (19) 14 (26)
Provoked second VTE 51 (39) 30 (39) 21 (39)
Surgery or immobilization 21 (16) 14 (18) 7 (13)
Oral contraceptive use 11 (8.4) 8 (10) 3 (5.6)
Long flight 8 (6.1) 5 (6.5) 3 (5.6)
Pregnancy 7 (5.3) 4 (5.2) 3 (5.6)
Active malignancy 11 (8.4) 1 (1.3) 10 (19)
Median time between first and second VTE in 
years (IQR)
6.2 (3.3-12) 7.2 (3.6-13)  5.8 (3.2-10)
1-5 years 55 (42) 31 (40) 24 (44)
5-10 years 35 (27) 18 (23) 17 (31)
>10 years 41 (31) 28 (36) 13 (24)
Treatment duration in months
3 NA 5 (6.5) NA
6 NA 26 (34) NA
12 NA 46 (60) NA 
Time in therapeutic range*
<60% NA 6/67 (9.0) NA
≥60% NA 61/67 (91) NA
Note: SD: standard deviation; COPD: chronic obstructive pulmonary disease; VTE: venous thromboembo-
lism; DVT: deep vein thrombosis; PE: pulmonary embolism; IQR: interquartile range; NA: not applicable; 
*only available from 67 patients due to 10 patients who were treated by a Thrombosis Service in another 
region.
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The patient with cancer received the last dose of chemotherapy for testicular cancer 
at the moment of the second VTE, after which he was in complete remission, allowing 
treatment cessation according to the Dutch guidelines.
Five patients (6.5%) were treated for only 3 months based on the argument that the 
late recurrent event was caused by a transient provoking factor, 26 patients (34%) were 
treated for 6 months and the majority of the 46 patients (60%) were treated for 12 months 
after the diagnosis of late second VTE. Seven patients (9.1%) died during the follow-up 
after cessation of anticoagulation. Six of the deaths were not related to VTE: two patients 
had end-stage metastatic malignancy diagnosed during follow-up, one patient commit-
ted suicide, one patient developed non-anticoagulation-associated intracranial bleeding, 
one patient had end-stage heart failure and one patient died as a direct result of a traffic 
accident. The cause of death could not be retrieved for one patient, who died at the age 
of 91, 6 years after cessation of anticoagulant treatment for recurrent DVT.
Overall, 26 of the 77 patients were diagnosed with a third VTE during a cumulative 
follow-up of 277 patient-years. The third VTE was of the same type as the second VTE in 
24 patients: of the 16 patients who developed DVT as the third VTE event, only one had 
PE as the second VTE and of the ten patients with PE as the third VTE only one had DVT 
as the second VTE. Of the 16 patients who developed DVT as the third VTE, 12 (75%) had 
been previously diagnosed with DVT on the same side (either as first or second VTE). 
Seven of the 26 patients had a provoked second VTE, of whom two patients (29%) expe-
rienced a provoked third VTE and five (71%) an unprovoked third VTE. The remaining 19 
patients had an unprovoked second VTE: in four cases (21%) the third VTE was provoked, 
whereas in the other 15 (79%) the third VTE was also unprovoked.
The incidence rate of a third VTE after limited treatment was 9.4 per 100 patient-years 
(95% CI: 6.1–14), and 1-, 2-, 3- and 5-year cumulative VTE rates were 15% (95% CI: 3.1–34), 
19% (95% CI: 6.1–38), 25% (95% CI: 10–42) and 33% (95% CI: 18–49), respectively. When 
the unexplained death was considered as attributable to recurrent VTE, the incidence 
rate was 9.7/100 patient-years (95% CI: 6.4–14).
Treatment of indefinite duration
For 39 of the 54 patients who were treated for an indefinite duration, the reason for this 
decision was documented: ten patients (19%) had an active malignancy, ten patients 
(19%) had known hereditary thrombophilia, nine patients (17%) had an additional 
indication for anticoagulant treatment, in four patients (7.4%) it was the patients’ strong 
preference to continue treatment, in four patients (7.4%) antiphospholipid syndrome 
was diagnosed, one patient (1.9%) was persistently immobile, one patient (1.9%) had a 
strongly positive family history and in one patient (1.9%) the large thrombotic load of 
the second VTE was considered as a reason for continuing treatment. For the remaining 
15 patients (28%), no specific reason was documented.
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Among the patients on anticoagulant treatment for an indefinite period, 13 died dur-
ing follow-up (24%): in 11 of these patients, VTE was ruled out as the cause of death, 
whereas the cause of death could not be retrieved for the other two patients.
Four patients developed a third VTE while being treated with anticoagulants during 
a cumulative follow-up of 332 patient-years, resulting in an incidence rate of 1.2/100 
patient-years (95% CI: 0.33–3.1) (Figure 1). None of these events was fatal. When the 
unexplained deaths were considered as attributable to recurrent VTE, the incidence 
rate was 1.8/100 patient-years (95% CI: 0.66–3.9). Major hemorrhage occurred in eight 
patients, resulting in an incidence rate of 2.4/100 patient-years (95% CI: 1.0–4.7). None 
of these hemorrhages were fatal.
Figure 1.  Cumulative incidence rate of a third venous thromboembolism in patients treated for a limited 
duration and patients treated for an indefinite duration.
Note: nrVTE: number of recurrent VTE; PAR: patients at risk. Follow-up started at the time of the second 
venous thromboembolism diagnosis for both categories. 
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Subgroup analyses in the patients treated for a limited duration
Cox-regression analysis demonstrated a higher risk of recurrence in patients with an 
unprovoked second VTE than in those with a provoked second VTE (adjusted HR 2.8; 
95% CI: 1.1–7.2) (Figure 2). The incidence rate in patients with a provoked second VTE 
was 5.6/100 patient-years (95% CI: 2.2–12). The 1-, 2-, 3- and 5-year cumulative VTE rates 
were 10% (95% CI: 0.082–48), 10% (95% CI: 0.082–48), 14% (95% CI: 0.54–49) and 20% 
(95% CI: 1.8–53), respectively. The incidence rate in patients with an unprovoked second 
Figure 2.  Cumulative third venous thromboembolism event rate in patients with a provoked second VTE 
versus an unprovoked second VTE, treated for a maximum of 12 months.




VTE was 12/100 patient-years (95% CI: 7.4–19). The 1-, 2-, 3- and 5-year cumulative VTE 
rates were 17% (95% CI: 3.0–42), 25% (95% CI: 7.8–46), 30% (95% CI: 13–51) and 41% 
(95% CI: 22–59), respectively. In patients with both an unprovoked first and second VTE 
the incidence rate of a third VTE was 8.7/100 patient-years (95% CI: 3.5–18) whereas in 
those with a provoked first and second VTE it was 4.6/100 patient-years (95% CI: 1.3–12).
In patients with DVT as the second VTE, the incidence rate of a third recurrence 
was 8.3/100 patient-years (95% CI: 4.8–14). In patients with PE as the second VTE, the 
incidence rate was 12/100 patient-years (95% CI: 5.6–21). This difference between the 
two groups was not statistically significant (adjusted HR 0.65; 95% CI: 0.29–1.5). The 
incidence rate of a third VTE in patients <65 years old was 9.9/100 patient-years (95% 
CI: 6.1–15) whereas in those ≥65 years old it was 7.8/100 patient-years (95% CI:2.5–18), 
with an adjusted HR of 1.2 (95% CI: 0.43–3.4). Due to the low number of patients whose 
anticoagulation was in the therapeutic range for <60% of the time, we refrained from 
subgroup analyses based on this variable (Table 1). Finally, the VTE incidence rate in 
patients treated for 3 or 6 months was lower - although non-significantly - than that 
after a 12-month treatment period: 6.1/100 patient-years (95% CI: 2.8–12) versus 13/100 
patient-years (95% CI: 7.7–21), with an adjusted HR of 0.6 (95% CI: 0.25–1.4).
DISCUSSION
We evaluated the outcome in daily clinical practice of following the recommendation 
in the Dutch multidisciplinary guidelines to consider a limited duration of treatment in 
selected patients with a ‘late’ second VTE [3]. We found a VTE incidence rate of 9.4/100 
patient-years after cessation treatment of a limited duration, with a cumulative VTE rate 
of 15% after 1 year follow-up which increased to 33% after 5 years of follow-up. In order 
to weigh these results, two issues should be discussed.
First, the VTE incidence rate of 9.4/100 patient-years largely exceeds the risk of major 
hemorrhage associated with long-term anticoagulant treatment, which was estimated 
to be 2.7/100 patient-years in a meta-analysis and was 2.4/100 patient-years in our cohort 
of patients who were treated for an indefinite period [11]. Notably, the clinical impacts of 
recurrent VTE and major hemorrhage are frequently considered as equivalent, which is 
supported by the more or less comparable case-fatality rate varying from 3.8 to 11% for 
recurrent VTE and 9.1% (95% CI: 2.5–22) for major hemorrhage [11-13].
Second, we should compare our results to the 3–4% per year risk of recurrent VTE after 
a first VTE related to a transient provoking factor, since a limited duration of treatment 
is generally accepted for these patients [1,14]. The results of our subgroup analyses sug-
gest that patients with a provoked second VTE have a much lower risk of recurrence than 
have patients with an unprovoked second VTE. Despite the wide confidence interval, 
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the incidence rate of 5.6/100 patient-years (95% CI: 2.2–12) for a third VTE in patients 
with a provoked, late second VTE is relatively low and seems to approximate the risk of 
recurrent VTE after a first provoked VTE.
Based on these considerations, we argue that most patients with a late second VTE are 
generally better served by treatment of an indefinite duration. Furthermore, our results 
suggest that selecting patients with a relatively low VTE recurrence risk based on the 
interval between cessation of anticoagulant treatment and the second VTE is not an 
appropriate strategy. Nevertheless, it remains essential to weigh the risk-benefit ratio of 
extended anticoagulant treatment in every patient individually.
The introduction of new oral anticoagulants for the treatment of VTE must be consid-
ered in the context of our results, since these drugs are associated with a lower risk of 
bleeding complications than vitamin K antagonists, and yet have comparable efficacy 
[15]. The use of these drugs may, therefore, shift the risk-benefit ratio of long-term anti-
coagulant treatment in favor of indefinite duration of treatment for many patients.
The strengths of our study are the completeness of the data on recurrences, bleeding 
complications and follow-up. The large percentage of time that the patients spent in the 
therapeutic range of anticoagulation confirms the high quality of care they received. 
Moreover, we report previously undescribed outcomes in daily clinical practice of a 
unique treatment recommendation for patients with a second VTE. Finally, the recur-
rence risk in the group treated indefinitely as well as the observation that patients most 
frequently develop a recurrence of the same type, either DVT or PE, are in accordance 
with findings in previous large studies and therefore indicate that we studied a repre-
sentative cohort of patients [16].
Our analyses have limitations, of which the most important are related to the obser-
vational design of the study. As a result, the choice of patients who received treatment 
of a limited duration was not randomized, which may have resulted in a selection bias. 
As argued before, it is more likely that this would have resulted in an underestimation of 
the recurrence risk after a limited duration of treatment than in an overestimation. It is, 
therefore, very unlikely that our conclusions would have been different had a different 
study design been used. Also inherent to the design, is that 40% of the patients were 
treated for less than 12 months, despite the recommendation of a treatment duration of 
12 months in the Dutch multidisciplinary guidelines. We did not, however, find a higher 
recurrence risk in patients treated for 3 or 6 months compared to that in patients treated 
for 12 months suggesting that this factor was of no or only little influence on our results. 
In addition, in a meta-analysis by Van Dongen and colleagues it was demonstrated that 
the recurrence risk after VTE did not depend on the duration of treatment, although this 
concerned a study of patients with a first VTE [4]. The lack of long-term follow-up data of 
the larger population from which our study subjects were derived, i.e. all patients with a 
diagnosis of first or recurrent VTE, did not allow us to compare the recurrence rate after a 
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second VTE to that after a first VTE. Finally, due to the relatively small number of patients 
the confidence intervals for our primary and secondary endpoints were wide, especially 
for the subgroup analyses.
In conclusion, our study provides insight into the risk of recurrence after treatment 
of limited duration for a late second VTE, which exceeded the risk of hemorrhage as-
sociated with extended anticoagulant treatment in our cohort. We, therefore, argue 
that most patients with a late second VTE are generally better served by treatment of 
indefinite duration, although the risk-benefit ratio of extended anticoagulant treatment 
should be weighed for every individual patient in daily clinical practice.
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After diagnosis of cancer-associated venous thromboembolism (VTE), guidelines recom-
mend considering the continuation of anticoagulant treatment until the patient is cured 
of cancer, although the safety of stopping anticoagulant treatment after the patient is 
cured has never been evaluated.
Methods
We conducted a cohort study in consecutive patients in whom cancer-associated VTE 
was diagnosed at the Leiden University Medical Center between January 2001 and Janu-
ary 2010 and monitored for the effect of cancer treatment, occurrence of recurrent VTE, 
major hemorrhage, and death.
Results
Of the 358 patients with cancer-associated VTE, anticoagulant treatment was continued 
until the death of 207 patients. In another 12 patients anticoagulant treatment was 
continued because of an alternative indication despite their being cured of cancer. 
Anticoagulant treatment was stopped in 50 patients for reasons other than major hem-
orrhage despite active cancer, in 21 patients after major hemorrhage, and in 68 patients 
after they had been cured of cancer. Among these 68 patients, 10 patients received a 
diagnosis of symptomatic recurrent VTE during a cumulative follow-up of 311 years, re-
sulting in an incidence rate of 3.2 per 100 patient-years (95% CI, 1.5-5.9). Seven of these 
10 patients with recurrent VTE experienced a cancer relapse during follow-up. For the 
50 patients who stopped anticoagulant treatment despite active cancer the recurrent 
VTE incidence rate was 19 per 100 patient-years (11 events during 59 years of follow-up; 
95% CI, 9.3-33).
Conclusions
Our data support the recommendation to stop anticoagulant treatment of cancer-
associated VTE in patients cured of cancer. A cancer relapse seems to be a strong risk 
factor for recurrent symptomatic VTE.
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INTRODUCTION
Venous thromboembolism (VTE) is a well-recognized complication in the course of 
cancer and causes significant morbidity and mortality. Arterial and venous thromboem-
bolism has been reported to be the second leading cause of death among patients with 
cancer, after cancer itself [1]. Also, all-cause mortality is higher in patients with cancer-
associated VTE compared with matched patients with cancer but without concomitant 
VTE [2]. Established risk factors for cancer-associated VTE include metastatic disease, the 
presence of central venous catheters, chemotherapy, recent surgery, and immobiliza-
tion [3-4].
Treatment of cancer-associated VTE is challenging because of the high risk of both 
recurrent VTE and major hemorrhage under anticoagulant treatment, with hazard 
ratios of 3.2 (95% confidence interval [CI], 1.9-5.4) and 2.2 (95% CI, 1.2-4.1), respectively, 
compared with patients with VTE but without cancer. The 12-month cumulative risk of 
recurrent VTE and major hemorrhage in patients with cancer while receiving anticoagu-
lant treatment has been reported to be as high as 21% and 12%, respectively, compared 
with 6.8% and 4.9% in patients without cancer [5]. Both the type of anticoagulant treat-
ment and the optimal duration of treatment have been debated [6-9].  In the absence 
of evidence from clinical trials, treatment of cancer-associated VTE beyond the initial 
6 months after diagnosis remains controversial. Since the risk of recurrent VTE after the 
initial 6 months is believed to remain high, some authors have considered continuing 
anticoagulant treatment as long as the cancer is active [7-8,10-11]. The American Society 
of Clinical Oncology guideline recommends considering continuation of anticoagulant 
treatment only for selected patients with active cancer, such as patients with meta-
static disease or those receiving chemotherapy [11]. On the other hand, some patients 
with cancer-associated VTE successfully complete a curative anticancer treatment, 
for instance, radical surgery or adjuvant chemotherapy, and in these patients the VTE 
recurrence risk is assumed to be low since the provoking factor is no longer present. 
Consequently, in these patients who are cured of cancer anticoagulant treatment could 
possibly be stopped, although the safety of treatment withdrawal has never been in-
vestigated [7-8,10]. Therefore, we evaluated the treatment of cancer-associated VTE in 
daily clinical practice, with the aim of determining the safety of stopping anticoagulant 





This was an observational chart review study including all consecutive patients in whom 
cancer-associated VTE was diagnosed in the period from January 2001 to January 2010 
at the Leiden University Medical Center (Leiden, the Netherlands). VTE was defined as 
a diagnosis of either pulmonary embolism (PE), lower extremity deep vein thrombosis 
(DVT), or upper extremity DVT. PE had to be confirmed by contrast-enhanced CT scan or 
by ventilation-perfusion (V/Q) lung scan, and DVT had to be confirmed by (compression) 
ultrasonography or CT venography in accordance with current guidelines [7,12]. Patients 
with symptomatic VTE as well as those with incidentally diagnosed VTE were included 
in this study. Active cancer was defined as cancer diagnosed within 6  months of the 
diagnosis of VTE (excluding basal cell or squamous cell carcinoma of the skin), recently 
recurrent or progressive cancer, or any cancer that required anticancer treatment within 
the 6 months preceding the diagnosis of VTE. Patients with solid malignancies as well as 
those with hematologic malignancies were eligible.
Patients with cancer-associated VTE were treated according to local clinical practice. 
Before 2007, standard treatment of cancer-associated VTE was initially low-molecular-
weight heparin (LMWH) or unfractionated heparin followed by long-term vitamin K 
antagonists (VKA). From 2007, standard treatment consisted of weight-adjusted thera-
peutic nadroparin (171 International Units of anti-factor Xa/kg once daily). The initial du-
ration of treatment of cancer-associated VTE was 3 to 6 months. Thereafter an indefinite 
duration of treatment was considered for all patients with active cancer, although the 
guideline allowed physicians to consider a limited duration of treatment after weighing 
the risk of recurrent VTE and the risk of major hemorrhage. For patients with an upper 
extremity DVT associated with a central venous catheter that was removed, the stan-
dard duration of treatment was 4 weeks after removal of the central venous catheter. 
Incidentally diagnosed and symptomatic VTE were treated in the same way [7-8,10]. The 
institutional review board of the Leiden University Medical Center approved the study 
and waived the need for informed consent.
Study Aims, End Points, and Follow-up Procedures
The primary aim of this study was to determine the incidence rates of recurrent VTE 
and major hemorrhage after stopping anticoagulant treatment in patients who were 
considered to be cured of cancer. The secondary aims were (1) to evaluate the clinical 
course if a cancer relapse or new cancer was diagnosed, (2) to determine the incidence 
rates of recurrent VTE and major hemorrhage after anticoagulant treatment was 
stopped for reasons other than major hemorrhage in patients with active cancer, and 
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(3) to determine the incidence rates of recurrent VTE and major hemorrhage in patients 
while receiving anticoagulant treatment.
Recurrent PE was defined as a new intraluminal filling defect on pulmonary angi-
ography or computed tomographic pulmonary angiography, a new high-probability 
perfusion defect on V/Q scan or any new defects after earlier normalization of the 
scan, or confirmation of a new PE at autopsy. V/Q scans were evaluated according to 
PIOPED (Prospective Investigation of Pulmonary Embolism Diagnosis) criteria. Recurrent 
lower extremity DVT was defined as new noncompressibility by ultrasonography of the 
common femoral and/or popliteal vein in the transverse plane or as an increase in vein 
diameter under maximal compression, as measured in the abnormal venous segment, 
indicating an increase in thrombus diameter (≥ 4 mm). Recurrent upper extremity DVT 
was defined as evidence of VTE in the subclavian, axillary, and/or brachial vein on ultra-
sonography or CT venography [12].  Incidentally diagnosed VTEs detected on imaging 
for oncologic staging were not counted toward the end points in this study, since it is 
highly complicated to decide whether signs of VTE on a nondedicated imaging test after 
the initial VTE represent recurrent or residual VTE.
Secondary end points included fatal PE, major hemorrhage, fatal hemorrhage, a 
cancer relapse, a new diagnosis of cancer, and death. Major hemorrhage was defined 
in accordance with the International Society on Thrombosis and Haemostasis criteria 
[13]. The cause of death was verified by reviewing medical records and, if available, the 
pathology.
All patients were monitored regularly in the context of standard clinical care by their 
oncologist for new signs or symptoms of a malignancy according to relevant oncology 
guidelines, as well as the occurrence of symptomatic recurrent VTE. Patients were moni-
tored until their last visit to our hospital, until death, or until September 2014. Medical 
records were reviewed by two reviewers for the occurrence of end points of the study 
(T. v. d. H. and P. v. d. H.).
Patients were considered to be cured of cancer or “in complete remission” when the 
following criteria were fulfilled: (1) there were no signs and symptoms suggestive of 
residual or recurrent disease; (2) anticancer treatment with a curative intent had been 
completed, including adjuvant hormonal therapy and chemotherapy; (3) a reasonable 
chance of cure existed, taking into account the cancer type and stage (ie, nonmetastatic 
disease or an objectively determined response to treatment). The final decision as to 
whether a patient was considered to be cured was made by the treating oncologist. A 
new diagnosis or a recurrence of cancer had to be confirmed by tissue sampling.
Analyses and Statistics
To provide an overview of the total cohort, 6- and 12-month cumulative incidence rates 
of recurrent VTE, major hemorrhage while receiving anticoagulant treatment, and death 
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were calculated according to the Kaplan-Meier method, starting at the time of diagnosis 
of cancer-associated VTE.
For analysis of the primary and secondary end points, follow-up started at the time 
anticoagulant treatment was stopped and censored at the time of a recurrent VTE, 
major hemorrhage, death, or last follow-up, whichever came first. Incidence rates were 
calculated according to the Kaplan-Meier method with 95% CI. No direct comparisons 
between patient groups were performed.
All analyses were repeated after excluding patients with an incidentally diagnosed 
VTE. Data were analyzed with SPSS version 20 (SPSS Inc).
RESULTS
Three hundred and fifty-eight patients received a diagnosis of cancer-associated VTE 
(Table 1). The mean age was 59 years (SD, 15), 189 patients (53%) were male, and 282 
patients (79%) had metastatic cancer. Two hundred and thirty-one patients (65%) had 
PE (with or without DVT), 96 patients (27%) had an isolated DVT of the lower extremities, 
and 31 patients (8.7%) had an isolated DVT of the upper extremities. VTE was inciden-
tally diagnosed in 61 patients (17%), of whom 55 patients had PE, five patients had lower 
extremity DVT, and one patient had upper extremity DVT. Only in 17 of the 231 patients 
(7.4%) with PE was the diagnosis based on a V/Q scan; of these, two patients also 
received a diagnosis of DVT. In the remaining 214 patients with PE the diagnosis was 
based on CT scan. Of the 358 patients, 142 patients (40%) were treated with long-term 
LMWH, 205 patients (47%) with VKA, nine patients (2.5%) were treated with intravenous 
unfractionated heparin, one patient (0.3%) was in a terminal phase of cancer and anti-
coagulant treatment was withheld, and one patient (0.3%) was treated with an inferior 
vena cava filter only because of concurrent major hemorrhage. For the total cohort, the 
6- and 12-month cumulative mortality risks were 45% (SE, 0.026) and 57% (SE, 0.026), 
respectively. Of the 204 patients who died within the first 12 months of follow-up, the 
cause of death was directly related to the cancer in 167 patients (82%). Six patients 
(2.9%) had a fatal hemorrhage; seven patients (3.4%) had a (high suspicion of ) fatal PE; 
20 patients (9.8%) died of another, directly related cause; and in four patients (2.0%) the 
cause of death was unclear. Thirty-three recurrent VTE events occurred among patients 
while receiving anticoagulant treatment during a cumulative follow-up of 282 years, for 
an incidence rate of 12 per 100 patient-years (PY) (95% CI, 8.1-16). Major hemorrhage 
occurred in 53 patients while receiving anticoagulant treatment during a cumulative 
follow-up of 240 years, for an incidence rate of 22 per 100 PY (95% CI, 17-29). Outcomes 
while receiving anticoagulant treatment were comparable between patients with inci-
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dental VTE and those with symptomatic VTE, and in the period 2001-2005 compared 
with 2006-2010 (data not shown).




AC stopped after 
cure from cancer
n=68
AC stopped for 





Mean age (SD) 59 (15) 53 (17) 56 (15)
Male sex, n (%) 189 (53) 35 (51) 27 (54)
Previous VTE, n (%) 30 (8.4) 3 (4) 6 (12)
Metastatic cancer, n (%) 282 (79) 38 (56) 43 (86)
Surgery < 4 weeks, n (%) 64 (18) 25 (37) 5 (10)
Immobilization <4 weeks, n (%) 157 (44) 44 (65) 20 (40)
Incidentally diagnosed, n (%) 61 (17) 14 (21) 6 (12)
Cancer type, n (%)
Lung 54 (15) 2 (3) 4 (8)
Colorectal 24 (7) 3 (4) 3 (6)
Other gastrointestinal 42 (12) 10 (15) 2 (4)
Breast 28 (8) 0 (0) 7 (14)
Testicular 15 (4) 11 (16) 2 (4)
Gynaecological 22 (6) 6 (9) 5 (10)
Central nervous system 10 (3) 0 (0) 1 (2)
Other solid 98 (27) 17 (25) 9 (18)
Multiple Myeloma 10 (3) 2 (3) 6 (12)
Non-Hodgkin lymphoma 22 (6) 7 (10) 5 (10)
Other haematological 33 (9) 10 (15) 6 (12)
Type of VTE, n (%)
PE (±DVT) 231 (65) 48 (71) 31 (62)
Lower extremity DVT 96 (27) 15 (22) 14 (28)
Upper extremity DVT 31 (9) 5 (7) 5 (10)
Treatment, n (%)
LMWH 142 (40) 30 (44) 11 (22)
VKA 205 (57) 38 (56) 39 (78)
Other/none 11 (3) 0 (0) 0 (0)
Note: AC: anticoagulation; SD: standard deviation; VTE: venous thromboembolism; PE: pulmonary embo-
lism; DVT: deep vein thrombosis; LMWH: low-molecular-weight-heparin; VKA: vitamin K antagonists.
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Patients Cured of Cancer
Of the 358 patients, 80 patients (22%) were cured of cancer during follow-up, of whom 12 
patients had another indication for continuing anticoagulant treatment: eight patients 
received a diagnosis of atrial fi brillation, two had a persistent vena cava inferior fi lter, 
one patient had a history of recurrent VTE, and one patient was immobilized (Figure 1). 
In the remaining 68 patients, whose baseline characteristics are shown in Table 1, anti-
coagulant treatment was stopped after a median duration of 6.0 months (interquartile 
range, 4.7-6.7 months).
After anticoagulant treatment had been stopped, 10 patients had a symptomatic 
recurrent VTE during a cumulative follow-up of 311 years, for an incidence rate of 3.2 per 
100 PY (95% CI, 1.5-5.9) (Figure 2, Table 2). Three of these patients had PE, fi ve patients 
had a lower extremity DVT, and two patients had an upper extremity DVT. No incidental 
VTEs were diagnosed among these patients. In 15 of the 68 patients (22%) a cancer 
relapse was diagnosed, and three patients (4.4%) received a diagnosis of a new primary 
malignant tumor. Of the 10 recurrent VTE events, seven events occurred in patients who 
also experienced a cancer relapse: fi ve occurred in patients who shortly before or at the 
same time received a diagnosis of a cancer relapse, two patients experienced a cancer 
relapse 9 and 14 months after the recurrent VTE event, and three patients remained free 
of a cancer relapse. Seven of the 15 patients (47%) with a cancer relapse also experienced 
a recurrent VTE. A major hemorrhage occurred in four of the 68 patients after antico-
agulant treatment was  stopped during a cumulative follow-up of 303 years, resulting 
Figure 1.  Management of cancer-associated VTE in total cohort (n=358).
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in an incidence rate of 1.3 per 100 PY (95% CI, 0.4-3.4). None of the major hemorrhages 
occurred in patients in whom a cancer relapse or new cancer was diagnosed.
Patients Not Cured of Cancer in Whom Anticoagulant Treatment Was Stopped
In 50 of the 278 patients with active cancer, anticoagulant treatment was stopped for 
reasons other than the occurrence of a major hemorrhage after a median duration of 
5.8 months (interquartile range, 3.9-6.5 months). In nine of these 50 patients a reason 
for stopping anticoagulant treatment was documented, that is, a supposed high risk of 
major hemorrhage or frequently planned invasive procedures. In the remaining 41 pa-
tients a limited duration of treatment was considered to be sufficient, although it cannot 
be completely excluded that this decision was influenced by the presence of any relative 
contraindication, for instance, an estimated higher-than-standard risk of major hemor-
rhage. After anticoagulant treatment was stopped, a nonfatal recurrent VTE developed 
in 11 patients during a cumulative follow-up of 59 years, resulting in an incidence rate of 
19 per 100 PY (95% CI, 9.3-33) (Figure 2, Table 2). A major hemorrhage occurred in three 
patients after anticoagulant treatment was stopped during a cumulative follow-up of 59 
years, for an incidence rate of 5.1 per 100 PY (95% CI, 1.1-15).
DISCUSSION
The key finding of our study is the 3.2-per-100 PY (95%  CI, 1.5-5.9) incidence rate of 
recurrent VTE in patients whose anticoagulant treatment was stopped after they were 
cured of cancer. This rate is fully comparable to the VTE recurrence rate of 3.3 per 100 PY 
(95% CI, 2.8-3.9) after stopping anticoagulant treatment in patients with a first VTE re-
lated to a transient provoking factor, in whom a 3- to 6-month duration of anticoagulant 
Table 2.  Risk of recurrent VTE and major haemorrhage.
Category
Events / cumulative follow-up
Incidence rate 
(95% CI)
Recurrent VTE Major haemorrhage
While on anticoagulant treatment for 
total cohort 
33 / 282 years
12 / 100 PY
(8.1-16)
53 / 240 years
22 / 100 PY 
(17-29)
Anticoagulant treatment stopped 
after cure from cancer
10 / 311 years
3.2 / 100 PY 
(1.5-5.9)
4 / 303 years
1.3 / 100 PY
(0.4-3.4)
Anticoagulant treatment stopped 
for reasons other than major 
haemorrhage despite active cancer
11 / 59 years
19 / 100 PY
(9.3-33)
3 / 59 years
5.1 / 100 PY
(1.1-15)
Note: VTE: venous thromboembolism; CI: confidence interval; PY: patient years.
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treatment is generally accepted [7-8,14]. Also, the incidence rate of recurrent VTE after 
stopping anticoagulant treatment can be weighed relative to the risk of major hemor-
rhage associated with long-term anticoagulant treatment, which has been estimated 
to be 2.74 per 100 PY (95%  CI, 2.71-2.77) [15].  Since the case fatality rate for a major 
hemorrhage has been reported to be higher than that for a recurrent VTE, one ought to 
consider the clinical impact of major hemorrhage to be at least comparable to that of 
recurrent VTE. On the basis of both comparisons, we conclude that stopping anticoagu-
lant treatment of cancer-associated VTE in patients who are cured of cancer is justified. 
Although this is in accordance with current guidelines, this is to our knowledge the first 
study supporting this recommendation [7-8].
A second important observation from our study is the association between cancer 
relapse and the risk of recurrent VTE: 47% of the patients with a prior cancer-associated 
VTE event who experienced a cancer relapse were diagnosed with recurrent VTE. From 
another point of view, 70% of recurrent VTE events occurred among the patients with 
a cancer relapse. Given these results, although based on small numbers of patients, 
Figure 2.  Cumulative incidence rate of recurrent VTE and major haemorrhage in patients who stopped 
anticoagulation after cure from cancer (straight line) and after stopping anticoagulation for other reasons 
than major haemorrhage despite active cancer (dotted line).
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the question arises whether patients with cancer and previous cancer-associated VTE 
are candidates for ambulatory pharmacologic VTE prophylaxis. Until now, it has been 
proven difficult to identify patients with cancer who would benefit from thrombopro-
phylaxis [16-17]. The Khorana prediction score has been developed for this purpose, 
and in a validation cohort with an overall PE incidence of 2.1%  during 2.5  months of 
follow-up this score was successfully used to differentiate between patients with low, 
intermediate, and high risk of VTE (0.3%, 2.0%, and 6.7%, respectively) [18]. Whether the 
Khorana score is sufficient to identify patients at such a high risk that VTE prophylaxis 
is justified remains to be determined in a management study. Interestingly, this score 
does not award points for a history of VTE since this information was unavailable in 
the derivation cohort. Therefore, it seems relevant to investigate whether a history of 
(cancer-associated) VTE should be incorporated in prediction scores in future outcome 
studies.
Our study provides further insight in the long-term treatment of cancer-associated VTE 
in patients with persistently active cancer. The 19 per 100 PY incidence rate of recurrent 
VTE in patients in whom anticoagulant treatment was stopped for reasons other than 
major hemorrhage confirms the persistently high risk of recurrent VTE beyond the initial 
6-month period. It should be emphasized that in some of these patients anticoagulant 
treatment was stopped, based on an assessment of the risk-to-benefit ratio of continued 
anticoagulant treatment. This finding should, therefore, be interpreted cautiously.
The observational study design in a single academic hospital is the most important 
limitation of our study. As a result, the number of included patients cured of cancer 
was limited, our population may differ somewhat from those in other hospitals, and 
outcomes may not have been noted in the medical records and therefore missed in 
this study. Also, recommendations regarding the treatment of cancer-associated VTE 
changed during the study period, with LMWH replacing VKA as the treatment of choice 
being the most notable difference. However, the primary outcome of this study was to 
determine the risk of recurrent VTE after stopping anticoagulant treatment, which is 
unlikely be influenced by the type of initial treatment. The major strength of this study is 
the description of all patients with cancer-associated VTE, which enables the assessment 
of the external validity. The overall survival as well as the outcomes of patients while 
receiving anticoagulant treatment are in line with results from other studies on cancer-
associated VTE [5,19-20].
In conclusion, the VTE recurrence rate after stopping anticoagulant treatment of a 
cancer-provoked VTE in patients cured of cancer is low, which justifies stopping anti-
coagulant treatment in these patients. A cancer relapse in the further clinical course 
is a strong risk factor for recurrent VTE. Whether patients with cancer and a history of 
(cancer-associated) VTE warrant secondary pharmacologic VTE prophylaxis should be 
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Treatment of acute venous thromboembolism (VTE) in cancer patients is challenging, 
owing to a high risk of recurrent VTE and bleeding complications. The anticoagulants of 
choice are low molecular weight heparins (LMWH), because of a proven higher efficacy 
than vitamin K antagonists (VKA) and a similar bleeding profile. The recently introduced 
new oral anticoagulants (NOAC) have the potential to be alternative options for these 
patients, as these drugs share practical advantages with LMWH, are administered orally, 
and had similar efficacy to VKA but a lower bleeding risk in phase 3 studies in the general 
VTE population.
Methods
A systematic literature search was performed to identify phase 3 trials investigating 
NOAC for the treatment of VTE. The efficacy outcome was recurrent VTE, and the safety 
outcome was major and clinically relevant non-major bleeding. Pooled incidence rates 
and risk ratios (RR) were calculated for cancer patients and non-cancer patients sepa-
rately.
Results and discussion
Five studies were included, with 19 060 patients, of whom 973 (5.1%) had active cancer. 
The pooled incidence rates of recurrent VTE were 4.1% (95% confidence interval [CI] 
2.6–6.0) in cancer patients treated with NOAC, and 6.1%(95% CI 4.1–8.5) in patients 
treated with VKA (RR 0.66,95% CI 0.38–1.2). The pooled incidence rates of major or non-
major clinically relevant bleeding were 15%(95% CI 12–18) in cancer patients treated 
with NOAC, and 16% (95% CI 9.9–22) in patients treated with VKA (RR 0.94, 95% CI 
0.70–1.3). These results form a solid basis for the initiation of a head-to-head comparison 
of NOAC with LMWH in cancer patients.
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INTRODUCTION
Symptomatic acute venous thromboembolism (VTE) is a common complication in 
cancer patients, occurring in up to 15% of cancer patients during the course of their 
disease, and it is the second leading cause of death after the malignancy itself [1,2]. Anti-
coagulant treatment for acute VTE in cancer patients is complicated by both high risks of 
recurrent VTE and bleeding complications [3]. Hence, alternative treatment modalities 
are particularly interesting for this patient category.
In recent years, new oral anticoagulants (NOAC) have been developed, including direct 
factor IIa inhibitors (i.e. dabigatran) and direct FXa inhibitors (i.e. apixaban, edoxaban, 
and rivaroxaban), for which similar efficacy to that of vitamin K antagonists (VKA) and a 
superior safety profile have been reported for the treatment of patients with acute VTE 
[4–9]. A recent meta-analysis of phase 3 randomized controlled trials (RCT) comparing 
NOAC with VKA for the initial treatment of acute VTE demonstrated that the incidence of 
major bleeding (pooled risk ratio [RR] 0.60, 95% confidence interval [CI] 0.41–0.88) and 
of the combined endpoint of major bleeding and clinically relevant non-major bleeding 
(pooled RR 0.76, 95% CI 0.58–0.99) were significantly lower for patients treated with one 
of the NOACs, whereas the risk of recurrent VTE was similar (pooled RR 0.88, 95% CI 0.74 
–1.1) [10].
The efficacy and safety of NOAC in patients with cancer-associated VTE have not been 
specifically addressed so far, although these drugs would constitute an interesting op-
tion for this specific patient group, for several reasons. First, the improved safety profile 
of NOAC may be of particular relevance, owing to the higher anticoagulation-associated 
bleeding risk observed in cancer patients [3]. This is made even more relevant by the fact 
that current guidelines recommend continuation of anticoagulant therapy for as long 
as the cancer is active and the bleeding risk remains acceptable. As a result, patients 
are exposed to a high risk of bleeding complications for periods ranging from 6 months 
to many years [11,12]. Second, low molecular weight heparins (LMWH) are the current 
preferred anticoagulants for cancer-associated VTE, because of their superior efficacy in 
preventing VTE recurrences, and a similar bleeding profile to that associated with VKA. 
However, these drugs confront patients with the burden of daily subcutaneous admin-
istration [13,14]. For some patients, this may be the reason for asking for VKA. Hence, if 
shown to be equally effective and safe or even safer, NOAC would have clear advantages 
over LMWH. Undoubtedly, clinicians will be faced with the choice of whether to use 
NOAC in cancer patients in the near future. In order to address the lack of any data on 
the efficacy and safety of NOAC for cancer-associated VTE, we performed a systematic 




We systematically searched MEDLINE (via PubMed), EMBASE, the Cochrane Database of 
Systematic Reviews and the clinical trials registry from inception to May 2014 to identify 
randomized controlled trials comparing a NOAC with a VKA or a LMWH in patients with 
acute VTE, using a similar approach as in a recent meta-analysis [10]. From all identified 
studies, we included only those in whom outcomes for patients with active cancer were 
reported separately in the original publication, supplementary information, or related 
publications. In all included studies, the analysis specifically for cancer patients was a 
predefined subgroup analysis. If separate results for cancer patients were not available, 
we requested the pharmaceutical companies for additional information. The primary 
efficacy outcome of the current study was recurrent VTE, and the safety outcome was 
major bleeding or clinically relevant non-major bleeding while patients were receiving 
anticoagulant treatment. Two independent researchers performed the study selection 
and data abstraction. The quality of the studies was assessed with the Cochrane Col-
laboration’s tool for assessing risk of bias in randomized trials [15]. The only potential 
risk of bias identified was the open label design with blinded endpoint evaluation of 
the Einstein studies [10]. Incidence rates were pooled by the use of DerSimonian-Laird 
weights for the random effects model. RR with concomitant 95% CI were calculated with 
the Mantel–Haenszel random effects model, through REVIEW MANAGER (V. 5.1; The Nor-
dic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark). Assessment 
of heterogeneity was performed by calculation of the I2 statistic.
RESULTS AND DISCUSSION
We identified six potentially relevant studies [4-9], all comparing NOAC with VKA. 
Separate outcomes for patients with active cancer were reported for all studies except 
for the Amplify study, in which apixaban was investigated [9]. We asked the manufac-
turer for additional information, but this was not provided (the search strategy and flow 
chart are provided in Data S1 and Data S2 available at http://onlinelibrary.wiley.com/
journal/10.1111/(ISSN)1538-7836/). For the Re-Cover I and II studies, safety outcomes 
for cancer patients were only mentioned separately in an abstract presented at the 
Annual Meeting of the American Society of Hematology in 2013 [16]. Hence, we were 
able to include five studies, among which the results of the Re-Cover I and II studies are 
presented in combination.
The characteristics of the included RCT have been described in detail previously [4–10]. 
All studies compared a NOAC at a standard dosage with VKA treatment with a target 
International Normalized Ratio between 2.0 and 3.0. In total, the studies included 19 060 
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patients, of whom 973 (5.1%) had active cancer. Across the individual studies, the percent-
age of patients with an active malignancy ranged from 2.5% to 6.6%. Of the patients with 
active cancer, 514 (53%) were treated with a NOAC and 459 (47%) with a VKA.
The incidence rates of recurrent VTE in cancer patients treated with a NOAC varied 
from 1.8% to 5.8%, and those in cancer patients treated with a VKA varied from2.8% to 
7.4% (Table 1). The pooled incidence rates were 4.1% (95% CI 2.6–6.0) for NOAC and 
6.1% (95% CI 4.1–8.5) for VKA, with a non-significant pooled RR of 0.66 (95% CI 0.38–1.2) 
in favor of NOAC (Figure 1). For patients without active cancer, the recurrent VTE inci-
dence rate varied from 2.0% to 3.0% in patients treated with NOAC, and from 1.8% to 
3.5% in patients treated with VKA. The pooled incidence rates were 2.6% (95% CI 2.3–2.9) 
and 2.5% (95% CI 1.8–3.4) for NOAC and VKA, respectively, with a pooled RR of 0.98 (95% 
CI 0.83–1.2).
The incidence rate of the combined endpoint of major bleeding and clinically relevant 
non-major bleeding varied from 12% to 18% in cancer patients treated with NOAC, and 
from 9.9% to 25% in cancer patients treated with VKA. Pooled incidence rates were 15% 
(95% CI 12–18) and 16% (95% CI 9.9–22), respectively, and the corresponding RR was 
0.94 (95% CI 0.70–1.3) (Figure 1). In non-cancer patients, the incidence rate of major 
bleeding and clinically relevant non-major bleeding varied from 3.7% to 10% in patients 
treated with NOAC, and from 7.3% to 11% in patients treated with VKA. Pooled incidence 
rates were 7.4% (95% CI 4.8–11) and 9.1% (95% CI 7.3–11), with an RR of 0.81% (95% CI 
0.64–1.02) in favor of NOAC. The I2 of all evaluated efficacy and safety outcomes was 0%, 
indicating low heterogeneity.
In summary, the most important results of this study are the RR of 0.66 (95% CI 0.38–1.2) 
for recurrent VTE and 0.94 (95% CI 0.70–1.3) for major bleeding and clinically relevant 






Major bleeding and clinically 
relevant non-major bleeding
NOAC, no. (%) VKA, no. (%) NOAC, no. (%) VKA, no. (%)
Dabigatran,
Re-Cover I and II [16]
No (93.4) 58/2380 (2.4) 50/2392 (2.1) 86/2297 (3.7) 169/2310 (7.3)
Yes (6.6) 10/173 (5.8) 12/162 (7.4) 23/159 (14.5) 20/152 (13.2)
Rivaroxaban, 
Einstein-DVT [6]
No (94.0) 32/1613 (2.0) 46/1629 (2.8) 122/1600 (7.6) 124/1623 (7.6)
Yes (6.0) 4/118 (3.4) 5/89 (5.6) 17/118 (14.4) 14/88 (15.9)
Rivaroxaban, 
Einstein-PE [7]
No (95.4) 48/2305 (2.1) 41/2304 (1.8) 235/2298 (10.2) 264/2297 (11.5)
Yes (4.6) 2/114 (1.8) 3/109 (2.8) 14/114 (12.3) 10/108 (9.3)
Edoxaban,
Hokusai-VTE [8]
No (97.5) 126/4009 (3.1) 139/4023 (3.5) 329/3740 (8.1) 398/4023 (9.9)
Yes (2.5) 4/109 (3.7) 7/99 (7.1) 20/109 (18.3) 25/99 (25.3)
Note: NOAC, new oral anticoagulant; VKA, vitamin K antagonist.
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non-major bleeding, indicating that both the efficacy and safety of NOAC in cancer 
patients were at least comparable to those of VKA. These results require comment, and 
some of them should be interpreted with caution. First, none of the included studies 
gave a detailed definition of  ‘active cancer’. Only in the abstract of the Re-Cover studies 
was a definition given: ‘a diagnosis of cancer (other than basal-cell or squamous-cell 
carcinoma of the skin) within 5 years before enrolment; any treatment for cancer within 
5 years before enrolment; or recurrent or metastatic cancer’; the more generally used 
standard definition is ‘a diagnosis of cancer within 6 months prior to enrolment, any 
treatment for cancer within the previous 6 months, or recurrent or metastatic cancer’ 
[13,14]. This specific definition and the use of certain exclusion criteria in the trials (e.g. 
‘a limited life-expectancy’ and ‘a high bleeding risk’) suggest that the cancer patients 
in the studies were relatively healthy, and do not compare well with those in previous 
trials, which were specifically designed for patients with acute VTE and active cancer 
[17]. This is further emphasized by the observed VTE recurrence risk of 6.1% in cancer 
patients treated with VKA in the NOAC studies, which is considerably lower than the 16% 
and 17% reported in two previous studies specifically performed in a population with 
active cancer [13,14].
Second, NOAC were compared only with VKA in the available studies, whereas LMWH 
constitute the current treatment of choice for cancer-associated acute VTE [11,12]. 
Hence, NOAC should preferably be compared with LMWH to investigate their efficacy 
and safety in patients with cancer-associated VTE. In a Cochrane meta-analysis, it was 
Figure 1.  Meta-analysis.
Risk ratios of recurrent venous thromboembolism (A) and major bleeding and clinically relevant non-major 
bleeding (B) in cancer patients with acute VTE.
Figu e 1: Meta-analysis. 
Risk ratios of recurrent venous thromboembolism (VTE) (A) and major bleeding and 
clinically relevant non-major bleeding (B) in cancer patients with acute VTE are 
shown. 
Note: CI, confidence interval; d.f., degrees of freedom; MÐ H, MantelÐ Haenszel; 
NOAC,
New oral anticoagulant; VKA, vitamin K antagonist.
49
Note: CI, confidence interval; d.f., degrees of freedom; M–H, Mantel–Haenszel; NOAC,
New oral anticoagulant; VKA, vitamin K antagonist.
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demonstrated that LMWH have a similar safety profile to VKA (RR for major bleeding of 
1.05, 95% CI 0.53–2.1), with higher efficacy in preventing recurrent VTE (RR 0.47, 95% CI 
0.32–0.71) [17]. Interestingly, and supportive for future trials, the RR for NOAC as com-
pared with VKA in our meta-analysis show the same trend. A lack of power (973 patients 
in our meta-analysis vs. 1325 patients in the Cochrane meta-analysis) might be the cause 
of statistical significance not being reached for the efficacy outcome.
Third, whereas previous studies have demonstrated non-inferior safety of LMWH as 
compared with VKA with regard to the risk of major bleeding, only the numbers for the 
combined endpoint of major and clinically relevant non-major bleeding were available 
for NOAC. Major bleeds in cancer patients were not separately reported. Also, the num-
ber of VTE recurrences in the studies was too low for comparison of the severity of these 
events, i.e. risk of fatal pulmonary embolism or risk of recurrent deep vein thrombosis 
versus recurrent acute pulmonary embolism.
Fourth, NOAC share many of the advantages of LMWH over VKA, such as the lack of the 
need for monitoring of anticoagulant effect and the shorter half-life, which facilitates 
temporary interruptions for invasive procedures or when thrombocytopenia occurs 
[18]. On the other hand, the oral administration might raise concerns in cancer patients 
about gastrointestinal tract absorption during episodes of vomiting or mucositis. A po-
tential additional disadvantage of NOAC is the existence of drug interactions with sev-
eral chemotherapeutic agents and drugs used for supportive care through the CYP3A4 
enzyme and/or P-glycoprotein transporter, although the clinical implications of these 
interactions are not yet known. However, drug interactions also exist for VKA and several 
chemotherapeutic agents. Capecitabine, for instance, may enhance the anticoagulant 
effect of VKA, and thereby increase the risk of major bleeds [19].
A final concern is the current unavailability of specific antidotes for NOAC, which may 
be problematic in cases of severe life-threatening major bleeding or emergent invasive 
procedures. It is acknowledged that antidotes are under development, and phase 3 tri-
als with antidotes are currently being planned [20,21].
In conclusion, we have demonstrated that both the efficacy and safety of NOAC in the 
treatment of cancer-associated acute symptomatic VTE are at least comparable to those 
of VKA. This suggests that, for cancer patients without major bleeding risks, the use of 
NOAC is not contraindicated. However, the current NOAC trials in VTE management 
were clearly not designed to provide definite conclusions on the efficacy and safety of 
NOAC in cancer patients, relative to LMWH. Because of the lack of a direct comparison 
with LMWH with selective inclusion of cancer patients only, NOAC cannot yet be recom-
mended as the first-line treatment for VTE in cancer patients. Nonetheless, our results 
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Incidental pulmonary embolism (IPE) is defined as pulmonary embolism (PE) diag-
nosed on computed tomography scanning not performed for suspected PE. IPE has 
been estimated to occur in 3.1% of all cancer patients and is a growing challenge for 
clinicians and patients. Nevertheless, knowledge about the treatment and prognosis of 
cancer-associated IPE is scarce. We aimed to provide the best available evidence on IPE 
management.
Methods
Incidence rates of symptomatic recurrent venous thromboembolism (VTE), major hem-
orrhage, and mortality during 6-month follow-up were pooled using individual patient 
data from studies identified by a systematic literature search. Subgroup analyses based 
on cancer stage, thrombus localization, and management were performed.
Results
In 926 cancer patients with IPE from 11 cohorts, weighted pooled 6-month risks of 
recurrent VTE, major hemorrhage and mortality were 5.8% (95% confidence interval [CI] 
3.7–8.3%), 4.7% (95% CI 3.0–6.8%), and 37% (95% CI 28–47%). VTE recurrence risk was 
comparable under low molecular weight heparins (LMWH) and vitamin K antagonists 
(VKA) (6.2% vs. 6.4%; hazard ratio [HR] 0.9; 95% CI 0.3–3.1), while 12% in untreated 
patients (HR 2.6; 95% CI 0.91–7.3). Risk of major hemorrhage was higher under VKA than 
under LMWH (13% vs. 3.9%; HR 3.9; 95% CI 1.6–10). VTE recurrence risk was comparable 
in patients with a subsegmental IPE and those with a more proximally localized IPE (HR 
1.1; 95% CI 0.50–2.4).
Conclusion
These results support the current recommendation to anticoagulate cancer-associated 





Incidental pulmonary embolism (IPE) is defined as pulmonary embolism diagnosed on 
a computed tomography (CT) scan performed for reasons other than a clinical suspicion 
of pulmonary embolism (PE). In cancer patients, IPE has been estimated to occur in 2.2% 
to 4.1% [1]. Knowledge of the clinical implications of cancer-associated IPE is scarce and 
almost entirely based on small observational studies. Key finding of these studies was 
the similar prognosis with regard to recurrence risk, major hemorrhage, and mortality in 
cancer patients with IPE compared with those with proven symptomatic PE (SPE) [2-4]. 
Based on these observations, international guidelines recommend an identical antico-
agulant treatment regimen for cancer-associated IPE and SPE, and consequently, almost 
all patients with IPE receive anticoagulant treatment (ACCP level of Evidence 2B) [5, 6].
However, it should be noted that the supporting evidence for this recommendation 
is limited by the small size of the studies. In addition, essential clinical questions on the 
subject of IPE management remain unanswered, namely (i) the risks of recurrent venous 
thromboembolism (VTE) if left untreated, (ii) the risks of hemorrhage and its depen-
dence on the type of anticoagulation, and (iii) the relevance of subsegmental IPE versus 
more centrally located IPE. To provide the best available evidence on the management 
of IPE, we pooled individual patient data from 11 observational studies and ongoing 
registries, which were identified by a systematic literature search.
METHODS
Data sources, searches, and study selection
We searched PubMed, MEDLINE, EMBASE, Web of Science, Academic Search Premier, 
Science Direct, and the Cochrane Database of systematic reviews for publications con-
cerning cancer patients with IPE from inception to November 2013. The search strategy 
is provided in the Supplementary Data (all supplementary data is available at http://
onlinelibrary.wiley.com/journal/10.1111/(ISSN)1538-7836/). The electronic search was 
complemented by a manual review of reference lists of relevant articles, and we con-
tacted experts to ask about the existence of unpublished cohorts.
References were screened for relevance by two independent reviewers based on the 
title and abstract (T.v.d.H. and P.d.E.). Discrepancies were resolved by consensus after 
contacting a third reviewer (F.K.). Abstracts or fulltext articles identified by either reviewer 
as potentially relevant were retrieved for further evaluation. Predefined inclusion criteria 
for eligible cohorts were: (i) ≥ 20 consecutive patients with IPE; (ii) patients with a con-
comitant active cancer (both solid and hematologic cancer), defined as cancer diagnosed 
within 6 months before IPE, recurrence or progressive cancer or any cancer that neces-
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sitated curative or palliative treatment within the previous 6 months; (iii) at least 6 months 
of follow-up; (iv) information about the management of the IPE; and (v) reporting at least 
one of the predefined primary and/or secondary study end points. Completed studies and 
ongoing patient registries were eligible. An invitation, and study proposal were sent to the 
authors of the selected references as well as at least one reminder.
Patients and clinical data collection
IPE was defined as PE detected on a CT scan ordered for reasons other than a clinical 
suspicion of PE [7]. Patients were managed according to local practices. International 
guidelines available during the study periods recommended anticoagulant treatment 
for a period of at least 6 months with prolongation for as long as the cancer was active 
[5, 8, 9]. Low molecular weight heparin (LMWH) was the treatment of choice for cancer-
associated incidental VTE from 2004 on.
Individual patient-level data were collected, consisting of general baseline char-
acteristics, the location of IPE and the applied anticoagulant treatment regimen. The 
primary end point was the occurrence of symptomatic recurrent VTE, defined as a 
positive finding of the diagnostic workup of suspected acute PE or DVT of the lower or 
upper extremities [10]. Incidental VTE events were not adjudicated as recurrent events. 
Secondary end points included major hemorrhage, fatal hemorrhage, and mortality. The 
duration of follow-up was 6 months. DVT of the lower extremities was diagnosed in 
case of non-compressibility by compression ultrasonography at the trifurcation of the 
popliteal vein or above or, in case of an intraluminal filling defect above the trifurcation 
of the popliteal vein, by CT or venography [5, 10]. Recurrent PE was diagnosed in case of 
a new intraluminal filling defect in a subsegmental or larger pulmonary artery, in case 
of a ventilation/perfusion scanning with a high probability of PE in a new lung segment 
unaffected by the index IPE, or in case of a new intraluminal filling defect by pulmonary 
angiography [6]. Major hemorrhage was defined as overt and associated with a decrease 
in the hemoglobin level of ≥ 2 g/dL, requiring transfusion of ≥ 2 units of blood, occurring 
in a critical site (intracranial, intraspinal, intraocular, pericardial, intra-articular intramus-
cular with compartment syndrome, retroperitoneal), or contributing to death [11].
Statistical analysis
The end points were defined and all statistical analyses were performed according to a 
predefined statistical protocol, agreed on by all authors. Baseline characteristics were 
reported for the combined cohorts and for subgroups based on the management of 
the IPE. All outcomes were pooled using the DerSimonian–Laird weights in a random-
effects model. Additionally, baseline characteristics and outcomes were reported for 





For the subgroup analyses, outcomes were pooled using the DerSimonian–Laird 
weights in a random effects model. To calculate hazard ratios (HR), all cohorts and regis-
tries were combined and considered as one cohort. Subgroups analyses were performed 
for: (i) patients treated with LMWH, patients treated with vitamin K antagonists (VKA) 
after an initial course of LMWH, and those who were left untreated; (ii) patients with 
metastatic cancer and non-metastatic cancer; and (iii) patients with centrally located 
thrombi (defined as a central or lobar thrombus location) and more peripherally located 
thrombi (defined as a segmental or subsegmental thrombus location). Additionally, 
outcomes for patients with isolated subsegmental IPE were reported separately. The 
HR were calculated using Cox regression analysis. Regarding the subgroup analysis 
based on management, an intention-to-treat analysis was used for which patients were 
classified according to the initial management even when anticoagulant treatment 
was prematurely discontinued. Additionally, per-treatment analysis was performed for 
which outcomes were related to the management at the time the outcome occurred. 
A competing risk model was used for the survival tables for recurrent VTE and major 
bleeding with death as competing risk. spss, version 20 (SPSS Inc, Chicago, IL, USA) and 
StatsDirect software (StatsDirect Ltd, Cheshire, UK) were used for all analyses.
RESULTS
Identification of cohorts and registries
The initial search identified 106 records in PubMed, 61 unique references in MEDLINE, 
153 unique references in EMBASE, 28 unique references in Web of Science, 12 unique 
references in the Cochrane Database of Systematic Reviews, and two unique references 
in Academic Search Premier, resulting in a total of 362 references. Based on screening 
titles and abstracts, 44 references were extensively studied and, when available, read in 
full text. Of these 44 references, 11 references were excluded because no or only limited 
follow-up was reported, 12 because they concerned < 20 patients, one because IPE were 
diagnosed on additionally performed CT pulmonary angiography after the initial CT 
scan, and one because it did not meet the definition of IPE (see Supplementary Data 
for excluded references available at http://onlinelibrary.wiley.com/journal/10.1111/
(ISSN)1538-7836/). Finally, 19 references from the literature search and one unpublished 
registry that met our inclusion criteria were included. Patients of the unpublished reg-
istry were collected in the Ramón y Cajal Hospital in Madrid, Spain. Of these 20 cohorts, 
the authors of four references refrained from participating [12-15] and the authors of 
five references [16-20] did not respond to repeated invitations, resulting in the inclusion 




The number of patients of the 11 included individual cohorts and registries varied from 
21 to 204 patients  (Table S1). All cohorts and registries were collected from 2001 and 
2013. Nine of the 11 cohorts and registries were retrospectively collected and two were 
prospectively collected. In total, individual patient data of 945 patients were available, 
of which 6-month follow-up data were complete for 926 patients (98%) and these 
comprised the study patients for whom baseline characteristics are shown in Table 1. 
A total of 732 (79%) patients were treated with prolonged therapeutic LMWH, 100 
(11%) patients were treated with VKA, 41 (4.4%) patients received another treatment (ie, 
inferior vena cava filter or unfractionated heparin), and 53 (5.7%) patients received no 
treatment.
Symptomatic recurrent VTE
Data regarding the occurrence of recurrent VTE were available from 10 of the 11 cohorts 
that included 857 patients, of whom 19 developed an objectively proven DVT and 22 
recurrent PE (with or without DVT), and for three patients, the type of the recurrent 
VTE was unspecified. Nine (20%) of these 44 recurrent VTE occurred while anticoagulant 
treatment was discontinued: four events during temporary discontinuation of LMWH 
and five after treatment with LMWH was permanently stopped. Outcomes of the indi-
vidual cohorts are avaliable in Table S2.
Figure 1.  Flow chart selection of cohorts.




Based on the intention-to-treat analysis, the weighted pooled 6-month risk of recur-
rent VTE was 6.2% (95% CI 3.5–12%) in patients treated with LMWH and 6.4% (95% CI 
2.2–12%) in those who received VKA (Table 2A, Figure 2), with a HR adjusted for sex, age, 
type of cancer, and cancer stage of 0.92 (95% CI 0.3–3.1). In the 10 cohorts that reported 
data on recurrent VTE, a total of 42 (4.9%) patients did not receive any anticoagulant 
treatment, of whom four developed symptomatic VTE, resulting in a weighted pooled 
6-month risk of 12% (95% CI 4.7–23%). Of these 42 patients, seven had a centrally located 
IPE, 18 had a segmental IPE, four had a subsegmental IPE, and in 13 patients, the throm-
bus location was unspecified. Of the four patients who did not receive anticoagulant 
treatment and developed a recurrent VTE, two had a subsegmentally located IPE and 
the other two had a segmentally located IPE. Compared with patients who were treated 
with either LMWH or VKA, the HR of symptomatic recurrent VTE in patients who did not 











Mean age (SD; range) 65 (12; 19-94) 64 (12; 19-94) 68 (12; 20-91) 68 (13; 28-90) 65 (14; 27-91)
Male sex, n (%) 491 (53) 378 (52) 60 (60) 22 (54) 31 (58)
Heart failure, n (%) 27/470 (5.7) 19/382 (5.0) 4/56 (7.1) 1/10 (10) 3/22 (14)
COPD, n (%) 35/471 (7.4) 25/383 (6.5) 7/56 (13) 0/10 (0) 3/22 (14)
Previous VTE, n (%) 47/566 (8.3) 32/435 (7.4) 10/86 (12) 1/13 (7.7) 4/32 (13)
Stage of malignancy, n (%)
Metastatic cancer 501 (54) 400 (55) 56 (56)  12 (29)  33 (62)
Non-metastatic cancer 192 (21) 143 (20) 34 (34) 3 (7.3) 12 (23)
Unspecified 233 (25) 189 (26) 10 (10)  26 (63) 8 (15)
Type of malignancy, n (%)
Lung 176 (19) 135 (18) 16 (16) 7 (17) 18 (34)
Colorectal 185 (20) 150 (20) 20 (20) 6 (15) 9 (17)
Other gastrointestinal 187 (20) 147 (20) 15 (15) 12 (29) 13 (25)
Breast 65 (7.0) 52 (7.1) 10 (10) 2 (4.9) 1 (1.9)
Gynaecological 64 (6.9) 56 (7.7) 5 (5.0) 3 (7.3) 0 (0)
Other or unknown 206 (22) 155 (21) 31 (31) 10 (24) 10 (19)
Haematological 43 (4.6) 37 (5.1) 3 (3.0) 1 (2.4) 2 (3.8)
Largest artery involved, n (%)
Central 292 (32) 230 (31) 30 (30) 21 (51) 11 (21)
Segmental 301 (33) 238 (33) 35 (35) 7 (17) 21 (40) 
Subsegmental 193 (21) 156 (21) 27 (27) 2 (4.9) 8 (15)
Unspecified 140 (15) 108 (15) 8 (8.0) 11 (27) 13 (25)
Note: COPD: chronic obstructive pulmonary disease; VTE: venous thromboembolism; LMWH: low molecu-
lar weight heparins; VKA: vitamin K antagonists.
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receive anticoagulant treatment was 2.0 (95% CI 0.65–5.9) adjusted for age, sex, type of 
cancer, and cancer stage. Outcomes stratified for cancer type are available in Table S3 .
The risk of recurrent VTE was non-significantly higher in patients with metastatic 
cancer at time of diagnosing IPE compared with those with non-metastatic cancer with 
a HR of 1.4 (95% CI 0.59–3.2) adjusted for age, sex, type of cancer, and management 
(Table S4). Regarding the location of the IPE, the weighted pooled 6-month risk of 
recurrent VTE was comparable in patients with a centrally located IPE compared with 
those with peripherally located IPE, 5.6% (95% CI 3.1–8.7%) and 6.6% (95% CI 3.5–11%), 
respectively, with a HR of 0.65 (95% CI 0.22–1.9) adjusted for age, sex, type of cancer, 
cancer stage, and management (Table S5). When patients with a subsegmental IPE were 
compared with those with a more centrally located IPE, incidence rates were 7.8% (95% 
CI 2.8–14.9%) and 5.5% (95% CI 2.9–8.8%), respectively, with a HR of 1.3 (95% CI 0.57–3.0) 
adjusted for age, sex, type of cancer, cancer stage, and management.
Based on the per-treatment analysis, the incidence rates of recurrent VTE were 12 per 
100 patient years (PY) (31 events during 252 years of treatment; 95% CI 8.3–17) and 
9.8 per 100 PY (3 events during 31 years of treatment; 95% CI 2.0–29) while receiving 
LMWH and VKA, respectively. For patients who did not receive anticoagulant treatment, 
either from the initial diagnosis or after LMWH or VKA were stopped within 6 months for 
reasons other than death, the incidence rate was 20 per 100 PY (nine events during 45 
years of treatment; 95% CI 9.2–38) (Table 2B).
Table 2.  Pooled outcomes after 6 months of follow-up for total cohort and stratified by management.
A: Pooled outcomes after 6 months of follow-up and stratified by initial management.
Outcome
Weight pooled risk in % 
(95%CI)
Total cohort LMWH VKA Other None
Recurrent VTE 5.8 (3.7-8.3) 6.2 (3.5-9.6) 6.4 (2.2-12) 4.3 (3.3-12) 12(4.7-23)
Major haemorrhage 4.7 (3.0-6.8) 3.9 (2.3-5.9) 13 (6.4-20) 6.4 (0.2-20) 6.4 (1.3-15)
Mortality 37 (28-47) 37 (29-44) 28 (18-40) 58 (38-77) 47 (28-66)
B: Incidence rates per 100 patient-years and stratified by management based on a per-protocol analysis.
Outcome
Weight pooled risk in % 
(95%CI)
LMWH VKA Other None
Recurrent VTE 12 (8.3–17) 9.8 (2.0–29) 9.5 (0.24–53) 30 (8.2–77)
Major haemorrhage 10 (6.6–15) 26 (11–52) 18 (2.2–66) 4.6 (0.55–17)





Figure 2.  Cumulative risk of recurrent venous thromboembolism related to management.
Note: VKA: vitamin K antagonists; LMWH: low molecular weight heparins. Based on a competing risk 
analysis.
Figure 3.  Cumulative risk of major haemorrhage complications according to anticoagulant treatment.





Information regarding major hemorrhage was available for 10 cohorts concerning a total 
of 857 patients of whom 38 patients experienced a major hemorrhage. Overall weighed 
pooled incidence rates are provided in Table 2. The risk of major hemorrhage was compa-
rable in patients with metastatic and non-metastatic cancer and in patients with a centrally 
located IPE compared with those with a peripherally located IPE, with a HR of 1.8 (95% CI 
0.68–4.8) adjusted for age, sex, type of cancer, and management and 1.0 (95% CI 0.31–3.0), 
adjusted for age, sex, type of cancer, cancer stage, and management (Tables S4 and S5).
Based on the intention-to-treat analysis, the weighted pooled 6-month risk of major hem-
orrhage was significantly higher in patients treated with VKA compared with those treated 
with LMWH, 13% (95% CI 6.4–20%) versus 3.9% (95% CI 2.3–5.9%) with a HR of 4.0 (95% 
CI 1.5–10) adjusted for age, sex, type of cancer, and cancer stage (Table 2A, Figure 3). The 
weighted 6-month pooled risk of major hemorrhage in patients who were left untreated 
was 6.4% (95% CI 1.3–15%). Based on the per-treatment analysis, the incidence rate of major 
hemorrhage while receiving VKA treatment was 26 per 100 PY (eight events during 30 years 
of treatment; 95% CI 11–52), and while receiving LMWH treatment, the incidence rate was 10 
per 100 PY (26 events during 257 years of treatment; 95% CI 6.6–15) (Table 2B).
Mortality
Of the 926 patients, 331 died during follow-up, resulting in a weighted pooled 6-month 
mortality of 37% (95% CI 28–47%; Table 2A). Mortality varied between cancer type and 
cancer stage (Tables S3 and S4). The weighted pooled 6-month mortality was higher in 
patients with a centrally located IPE compared with those with a peripherally located 
IPE: 42% (95% CI 33–52%) versus 30% (95% CI 25–36%) with a HR of 1.5 (95% CI 1.1–2.0) 
adjusted for age, sex, type of cancer, cancer stage, and management. Patients with a 
centrally located IPE more frequently had metastatic cancer (79%) compared with those 
with a more peripherally located IPE (67%) (χ2 test: P < 0.01).
The weighted pooled 6-month mortality was 37% (95% CI 29–44%) in patients treated 
with LMWH and 28% (95% CI 18–40%) in those treated with VKA (HR 1.1; 95% CI 0.70–1.6 
adjusted for age, sex, cancer type, and cancer stage). In patients who did not receive any 
treatment, the weighted pooled 6-month mortality was 47% (95% CI 28–66%).
DISCUSSION
This study of individual patient data of 926 patients from 11 registries is the largest study 
on cancer-associated IPE thus far and provides several important new findings.
First, this study demonstrates a 6-month VTE recurrence risk of 12% (95% CI 4.7–23%) 




untreated for a specific reason, that is, a high risk of hemorrhage, a poor overall prog-
nosis, or a supposed low risk of recurrent VTE, the patient’s characteristics did not differ 
greatly from those of treated patients. Importantly, the higher mortality in the untreated 
patients may even have resulted in an underestimation of the pooled 6-month VTE 
recurrence risk due to significant competing risk of death. In the per-treatment analysis, 
the incidence rate of recurrent VTE in patients who did not receive anticoagulant treat-
ment was even 30 per 100 PY (95% CI 8.2–77). Thus, this observation emphasizes the 
high risk of symptomatic recurrent VTE in cancer patients with IPE and recalls the effect 
size of anticoagulants used in SPE, thereby supporting the initiation of anticoagulation 
in cancer-associated IPE [5, 6].
Second, we observed a comparable efficacy of VKA and LMWH with a significantly 
higher risk of major hemorrhage in patients who were treated with VKA. Although these 
findings should be interpreted with caution due to the observational study design and 
the lack of information about the quality of anticoagulant treatment, it seems unlikely 
that patients with a high risk of major hemorrhage were predominantly assigned to 
receive VKA. This is reflected by the comparable baseline characteristics of both groups 
and by the non-significantly lower mortality in patients treated with VKA. Notably, a 
comparable risk of major hemorrhage between oral and parenteral anticoagulants has 
been demonstrated in cancer patients with proven clinically suspected PE, while the 
recurrence risk was lower in those treated with LMWH [29]. This notable difference be-
tween the efficacy and safety of oral versus parenteral anticoagulants in IPE and SPE may 
be caused by the observational design of our study in which all cancer patients with IPE 
were included, whereas patients with a high risk of major hemorrhage were excluded 
from the trials in cancer patients with SPE. A second explanation could be poor quality 
of anticoagulant treatment, on which information was unfortunately unavailable for our 
study subjects. However, the comparable risk of recurrent VTE in patients treated with 
VKA and LMWH argues against a poor quality of anticoagulant management. Regard-
less, the observations from the current study supports LMWH as treatment of choice for 
cancer-associated VTE [5, 6].
Given the debate regarding the clinical relevance of isolated subsegmental SPE, the 
clinical significance and management of subsegmental IPE may be even less clear [30, 
31]. Therefore, the comparable risk of recurrent VTE in cancer patients with a subseg-
mental IPE versus more centrally located IPE and the observation of recurrent events 
in untreated patients with subsegmental IPE are further key findings of this study. Both 
observations argue against subsegmental IPE as a distinct disease entity and support 
an identical management. Since the presence of (asymptomatic) DVT in patients with a 
subsegmental IPE was not investigated in the cohorts, conclusions regarding the clinical 
relevance of isolated subsegmental IPE can not be drawn. The finding that subsegmen-
tal PE is not associated with a more favorable prognosis with regard to VTE recurrences 
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was recently described in non-cancer patients with SPE as well [32]. Notably, in line 
with the observation of O’Connell and colleagues, centrally located IPE was associated 
with a higher mortality than distally located PE in the current analysis [24]. Two likely 
explanations for this phenomenon could be a higher mortality directly related to VTE, as 
observed for SPE, or a higher cancer-related mortality [33].
Strengths of this study are the systematic literature search for potential studies and 
ongoing registries; the high number of included patients, far exceeding previously 
published cohorts; the strict and identical diagnostic criteria for IPE among the included 
studies and registries; the reporting of objectively established outcomes; and the use of 
patient-level data.
The most relevant limitation of this study is related to the observational and predomi-
nantly retrospective designs of the individual registries and the unavailability of results 
from nine identified cohorts that may have introduced selection bias. Since four cohorts 
were only described in a meeting abstract and the risk of recurrent VTE is only described 
for one of five cohorts published in a peer-reviewed journal, our study seems to be a 
good representation of existing literature. It should be mentioned that patients were 
not randomly assigned to treatment and no uniform management protocol was applied, 
and it is unknown whether the presence of asymptomatic DVT had been investigated 
and influenced management decisions. Also, initial CT results and outcomes were not 
adjudicated by an independent committee. The impact of ongoing oncologic manage-
ment (e.g., systemic chemotherapy) and its potential contribution to the risk of recurrent 
VTE and/or cancer related prognosis are additional confounding factors that cannot 
fully be accounted for in this study. Due to the study design, we were unable to provide 
a reliable estimation of the burden of recurrent VTE on mortality. Ideally, a randomized 
clinical trial should be performed to provide more definite answers. However, given all 
available evidence to date, we consider conducting a randomized clinical trial allocating 
patients with cancer-associated IPE to placebo or anticoagulant treatment as ethically 
very challenging. This is supported by the results of the enquiry among physicians, of 
whom 89–100% judged treatment of cancer-associated IPE to be necessary [34].
In conclusion, this study demonstrates a substantial risk of symptomatic recurrent VTE 
in cancer patients with IPE and suggests an even higher recurrence risk when anticoagu-
lant treatment is withheld. An LMWH-based treatment regimen was associated with a 
lower risk of major hemorrhage than treatment with VKAs. These observations support 
the current guideline recommendations to initiate anticoagulant treatment with LMWH 
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The studies described in this thesis aim to improve both the diagnostic strategy in 
patients with suspected pulmonary embolism as well as the therapeutic management 
in patients with proven acute pulmonary embolism. Chapter 1 consists of a general 
introduction and overview of the presented studies. Chapter 2 gives an overview of the 
currently available diagnostic strategies for clinically suspected acute pulmonary em-
bolism and the treatment of acute pulmonary embolism. The different clinical decision 
rules, the D-dimer test and the different imaging tests will be discussed. Furthermore, 
the current situation concerning the treatment of acute pulmonary embolism including 
risk stratification, the possibility of outpatient treatment, indications for thrombolysis, 
the available anticoagulants and the optimal duration of treatment will be addressed.
Part I: Diagnostic management in suspected pulmonary embolism
Chapter 3 discusses the results of a systematic review and patient-level meta-analysis 
on the efficiency and safety of the exclusion of pulmonary embolism based on a Wells 
score combined with D-dimer testing. This is the most applied diagnostic strategy to 
exclude pulmonary embolism without an imaging test worldwide. The results of this 
study confirm results of earlier studies that proved the efficiency and safety of this 
strategy for the total group of patients. What this study adds, is the confirmation of the 
safety of the strategy in different clinically relevant subgroups: inpatients, patients with 
cancer, chronic obstructive pulmonary disease and venous thromboembolism in their 
medical history and patients who present themselves late to the clinician. In all groups, 
the risk of a venous thromboembolism was less than 3 % during 3 months after the 
initial exclusion of pulmonary embolism based on the Wells score and a D-dimer test. 
Also, it was shown that the use of an age-adjusted D-dimer threshold (calculated by 
multiplying the patients age by ten for patients over 50 years of age) instead of the 
fixed threshold of 500 µg/L fot the total group leads to an increase of patients in whom 
pulmonary embolism could be ruled out without an imaging test from 28% to 33%. 
Finally, it is mentioned that the profits of the application of the age-adjusted D-dimer 
threshold differs between subgroups, being logically the highest in the older patients.
In chapter 4, the safety of exclusion of pulmonary embolism based on a normal CTPA 
is examined. For most patients, the safety of a normal CTPA is undisputed, but in patients 
with a high pre-test probability, this remains controversial in literature. To clarify this 
issue, the results of 4 earlier studies on the safety and efficiency of the diagnostic man-
agement of suspected pulmonary embolism were combined. This study confirmed that 
in the total group of patients, the risk of venous thromboembolism after a normal CTPA 
is very low: 2.0% during the first 3 months. In specific patient groups however, the risk of 
venous thromboembolism is higher, despite a normal CTPA: this concerns patiens with a 
very high pre-test probability (Wells score >6), patients with complaints of deep venous 
thrombosis and patients with a malignancy.
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It is difficult to determine whether and to which extent this higher risk is caused by 
missed diagnoses of venous thromboembolism at presentation of by newly developed 
venous thromboembolism in the period thereafter. A strategy to diminish the risk of 
venous thromboembolism is also unclear.
The following two chapters set out two studies that investigated improvement of 
the diagnostic process in suspected pulmonary embolism. In chapter 5 the possibility 
of applying a higher D-dimer threshold in patients with a low pre-test probability was 
examined, using the combined results of two earlier studies. Instead of the dichotomous 
algorithm, the trichotomous algorithm based on the Wells score was used. In patients 
with a low pre-test probability of PE, based on a Wells score of <2 points, a D-dimer 
threshold of <1000 µg/L was used; in patients with a moderate pre-test probability, 
based on a Wells score of 2-6 points, the D-dimer threshold was <500 µg/L and only 
in patienst with a high risk on PE based on a Wells score of >6 points, a CTPA was per-
formed directly. The results show that this strategy leads to improved efficiency in the 
diagnostic process: the percentage of patients in whom PE could be excluded without a 
CTPA rises from 26% to 36%. The number of missed diagnoses of PE seems to be small, 
though it requires a prospective validation study to confirm this.
Chapter 6 shows the results of the YEARS study: a prospective validation study of 
a highly simplified diagnostic algorithm for suspected PE. In the YEARS algorithm, the 
Wells score was replaced by three YEARS items: clinical signs of deep veen thrombosis, 
hemopthysis and whether the treating clinician thinks pulmonary embolism is the 
most probable diagnosis. These items are scored, and subsequently a D-dimer test 
is performed in all patients. When no YEARS item is present and the D-dimer result is 
<1000 µg/L, PE is excluded without the use of CTPA. In patients with one or more YEARS 
items, the D-dimer threshold is set at <500 µg/L to be able to exclude PE without a CTPA. 
This algorithm wat tested prospectively in the YEARS study in 3465 patients. Results 
reveal that this algorithm can be applied safely: the risk of venous thromboembolism 
after exclusion of PE was only 0.61%. Benefits of the YEARS algorithm are the simplified 
procedure: there are only three items to score and in all patients a D-dimer test can be 
performed instead of only those with an unlikely pre-test probabilty. The main benefit, 
however, is the 14% increase of the the number of patients who can be managed safely 
without a CTPA in comparison with the standard algorithm, 48% versus 34% respectively.
Part II: Treatment of acute pulmonary embolism
In the treatment of pumonary embolism and deep venous thrombosis, one of the 
most important developments of the past years is the introduction of the direct oral 
anticoagulants. These oral drugs directly inhibit thrombine (factor IIa) or factor Xa. Their 
largest benefit is a more stable famockinetic and farmacodynamic profile, which makes 
routine evaluation of the anticoagulant effect, as in vitamin K antagonists, not required. 
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Also, several studies report lower risks of bleeding complications. Chapter 7 describes a 
meta-analysis of individual studies of the direct oral anticoagulants for the treatment of 
acute PE and deep venous thrombosis. The results confirm that direct oral anticoagulants 
are equally effective in the prevention of recurrent venous thromboembolism with a 
relative risk of 0.88 (95% confidence interval 0.74-1.05). Also, this meta-analysis confirms 
the indication of a lower risk of bleeding complications when direct oral anticoagulants 
are used: the relative risk of major bleeding is 0.60 (95% confidence interval 0.41-0.88). 
It should be emphasized, however, that the absolute risks of both recurrent venous 
thromboembolism and major bleeding are small, and therefore so are the differences 
between absolute risks.
In chapter 8, a very specific recommendation from the Dutch Guideline on Diagnos-
tics, Prevention and Treatment of Venous Thromboembolism and Secondary Prevention 
Arterial Thrombosis is evaluated. In general, it is costumary to advise anticoagulant treat-
ment for indefinite duration to all patients who have had a second venous thromboem-
bolism. However, the guideline also advises to consider limited duration of treatment of 
twelve months in patients in whom the second thromboembolism appeared more than 
one year after the cessation of anticoagulant treatment for the first event. There was 
solely indirect evidence fort his recommendation. This chapter reveals the outcomes 
of the application of this specific recommendation in the Leiden Universitry Medical 
Centre. Of 131 patients with second venous thromboembolism more than one year after 
stopping anticoagulant treatment, 77 patients were treated for a limited duration. After 
stopping anticoagulant treatment, the incidence of venous thromboembolism was 9.4 
per 100 patientyears (95% confidence interval 6.1-14), and the risk seems even higher in 
patients with an idiopathic second venous thromboembolism and lower in those with a 
provoked venous thromboembolism. Although this is an observational study, it is highly 
probable that this high risk of recurrent venous thromboembolism exceeds the risk of 
continuing anticoagulant treatment, mainly bleeding complications. Therefore, this 
study does not support the recommendation of the Dutch Guideline.
The three chapters that follow adress the treatment of cancer-associated venous 
thromboembolism. In chapter 9, a cohort study is described which evaluates the safety 
of stopping anticoagulant treatment in cancer-assiciated venous thromboembolism in 
patients cured from cancer. Out of 358 included patients with cancer-associated venous 
thromboembolism, anticoagulant treatment could be discontinued in 68 patients after 
they were cured from their malignancy. The risk of recurrent venous thromboembolism 
in this group was low with an incidence of 3.2 per 100 patientyears (95% confidence 
interval 1.5-5.9). Notable in this study is the observation that in 7 out of the 10 patients 
with recurrent venous thromboembolism, a recurrence of the malignancy was observed 
at the same moment or shortly after the diagnosis of recurrent venous thromboem-
bolism. These results support the current guideline to discontinue anticoagulant treat-
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ment for cancer-associated venous thromboembolism in patients cured from cancer. 
Chapter 10 outlines a meta-analysis of the use of direct oral anticoagulants voor cancer-
associated venous thromboembolism. The method of this study is identical to the study 
described in chapter 7, but in this chapter the focus was on cancer-associated venous 
thromboembolism only. A total of 19,060 patients were included in the five separate 
studies, of which 973 were known to have an active malignancy. The risks of recurrent 
venous thromboembolism and bleeding complications were relatively high, compared 
to patients without cancer, which is in accordance with current literature. The relative 
risk for recurrent venous thromboembolism for direct oral anticoagulants compared to 
vitamin K antagonists was 0.66 (95% confidence interval 0.38-1.2) and the risk for major 
and clinically relevant bleeding 0.94 (95% confidence interval 0.70-1.3). It must be men-
tioned that little information was provided about the nature and dissemination of the 
cancer as well as anti-cancer treatment. Furthermore, the treatment in the control arm of 
this study, vitamin K antagonists, is not the treatment of first choice in cancer-associated 
venous thromboembolism. For these reasons, the results of this study should be inter-
preted cautiously. The results may serve as a strong stimulant to investigate direct oral 
anticoagulants in the treatment of cancer-associated venous thromboembolism, which 
is currently underway.
Chapter 11 finally focuses on coincidental diagnosed pulmonary embolism, generally 
referred to as incidental pulmonary embolism. This is a relatively new clinical presenta-
tion predominantly seen in cancer patients, due to the relatively high risk of venous 
thromboembolism and by the frequent performance of high quality CT-scanning in 
these patients. Based on observational, often small studies it is recommended to treat 
incidental pulmonary embolism in the same way as clinically suspected pulmonary 
embolism. This chapter aimed to collect as much data as possible out of the individual 
observational studies in order to find the best available evidence on the treatment of 
incidental pulmonary embolism. Information concerning a total of 926 patients out of 
11 different studies was collected. The most important results include a comparable risk 
of recurrent venous thromboembolism in patients treated with low molecular weight 
heparins compared to vitamin K antagonists: 6.2% vs 6.4% during 6 months after the 
diagnosis. The risk in 53 patients who were not treated with anticoagulant treatment, for 
which the reason was unknown, was 12%. The risk of major bleeding was considerably 
higher in patients treated with vitamine K antagonists: 13% versus 3.9% in the group 
treated with low molecular weight heparins. Despite several important limitations due 
to study design, these results suggest that anticoagulant treatment lowers the risk of 
recurrent venous thromboembolism and that low molecular weight heparins are favour-
able over vitamin K antagonists. Both conclusions support the recommendations of 
current guidelines.
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Perspective for the future
A diagnostic algorithm such as the YEARS algorithm allows clinicians to exclude pulmo-
nary embolism in patients in which they suspect pulmonary embolism, without the use 
of potentially harmfull CTPA. For the future, it remains a challenge to further diminish 
the need for CTPA. It does not seem to be very likely however that any more profit can be 
achieved from alterations in the clinical decision rule or D-dimer thresholds.
Perhaps, in the future CTPA can be replaced by alternative imaging such as an MRI 
scan, to overcome concerns on radiation exposure. For now, the low sensitivity and 
high risk of inconclusive results are the most important limitations of MRI scanning for 
suspected PE. Another challenge for the future is the suspicion of pulmonary embolism 
in pregnant women. This is a relatively common clinical challenge, in which the risk of 
radiation exposure for the unborn child forms an extra concern and argument to make 
an effort to reduce the use of CTPA. Untill now, no diagnostic strategy was validated to 
exclude pulmonary embolism in pregnant women without an imaging test, emphasiz-
ing the urgent need for a prospective study of an algorhitm such as the YEARS algorhitm 
in this group.
The introduction of the direct oral anticoagulant poses several important unanswered 
questions concerning the optimal treatment of acute pulmonary embolism. These 
drugs have now become the treatment of choice for the majority of patients with acute 
pulmonary embolism. In cancer patients, the efficacy and safety of these drugs is being 
investigated. Also, the low risk of bleeding complications has influence on the risk-
benefit ratio of extending anticoagulant treatment. Therefore, the introduction of these 
drugs may have consequences for the choices on the duration of treatment. Clinicians 
and patients will tend to continuing anticoagulant treatment indefinitely, also for a first 
episode of venous thromboembolism, due to the lower bleeding risks. This will have 
important consequences and will lead to higher health care costs and over-treatment, 
since many patients never develop a recurrent venous thromboembolism. Furthermore, 
it is interesting whether the risk of a recurrent event evolves over time: does anticoagu-
lant treatment prevent a recurrence only during therapy, or does the risk decline over 
time, which creates a possibility to stop anitocagulant treatment later on? 
In incidental pulmonary embolism, the advantage of anticoagulant treatment remains 
unclear. Indirect evidence, as in this thesis, suggests a lower risk of recurrent venous 
thromboembolism when treated, and therefore a benefit for patients. Cancer patients, 
however, are also known to have a considerably higher risk of bleeding complications 
during anticoagulant treatment. A definite answer to this question requires a random-
ized trial directly comparing no or only very short duration of treatment to indefinite 








De studies beschreven in dit proefschrift zijn gericht op het verbeteren van de diagnos-
tiek bij patiënten met een klinische verdenking op acute longembolie en het optimali-
seren van de behandeling van patiënten met bewezen acute longembolie. Hoofdstuk 
1 bevat een algemene introductie en een overzicht van de studies in dit proefschrift. 
Hoofdstuk 2 betreft een uitgebreid overzicht van de huidige diagnostiek bij verdenking 
op acute longembolie en de behandeling. Hierbij komen de verschillende klinische 
beslisregels, de D-dimeer test en het radiologisch onderzoek aan de orde. Wat betreft 
de behandeling van bewezen acute longembolie worden de huidige stand van zaken 
betreffende risicostratificatie, de mogelijkheid van thuisbehandeling, de indicaties voor 
trombolyse, de beschikbare antistollingsbehandeling en de optimale behandelduur 
besproken.
Deel 1: Diagnostiek bij verdenking acute longembolie
In hoofdstuk 3 worden de resultaten beschreven van een systematische review en indi-
viduele patiënten-data meta-analyse naar de efficiëntie en veiligheid van het uitsluiten 
van longembolie op basis van een Wells score in combinatie met de D-dimeer test. Dit 
is wereldwijd de meest gebruikte strategie voor het uitsluiten van longembolie zonder 
het verrichten van radiologisch onderzoek. De resultaten van deze studie bevestigen 
de resultaten van eerdere studies waarin de veiligheid en efficiëntie van deze strate-
gie voor de totale groep patiënten was aangetoond. In aanvulling op de individuele 
studies bevestigt deze studie de veiligheid van de strategie in verschillende klinisch 
relevante subgroepen, te weten klinische patiënten, patiënten met kanker, chronische 
obstructieve longziekte (COPD), veneuze trombo-embolie in de voorgeschiedenis en 
patiënten die zich relatief laat hebben gepresenteerd. In alle groepen was het risico op 
veneuze trombo-embolie minder dan 3% gedurende 3 maanden nadat longembolie 
was uitgesloten op basis van de Wells score en de D-dimeer test. Daarnaast toont deze 
studie dat gebruik van de leeftijdsafhankelijke D-dimeer afkapwaarde (te berekenen 
door de leeftijd van een patiënt te vermenigvuldigen met 10 voor patiënten ouder dan 
50 jaar) in plaats van een vaste afkapwaarde van 500 µg/L voor de totale groep leidt 
tot een toename van 28% naar 33% van de patiënten waarbij longembolie kan worden 
uitgesloten zonder het verrichten van radiologisch onderzoek. Ten slotte laat de studie 
zien dat de winst van de leeftijdsafhankelijke D-dimeer afkapwaarde verschilt tussen 
belangrijke subgroepen, waarbij de winst logischerwijs voornamelijk gezien wordt bij 
patiënten op hogere leeftijd. Hoofdstuk 4 heeft betrekking op de veiligheid van het 
uitsluiten van longembolie op basis van een normale CT-scan. Voor de meeste patiënten 
met een normale CT-scan is de veiligheid onomstreden, maar voor patiënten met een 
hoge voorafkans op longembolie is de veiligheid van een normale CT-scan nog altijd 
omstreden in de literatuur. Om dit te onderzoeken werden de resultaten van 4 eerder 
verrichte studies naar de veiligheid en efficiëntie van de diagnostiek bij verdenking 
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longembolie gecombineerd. De resultaten van deze studie bevestigde dat voor de totale 
groep patiënten waarbij longembolie wordt uitgesloten door middel van een normale 
CT-scan het risico op veneuze trombo-embolie erg laag is, namelijk 2,0% gedurende de 
3 maanden nadien. Echter in specifieke patiëntgroepen is er sprake van een hoger risico 
op veneuze trombo-embolie ondanks een normale CT-scan, in het bijzonder patiënten 
met een zeer hoge vooraf kans (op basis van een Wells score >6 punten), patiënten 
met klachten verdacht voor een diep veneuze trombose en patiënten met kanker. Het 
is echter niet vast te stellen of en in welke mate dit hogere risico wordt veroorzaakt 
door gemiste diagnoses van veneuze trombo-embolie bij presentatie of door nieuw 
ontwikkelde veneuze trombo-embolie in de periode nadien. Ook is het onduidelijk hoe 
dit risico op veneuze trombo-embolie verlaagd zou kunnen worden.
In de twee volgende hoofdstukken worden 2 studies beschreven waarin onderzocht 
is of de diagnostiek bij verdenking longembolie verder verbeterd kan worden. In 
hoofdstuk 5 wordt een studie beschreven welke heeft onderzocht of het mogelijk is de 
D-dimeer afkapwaarde te verhogen in patiënten met een lage voorafkans op longem-
bolie. Hiervoor werden de resultaten van 2 eerder verrichte studies gebruikt. In plaats 
van de dichotome algoritme werd het trichotome algoritme op basis van de Wells score 
gebruikt. Voor patiënten met een lage vooraf kans op longembolie op basis van een 
Wells score <2 punten werd een D-dimeer afkapwaarde van <1000 µg/L gebruikt, in 
patiënten met een matig risico op longembolie op basis van een Wells score van 2-6 
punten werd een D-dimeer afkapwaarde van <500 µg/L gebruikt en alleen patiënten 
met een hoog risico op longembolie op basis van een Wells score >6 punten werd direct 
een CT-scan verricht. De studie laat zien dat deze strategie leidt tot een verbetering 
van de efficiëntie van de diagnostiek, het percentage van de patiënten waarbij long-
embolie kan worden uitgesloten zonder CT-scan stijgt van 26% naar 36%. Tevens laat 
de studie zien dat dit mogelijk zal leiden tot een klein aantal gemiste diagnoses long-
embolie, maar om vast te stellen of dit inderdaad het geval zal zijn is een prospectieve 
validatie studie noodzakelijk. In hoofdstuk 6 worden de resultaten van de YEARS studie 
beschreven. Dit betreft een prospectieve validatie studie van een sterk vereenvoudigd 
diagnostisch algoritme voor verdenking longembolie. In het YEARS algoritme is de Wells 
score vervangen door slechts 3 YEARS items, te weten: klinische tekenen van diep ve-
neuze trombose, hemoptoë en of een longembolie de meest waarschijnlijke diagnose is 
volgens de verantwoordelijk arts. Vervolgens wordt bij alle patiënten een D-dimeer test 
verricht. Wanneer geen van de YEARS items aanwezig is en de D-dimeer concentratie 
<1000 µg/L is kan een longembolie worden uitgesloten zonder het verrichten van een 
CT-scan. Voor patiënten waarbij één of meer van de YEARS items aanwezig is moet er 
sprake zijn van een D-dimeer concentratie <500 µg/L om een longembolie uit te kun-
nen sluiten zonder het verrichten van een CT-scan. In de YEARS studie is dit algoritme 




veilig kan worden toegepast: het risico op veneuze trombo-embolie nadat longembolie 
was uitgesloten was slechts 0,61%. Het voordeel van het YEARS algoritme is de sterke 
vereenvoudiging van de diagnostiek, in plaats van de bestaande Wells score hoeven 
nu maar 3 items te worden bekeken en in alle patiënten kan direct een D-dimeer test 
worden verricht in plaats van alleen in patiënten met een lage voorafkans op longem-
bolie. De grootste winst van het YEARS algoritme is echter de grote toename van het 
percentage patiënten waarbij longembolie kan worden uitgesloten zonder CT-scan. In 
vergelijking met het meest gebruikte algoritme bestaande uit de Wells score en een 
D-dimeer afkapwaarde van <500 µg/L leidt het YEARS algoritme tot een toename van 
34% naar 48% van de patiënten waarbij longembolie kan worden uitgesloten zonder 
CT-scan, een verschil van 14%.
Deel 2: Behandeling van bewezen acute longembolie
Een van de belangrijkste ontwikkelingen van de afgelopen jaren met betrekking op de 
behandeling van longembolie en diep veneuze trombose betreft de introductie van de 
directe orale anticoagulantia. Deze orale middelen remmen direct trombine (factor IIa) 
of factor Xa en hebben als grootste voordeel een stabielere farmacokinetiek en farma-
codynamiek, waardoor routinematige controle van het antistollingseffect zoals bij het 
gebruik van vitamine K antagonisten niet noodzakelijk is. Daarnaast lijkt er sprake van 
lager risico op bloedingscomplicaties in de afzonderlijke studies. In hoofdstuk 7 wordt 
een meta-analyse beschreven van de individuele studies van de directe orale anticoa-
gulantia voor de behandeling van acute longembolie en diep veneuze trombose. De 
resultaten van de meta-analyse bevestigen dat de directe orale anticoagulantia even 
effectief zijn in het voorkomen van een recidief veneuze trombo-embolie met een 
relatief risico van 0,88 (95% betrouwbaarheidsinterval 0,74-1,05). Tevens bevestigt de 
meta-analyse de aanwijzingen uit de individuele studies dat het risico op bloedings-
complicaties lager is bij gebruik van de directe orale anticoagulantia. Zo is het relatief 
risico op majeure bloedingscomplicaties 0,60 (95% betrouwbaarheidsinterval 0,41-
0,88). Overigens dient vermeld te worden dat de absolute risico’s op zowel een recidief 
veneuze trombo-embolie als een majeure bloeding klein zijn en daarmee het verschil in 
absolute risico’s relatief klein is.
In hoofdstuk 8 wordt een heel specifieke aanbeveling uit de Nederlandse richtlijn 
Diagnostiek, Preventie en Behandeling van Veneuze Trombo-Embolie en Secundaire 
Preventie Arteriële Trombose onderzocht. In het algemeen kan gesteld worden dat 
het wereldwijd gebruikelijk is om patiënten met een recidief veneuze trombo-embolie 
te adviseren om de antistollingstherapie levenslang te continueren. In de genoemde 
Nederlandse richtlijn wordt echter geadviseerd om bij patiënten waarbij het recidief 
veneuze trombo-embolie meer dan 1 jaar het staken van de antistollingstherapie voor 
de eerste veneuze trombo-embolie is opgetreden een beperkte behandelduur van 12 
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maanden te overwegen. Voor deze aanbeveling bestond echter alleen indirect bewijs. 
In hoofdstuk 8 worden de uitkomsten beschreven van het toepassen van deze aanbeve-
ling in het Leids Universitair Medisch Centrum. Van de 131 patiënten met een recidief 
veneuze trombo-embolie meer dan 1 jaar het staken van de antistollingstherapie die 
werden geïncludeerd in de studie werden 77 patiënten voor een beperkte duur behan-
deld. Na staken van de antistollingstherapie was het incidentie cijfer voor veneuze trom-
bo-embolie 9,4 per 100 patiëntjaren (95% betrouwbaarheidsinterval 6,1-14) waarbij het 
risico in patiënten met een idiopathische tweede veneuze trombo-embolie nog hoger 
lijkt en het risico in patiënten met een uitgelokte tweede veneuze trombo-embolie lager. 
Hoewel het een observationele studie betreft is het zeer aannemelijk dat dit hoge risico 
op een recidief veneuze trombo-embolie de risico’s, met name bloedingscomplicaties, 
van het continueren van de antistollingstherapie overtreft. Daarmee biedt deze studie 
geen ondersteuning voor deze specifieke aanbeveling in de Nederlandse richtlijn.
De volgende drie hoofstukken hebben betrekking op de behandeling van kanker-ge-
associeerde veneuze trombo-embolie. In hoofdstuk 9 wordt een cohort studie beschre-
ven waarbij met name onderzocht is of het veilig is om de antistollingstherapie voor 
een kanker-geassocieerde veneuze trombo-embolie te staken in patiënten die genezen 
zijn van kanker. Van de 358 geïncludeerde patiënten met een kanker-geassocieerde 
veneuze trombo-embolie kon de antistollingstherapie gestaakt worden in 68 patiënten 
nadat zij genezen waren van kanker. Het risico op een recidief veneuze trombo-embolie 
in deze patiënten was laag met een incidentie cijfer van 3,2 per 100 patiëntjaren (95% 
betrouwbaarheidsinterval 1,5-5,9). Opvallend hierbij is dat bij 7 van de 10 patiënten met 
een recidief veneuze trombo-embolie ook een recidief van de kanker werd vastgesteld 
voor of kort na de diagnose recidief veneuze trombo-embolie. Deze studie ondersteunt 
de huidige richtlijn om de antistollingstherapie voor kanker-geassocieerde veneuze 
trombo-embolie te staken in patiënten die genezen zijn van kanker. In hoofdstuk 10 
wordt een meta-analyse beschreven naar het gebruik van de directe orale anticoagulan-
tia voor kanker-geassocieerde veneuze trombo-embolie. De methode van deze studie is 
identiek aan de methode van de studie uit hoofdstuk 7, maar nu is voor de resultaten spe-
cifiek gekeken naar patiënten met een kanker-geassocieerde veneuze trombo-embolie. 
In de vijf afzonderlijke studies zijn in totaal 19.060 patiënten geïncludeerd waarvan er 
973 bekend waren met een actieve kanker. In vergelijking met patiënten zonder actieve 
kanker waren het risico op een recidief veneuze trombo-embolie en bloedingscomplica-
ties relatief hoog, wat overigens geheel in overeenkomst is met bestaande literatuur. Het 
relatief risico voor directe anticoagulantia vergeleken met vitamine K antagonisten voor 
recidief veneuze trombo-embolie was 0,66 (95% betrouwbaarheidsinterval 0,38-1,2) 
en voor majeure en klinisch relevante bloedingen 0,94 (95% betrouwbaarheidsinterval 
0,70-1,3). Belangrijk om hierbij te vermelden is dat er zeer beperkte informatie beschik-




de behandeling in de controle arm, vitamine K antagonisten, niet de behandeling van 
eerste keuze voor kanker-geassocieerde veneuze trombo-embolie. Om deze redenen 
dienen de resultaten van deze studie voorzichtig geïnterpreteerd te worden. Wel dienen 
ze als sterke aansporing om de directe anticoagulantia te onderzoeken voor de behande-
ling van kanker-geassocieerde veneuze trombo-embolie, wat overigens op dit moment 
ook gebeurt. Hoofdstuk 11 richt zich tenslotte op bij toeval gevonden longembolie, dit 
is een relatief nieuwe klinische presentatie voornamelijk optredend bij patiënten met 
kanker. Dit wordt veroorzaakt door het relatief hoge risico op veneuze trombo-embolie 
in patiënten met kanker en door het frequent toepassen van steeds van betere kwaliteit 
zijnde CT-scans in deze patiëntengroep. Op basis van observationele, veelal kleine 
studies wordt geadviseerd bij toeval gevonden longembolie hetzelfde te behandelen 
als longembolie vastgesteld bij patiënten waarbij een klinische verdenking bestond. In 
hoofdstuk 11 is getracht om zoveel mogelijk gegevens van individuele observationele 
studies te verzamelen om daarmee het best beschikbare bewijs betreffende de behan-
deling van bij toeval gevonden longembolie te verkrijgen. In totaal werden gegevens 
van 926 patiënten uit 11 verschillende studies verzameld. De belangrijkste resultaten 
van deze studie waren een vergelijkbaar risico op een recidief veneuze trombo-embolie 
onder behandeling met laag moleculair gewicht heparine en vitamine K antagonisten, 
respectievelijk 6,2% en 6,4% gedurende 6 maanden na diagnose. Het risico in 53 patiën-
ten die om onbekende reden niet zijn behandeld met antistollingstherapie was 12%. Het 
risico op majeure bloedingen was aanzienlijk hoger onder behandeling met vitamine K 
antagonisten, 13% vergeleken met 3,9%. Ondanks een aantal belangrijke beperkingen 
ten gevolge van de studie opzet suggereert deze studie dat antistollingstherapie het 
risico op een recidief veneuze trombo-embolie verlaagt en dat laag moleculair gewicht 
heparine de voorkeur verdient boven vitamine K antagonisten. Beide ondersteunen de 
aanbevelingen in de huidige richtlijnen.
Toekomstperspectief
Een diagnostisch algoritme zoals het YEARS algoritme stelt artsen in staat om bij een 
steeds groter gedeelte van de patiënten met een klinische verdenking op longembolie 
de diagnose uit te sluiten zonder het verrichten van een potentieel schadelijke CT-scan. 
Het blijft een uitdaging voor toekomstig onderzoek om de noodzaak voor het verrichten 
van een CT-scan verder terug te dringen. Het is echter niet te verwachten dat er nog een 
grote winst behaald kan worden door verdere aanpassingen aan een klinische beslisre-
gel of de D-dimeer afkapwaarden. Wellicht dat in de toekomst de CT-scan vervangen kan 
worden door een alternatief radiologisch onderzoek zoals de MRI-scan, zodat in ieder 
geval de zorgen over stralenbelasting weggenomen kunnen worden. Vooralsnog zijn 
de relatief lage sensitiviteit en een hoog percentage onduidelijke uitslagen hiervoor de 
belangrijkste beperkingen. Een andere uitdaging vormt de patiëntengroep zwangere 
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vrouwen waarbij een klinische verdenking op longembolie bestaat. Dit is een relatief 
frequent voorkomende situatie waarin naast de zorgen over stralenbelasting voor de 
vrouw ook de stralenbelasting voor het ongeboren kind reden zijn om te streven het 
gebruik van de CT-scan te reduceren. Tot op heden is er geen enkele diagnostische stra-
tegie waarbij longembolie werd uitgesloten zonder radiologisch onderzoek gevalideerd 
in zwangere vrouwen. Aan een prospectieve studie in deze groep naar een diagnostisch 
algoritme zoals het YEARS algoritme is dringend behoefte.
Enkele belangrijke onbeantwoorde vragen met betrekking tot de optimale behandeling 
van acute longembolie zijn gerelateerd aan de introductie van de directe orale anti-
coagulantia. Deze medicamenten zijn inmiddels de eerste keuze behandeling voor de 
meerderheid van patiënten met acute longembolie. Onderzoek naar de effectiviteit en 
veiligheid van deze medicamenten bij patiënten met een maligniteit is op dit moment 
gaande. Daarnaast zal het gunstige bijwerkingenprofiel van de directe orale anticoagu-
lantia gevolgen gaan hebben voor de keuze van de behandelduur. Door het lage risico 
op bloedingscomplicaties zullen artsen en patiënten waarschijnlijk sneller geneigd zijn 
de behandeling ook na een eerste veneuze trombo-embolie voor onbepaalde tijd te 
continueren. Dit zal belangrijke effecten hebben zoals hogere kosten maar het zal ook 
leiden tot een toenemende overbehandeling, lang niet alle patiënten met een veneuze 
trombo-embolie ontwikkelen immers een recidief. Daarnaast is het ook een hele interes-
sante vraag of met het verlengen van de behandelduur alleen gedurende de behande-
ling een recidief wordt voorkomen of dat uiteindelijk het risico op een recidief afneemt 
en daarmee na verloop van de tijd de behandeling alsnog gestaakt zou kunnen worden. 
Wat betreft bij toeval gevonden longembolie in patiënten met kanker blijft de vraag of 
deze patiënten baat hebben bij antistollingstherapie. Indirect bewijs, zoals ook beschre-
ven in dit proefschrift, suggereert dat het risico op een recidief veneuze trombo-embolie 
wordt verlaagd door antistollingstherapie en dat patiënten daarmee baat hebben bij 
behandeling met antistollingstherapie. Anderzijds is bekend dat patiënten met kanker 
ook een aanzienlijk hoger risico op bloedingscomplicaties hebben tijdens behandeling 
met antistollingstherapie. Het antwoord op deze vraag kan alleen definitief worden 
beantwoord door een gerandomiseerde studie waarin geen behandeling of eventueel 
een korte behandelduur wordt vergeleken met een behandeling voor onbepaalde duur, 
maar waarschijnlijk zal deze studie nooit verricht gaan worden en zullen we het moeten 
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